Structural determinants of GnRH ligand-receptor interactions by Pfleger, Kevin D.G.
Structural Determinants of GnRH
Ligand-Receptor Interactions
Kevin D. G. Pfleger
Doctor of Philosophy






Amino Acid Numbering Scheme xii
List of Figures xiii
List of Tables xiv
Abstract xv
1 Introduction 1
2 Literature Review 2
2.1 GnRH and the Control of Human Reproduction 2
2.1.1 The Hypothalamic-Pituitary Axis 2
2.1.2 GnRH Regulation ofGonadotropin Synthesis 3
2.1.3 Control of Gonadal Function 3
2.1.4 Clinical Uses ofGnRH Agonists and Antagonists 5
2.1.5 Summary 6
2.2 Ligand-Receptor Pharmacology 7
2.3 G-Protein-Coupled Receptors (GPCRs) 11
2.3.1 G-Proteins 11
2.3.2 The Diversity ofGPCRs 14
2.3.3 The Structure ofGPCRs 16
2.3.4 Conserved Motifs 21
2.3.5 Summary 27
2.4 Comparison of Different GnRHs 28
2.5 Comparison of Different GnRH Receptors 30
11
2.6 GnRH Ligand Structure-Activity Relationships 36
2.6.1 The Bioactive Conformation ofGPCR Ligands 36
2.6.2 Substitutions that Enhance the Activity ofGnRH 37
2.6.3 GnRH Antagonists 38
2.6.4 Bioactive Conformations of GnRHs 39
2.6.5 Summary 44
2.7 Receptor Structure-Activity Relationships 45
2.7.1 The Use of Chimeric Receptors 45
2.7.2 Residues Involved in Ligand-Receptor Interactions 47
2.7.3 Summary 53
General Materials and Methods 54
3.1 Amino Acid Numbering Scheme 54
3.2 Molecular Cloning Techniques 54
3.2.1 The Polymerase Chain Reaction (PCR) 54
3.2.2 Digestion ofDNA using Restriction Endonucleases 56
3.2.3 Ligation of DNA 57
3.3 Bacterial Production of Plasmid DNA 57
3.3.1 Microbiological Sterile Technique 57
3.3.2 Preparation of LB Agar Plates 58
3.3.3 Transformation of E. coli 58
3.3.4 Amplification and Purification 59
3.4 Additional DNA Purification Techniques 60
3.4.1 Ethanol Precipitation 60
3.4.2 Extraction with Phenol/Chloroform 60
3.4.3 Purification Columns 60
3.4.4 Gel Purification 61
Ill
3.5 Analysis of DNA 62
3.5.1 Agarose Gel Electrophoresis 62
3.5.2 Spectrophotometric Analysis 62
3.5.3 DNA Sequencing 62
3.6 Engineered Human GnRH Receptor cDNA 64
3.7 Transient Transfection of COS-7 Cells 68
3.7.1 Origin of the COS-7 Cell Line 68
3.7.2 Cell Culture 68
3.7.3 Transfection Reagent 68
3.7.4 Transfection Protocol 68
3.7.5 Optimisation ofTransfection Protocol 69
3.8 Radioligand Binding Assays 74
3.8.1 lodination of [His5,D-Tyr6]-GnRH 74
3.8.2 Whole Cell Binding Assay 74
3.8.3 Membrane Binding Assay 75
3.8.4 Selection ofBinding Assay for Studies 75
3.9 Data Reduction and Statistical Analysis 75
The Effect of Ligand Conformational 77
Constraint on GnRH Receptor Binding
4.1 Introduction 77
4.2 Materials and Methods 79
4.2.1 GnRH Analogues 79
4.2.2 GnRH Receptor cDNA 79
4.2.3 Cell Culture and Transfection 80
4.2.4 Receptor Binding Assays 80




5 Extracellular Loop Interactions 100
Differentially Affect mGnRH, GnRH II,
Superagonist and Antagonist Binding
5.1 Introduction 100
5.2 Materials and Methods 102
5.2.1 Amino Acid Numbering Scheme 102
5.2.2 GnRH Analogues 102
5.2.3 Human and Catfish GnRH Receptor cDNA 103
5.2.4 Production of Chimeric GnRH Receptor cDNA 103
5.2.5 Cell Culture and Transfection 105
5.2.6 Receptor Binding Assays 105
5.2.7 Data Reduction and Statistical Analysis 105
5.3 Results 105
5.4 Discussion 113
6 The Effect of Extracellular Loops 2 119
and 3 on GnRH Analogue Binding
6.1 Introduction 119
6.2 Materials and Methods 121
6.2.1 Amino Acid Numbering Scheme 121
6.2.2 GnRH Analogues 121
6.2.3 GnRH Receptor cDNA Supplied to the Study 121
6.2.4 Production of Chimeric GnRH Receptor cDNA 122
6.2.5 Cell Culture and Transfection 123
6.2.6 Receptor Binding Assays 123
6.2.7 Data Reduction and Statistical Analysis 123
6.3 Results 125
6.4 Discussion 133
7 Concluding Discussion 138
Bibliography 141
Appendix I: Composition of Reagents 173
Appendix II: Addresses of Suppliers 176
Appendix III: Sequences of Oligonucleotide Primers 177
Appendix IV: Publications and Presentations 179
vi
Declaration
I declare that this thesis has been composed by myself, that the work is my own,
and that when a substantial contribution has been made by another individual, his or her
contribution has been clearly indicated. This work has not been submitted for any other
degree or professional qualification, and all publications of material from this thesis
prior to submission have been recorded in Appendix IV.
Acknowledgements
vii
The following individuals made important contributions to the studies described
in this thesis. I would like to acknowledge and thank: Phil Taylor and Gwen Crawford
(CRB Sequencing Service) for automated DNA sequencing; Robin Sellar and Nicola
Millar for maintaining, passaging and plating out COS-7 cells prior to transfection; and
Phil Taylor and Robin Sellar for iodinating the radioligand, 125I-[His5,D-Tyr6]-GnRH.
These individuals are at the top of a long list of people without whom this thesis
would still be a group of trees growing in a forest somewhere! I am very grateful to
both of my supervisors: Robert Millar, for his guidance and invaluable critical
evaluation of my work; and Alan McNeilly, for his continual encouragement. Thanks
are also due to Karin Eidne for enabling me to do both my PhD in Edinburgh and my
postdoctoral research in Australia. I would like to thank all of the members of my
research group, past and present, for their help, encouragement and friendship over the
past three and a half years. In particular, I would like to pay tribute to Robin Sellar,
Nicola Miller and Alison Robertson for their expert technical assistance and advice, their
ability to run the lab like a well-oiled machine, and their willingness to plate out millions
of COS-7 cells every Monday and Thursday without fail! I would like to thank all the
postdoctoral fellows, particularly Adam Pawson and Thomas Ott for training me in the
mysterious arts of molecular biology. I would also like to thank Adam for being my
unofficial mentor and continuing work begun in this thesis.
I have really enjoyed working in Edinburgh with so many wonderful people,
particularly my fellow PhD students, Sasha and Alex Mitchell, and Lynda Chang.
Thank you to Gwen Crawford, Lynda Chang, Greg Burns, Mat Goodyear, Emlyn Scott
and Beverley Lewis for reminding me that there was a world outside the CRB, and when
I was climbing up the walls, they were there at the end of the rope! Thanks also to Jim
Francis (the coolest minister ever!) and his lovely wife Lorraine.
I would like to thank my family for their unequivocal love and support over the
last 25 years. For always being there for me, and enabling me to pursue my dreams and
ambitions, wherever they may lead. Finally, I would like to thank my darling Gwen
who did me the great honour of becoming my wife on 9th August 2002. Gwen became
my friend and soulmate soon after my arrival in Edinburgh, and has since become the

























[Ca2+], Intracellular calcium concentration
5-HT 5-Hydroxytryptamine (serotonin)
6,7 y-lactam y-lactam ring between positions six and seven
ADP Adenosine diphosphate
AP-1 Activating protein 1
ARF ADP-ribosylation factor
BH Bolton Hunter conjugated
BOSS Bride of sevenless
bp Base pairs
BSA Bovine serum albumin
C5a Complement component 5a





cGnRH I Chicken GnRH I ([Gln8]-GnRH)
CIP Calf intestinal alkaline phosphatase
CMV promoter Human cytomegalovirus immediate-early gene
CRE cAMP response element
C-terminus Carboxy-terminus
D-aa6 D-amino acid in position six
DAG Diacylglycerol
ddNTP 2',3'-dideoxynucleoside triphosphate




































Enhanced green fluorescent protein








[His5,Trp7,Tyr8]-GnRH (chicken GnRH II)
GnRH receptor
G-protein coupled receptor
Guanyl nucleotide binding protein
Guanosine triphosphate
N-[2-Hydroxyethyl]piperazine-N'-[2-ethanesulfonic acid]
Inhibitory concentration of an unlabelled ligand that results
















PCR Polymerase chain reaction
PEI Polyethylenimine
pGlu Pyroglutamate
pH Potential of hydrogen ions (-log 10 [H+] in solution)
Pi Inorganic phosphate
PIP2 Phosphotidylinositol 4,5-bisphosphate
PKC Protein kinase C
R, R*, R', R", R° Receptor conformational states
RMS Root mean squared
S.E.M. Standard error of the mean
SDS Sodium dodecyl sulphate
SF-1 Steriodogenic factor 1





TSH Thyrotropin (thyroid-stimulating hormone)
VIP Vasoactive intestinal peptide
WT Wild type
Schematicrepresenta ionofthum nGnRHcep or.Residuesindicatedbluarrefe cepointsfota i oid numberingscheme(Ballest rosandWeinstein,1995).Oth rresidurnumb dr lativtohp i on ,.g.Asp261( 8)
List of Figures
xiii
Figure: Page: Figure: Page:
Figure 2.1 8 Figure 4.1 84
Figure 2.2 9 Figure 4.2 86
Figure 2.3 12 Figure 4.3 88
Figure 2.4 19 Figure 4.4 91
Figure 2.5 23 Figure 4.5 94
Figure 2.6 33
Figure 2.7 43 Figure 5.1 104
Figure 2.8 49 Figure 5.2 108
Figure 5.3 110
Figure 3.1 55 Figure 5.4 112
Figure 3.2 65
Figure 3.3 66 Figure 6.1 120
Figure 3.4 70 Figure 6.2 124
Figure 3.5 71 Figure 6.3 126
Figure 3.6 72 Figure 6.4 128
Figure 3.7 73 Figure 6.5 132
Figure 3.8 76 Figure 6.6 135
List of Tables
xiv
Table: Page: Table: Page:
Table 2.1 13 Table 4.1 82
Table 2.2 14 Table 4.2 83
Table 2.3 14 Table 4.3 90
Table 2.4 15 Table 4.4 93
Table 2.5 20
Table 2.6 22 Table 5.1 107
Table 2.7 25 Table 5.2 109
Table 2.8 29 Table 5.3 111








The aim of this thesis was to investigate how the spatial arrangements of
amino acids in both the ligand and receptor influence gonadotropin-releasing
hormone (GnRH) ligand-receptor interactions.
Mammalian GnRH (mGnRH) is believed to interact with mammalian GnRH
receptors in a (3-II' turn conformation involving residues five to eight. This
conformation can be constrained by substitution of a D-amino acid at position six or
by a lactam ring involving residues six and seven, thereby increasing receptor
binding affinity. It has been proposed that this is not the case for non-mammalian
GnRH receptors. However, this thesis shows that this conformational constraint
increases the binding affinity of mammalian, chicken and salmon GnRH for the
chicken and catfish receptors, as well as for the mouse receptor. Therefore, the
conclusion is that the (3-11' turn conformation enhances ligand binding for non-
mammalian as well as mammalian GnRH receptors. An exception, however, is
GnRH II where most substitutions of a D-amino acid in position six have limited
effect on binding affinity. It is suggested that this ligand is pre-configured through
intramolecular interactions, which accounts for its high binding affinity and total
conservation of primary structure over 500 million years of evolution.
A number of residues in the receptor extracellular loops (ECLs) have been
identified as interacting directly with ligands. Therefore, these regions play a crucial
role in ligand binding. Chimeric receptors, consisting of the human receptor
containing the three catfish receptor ECLs in all single, double and triple
combinations were produced. Certain combinations of ECLs were found to have
different effects on the binding of mGnRH, [D-Trp6]-GnRH, GnRH II, [D-Lys6]-
GnRH II and Antagonist 135-18. ECL3 appears to influence the binding ofmGnRH,
but not [D-Trp6]-GnRH, which correlates with previous studies. The difference in the
binding affinity of these two ligands could be attributed to the ECLs, as their
affinities at the triple-ECL substituted chimeric receptor were not significantly
different to those at the wild type catfish receptor. Substitution of the ECLs did not
simulate binding at the wild type catfish receptor for GnRH II, [D-Lys6]-GnRH II or
Antagonist 135-18. This implies that these ligands form different interactions with
GnRH receptors compared with those formed by mGnRH and [D-Trp6]-GnRH.
Potential interactions between ECLs were investigated with additional mutant
receptors. ECL interactions may influence ligand binding by altering the spatial
xvi
arrangement or accessibility of ligand contact sites. Interactions between ECLs 2
and 3 appear to be particularly important: they are partly responsible for differences
in the binding of GnRH II at the catfish compared with at the human receptor; a
single residue in ECL2, namely Glu5 35, is likely to be responsible for the different
affinity of GnRH II at the rat receptor compared with at the mouse and human
receptors as a result of repulsion between ECLs 2 and 3; and human and chicken
GnRH receptors appear to have important differences in ECLs 2 and 3 such that
agonist binding at human-chicken chimeric receptors is severely affected.
An appreciation of how ligand-receptor contact sites are configured is crucial
to understanding how GnRH binds and activates its cognate receptor. This thesis
provides insights into both ligand and receptor conformation thereby advancing our
understanding of the ligand-receptor interaction.
1
1 Introduction
Gonadotropin-releasing hormone (GnRH) and its cognate receptor are
molecules of considerable importance in the control of reproduction, and are
therefore of particular scientific and clinical interest. This thesis aims to investigate
how the spatial arrangements of amino acids in both the ligand and receptor
influence GnRH ligand-receptor interactions.
Chapter 2 is a critical review of the current literature regarding: the role of
GnRH in the control of human reproduction (including clinical uses of GnRH
agonists and antagonists); the concepts and definitions of ligand-receptor
pharmacology; G-protein coupled receptors in general (with particular emphasis on
structure); similarities and differences between GnRHs and GnRH receptors from
different species; the bioactive conformation ofGnRH and substitutions that enhance
its activity; the use of chimeric receptors in the study of ligand-receptor interactions;
and the residues involved in interactions between GnRHs and GnRH receptors.
Chapter 3 describes the general materials and methods used in this thesis,
with reagents, suppliers and oligonucleotide primers listed in Appendices I, II and
III.
The experimental chapters (Chapters 4 to 6) describe studies investigating
structural features of both GnRH ligands and receptors that determine their
presentation for interaction with each other. Materials and methods specific to
particular studies are described in each of these chapters.
Chapter 7 is a concluding discussion. There are two major findings. Firstly,
conformational constraint of the (3-IT turn for residues five to eight in mammalian,
chicken and salmon GnRHs, but not GnRH II, enhances binding at mammalian and
non-mammalian GnRH receptors. This provides evidence that these central residues
are pre-configured in a (3-IT turn in GnRH II. Secondly, the interactions of
extracellular loops (ECTs) differentially affect GnRH, GnRH II, superagonist and
antagonist binding to GnRH receptors. In particular, ECL3 conformation is
important for the binding of mammalian GnRH, and the interaction ofECLs 2 and 3
appear to influence the binding of GnRH II, [D-Lys6]-GnRH II and Antagonist 135-
18. Indeed, a single residue in ECL2 is believed to be responsible for the different




2.1 GnRH and the Control of Human Reproduction
2.1.1 The Hypothalamic-Pituitary Axis
Mammalian gonadotropin-releasing hormone (mGnRH) is a decapeptide
(pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-GlyNH2) that is synthesised as a
prohormone in conjunction with GnRH-associated peptide (GAP). Following
cleavage by processing enzymes (Wetsel et al., 1995) mGnRH is released into the
hypophyseal-portal capillaries from nerve terminals located in the lateral palisade
zone of the hypothalamic medial eminence (Johnson and Everitt, 1995; King et al.,
1985). It passes to the anterior pituitary where it acts upon a cognate G-protein
coupled receptor (GPCR) in the membrane of gonadotrope cells (Sealfon et al.,
1997).
Activation of the GnRH receptor results in coupling to Gq. Initially, increases
in phospholipase C activity lead to phosphotidylinositol 4,5-bisphosphate (PIP2)
hydrolysis, forming inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG)
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(Stojilkovic et al., 1994). Intracellular calcium concentration ([Ca ];) increases and
conventional isoforms of protein kinase C (PKC) are activated. Subsequently,
phospholipases A2 and D are also activated, mediating diverse signalling pathways
via arachidonic acid and different isoforms of PKC (Naor et al., 1998).
The complex calcium oscillations resulting from GnRH-induced calcium
mobilisation cause the exocytosis of the gonadotropins, luteinising hormone (LH)
and follicle-stimulating hormone (FSH), from the gonadotrope cells into the
peripheral circulation (Stojilkovic and Catt, 1992). Each elevation of [Ca2T]j results
in a burst of exocytosis and it is estimated that 540 vesicles are released due to a
single 10 s application of GnRH (Tse et al., 1993). Calcium from IP3-sensitive stores
appears to be responsible, with little if any contribution from extracellular calcium.
GnRH secretion is pulsatile and results in pulsatile secretion of the
gonadotropins (Leyendecker et al., 1990). The relationship between GnRH pulses
and LH pulses appears to be direct, however, non-GnRH-associated pulses of FSH
are evident (Padmanabhan et al., 1997). These may be caused by the interactions of
locally produced activin, inhibin and follistatin; or by an unidentified FSH-releasing
factor (Padmanabhan and McNeilly, 2001). Continuous exposure of gonadotrope
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cells to GnRH results in desensitisation and consequent decreases in gonadotropin
secretion (Conn and Crowley, 1994). The first GnRH pulse results in release of
stored LH and FSH within minutes. There is also movement of secretory granules
towards the plasma membrane, priming the cell for a much greater release of LH
following exposure to a second GnRH pulse (Johnson and Everitt, 1995).
2.1.2 GnRH Regulation of Gonadotropin Synthesis
LH and FSH are heterodimers composed of a common a-subunit and a
hormone-specific P-subunit. The a-subunit gene consists of 4 exons and 3 introns
and encodes a mature peptide of 92 amino acids. The LH P-subunit gene consists of
3 exons and 2 introns and encodes a mature peptide of 121 amino acids. The FSH |3-
subunit gene consists of another 3 exons and 2 introns and encodes a mature peptide
of 110 amino acids (Gharib et al., 1990).
Gene expression can be broadly divided into basal and GnRH-regulated
(Brown and McNeilly, 1999). Activation of the a-subunit promoter by GnRH
involves synergistic binding of a LIM homeodomain transcription factor and a factor
stimulated via the mitogen-activated protein kinase (MAPK) pathway (Roberson et
al., 1995). There is also evidence of a-subunit transcription stimulated by both
cAMP and extracellular calcium (Saunders et al., 1998).
GnRH stimulates LH P-subunit transcription mainly via the PKC pathway,
but also via MAPK and cAMP. The role of extracellular calcium is debatable
(Saunders et al., 1998; Week et al., 1998). Basal gene expression is controlled by
such transcription factors as steriodogenic factor 1 (SF-1). GnRH-regulated
transcription factors, such as early growth response protein 1 (Egr-1), synergise with
these factors (Halvorson et al., 1999). GnRH stimulates FSH P-subunit transcription
via the PKC pathway and activating protein 1 (AP-1) sites (Strahl et al., 1998).
2.1.3 Control of Gonadal Function
In the testis, LH binds to receptors on the Leydig cells. This results in
steriodogenesis, particularly testosterone synthesis. LH also partially stimulates
spermatogenesis, probably by elevating intratesticular testosterone levels (Amory
and Bremner, 2001). FSH binds to receptors on the Sertoli cell and spermatogonial
membranes. It is critical for stimulating seminiferous tubule growth during
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development and initiating spermatogenesis during puberty. It is also required by
adult men to produce the normal quantity of sperm (Amory and Bremner, 2001).
Both LH and FSH receptors are GPCRs that signal via activation of adenylate
cyclase.
In the ovary, lack of exposure to LH and FSH results in follicular atresia, and
FSH concentration controls the number of early antral follicles that are recruited for
development (Johnson and Everitt, 1995). LH binds to receptors on the theca interna
cells, stimulating androgen synthesis via cAMP production. This action is inhibited
by activin and enhanced by inhibin (Hillier, 1991). FSH binds to receptors on the
granulosa cells and stimulates the aromatisation of androgens (from thecal cells) to
oestrogens. Low concentrations of oestradiol have a negative feedback effect on
gonadotropin secretion. This is exerted directly at the pituitary (Brown and
McNeilly, 1999) and by altering GnRH secretion from the hypothalamus (Karsch
and Evans, 1996). One antral follicle, the dominant follicle, now enters the pre¬
ovulatory phase when the combination of oestradiol and FSH stimulate the first
appearance of LH receptors on the outer layer of granulosa cells (Shi and Segaloff,
1995). The rapid increase in oestradiol concentration resulting from aromatase
activity switches negative feedback to positive feedback. A GnRH surge results that,
combined with oestradiol action on the pituitary, triggers the LH surge (Kaynard et
al., 1988) and subsequent ovulation of the pre-ovulatory follicle.
Following ovulation, the cycle enters the luteal phase. The remaining follicle
becomes the corpus luteum, maintenance of which is dependent upon low levels of
LH (Johnson and Everitt, 1995). The granulosa cells become granulosa-lutein cells
and a proportion of thecal cells become thecal-lutein cells with an apparent increase
in LH receptors. The granulosa-lutein cells produce progesterone, and oestrogens in
primates, the latter from aromatisation of androgens produced by the thecal-lutein
cells. The high plasma concentration of progesterone enhances the negative
feedback effect of oestradiol and blocks the positive feedback effect (Johnson and
Everitt, 1995; Leyendecker et al., 1990)
Testicular and ovarian function is controlled by GnRH via the control of LH
and FSH. However, it is important to recognise that, in both the male and female,
downstream hormones also exert influence over GnRH via multiple feedback
mechanisms acting at both pituitary and hypothalamic levels (Amory and Bremner,
2001; Brown and McNeilly, 1999; Karsch and Evans, 1996). Therefore, GnRH has a
pivotal role in a complex and highly integrated reproductive endocrine system.
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2.1.4 Clinical Uses of GnRH Agonists andAntagonists
GnRH can be delivered in a pulsatile manner by infusion pumps, mimicking
normal physiological secretion. This is an important therapy for restoration of
reproductive function where there is aberrant endogenous GnRH secretion. In one
study, over 90% of women with amenorrhea ovulated following administration of
pulsatile GnRH (Santoro, 1990). The results were excellent in terms of single
folliculogenesis, single pregnancy and predictable outcome. The treatment was very
safe, even with prolonged intravenous administration. GnRH therapy is also
effective for treating hypogonadal men with conditions such as hypogonadotropic
hypogonadism and Kallmann's syndrome (Conn and Crowley, 1994).
Intramuscular depot delivery of a long-lasting GnRH agonist causes constant
receptor occupancy and results in desensitisation. Daily intranasal or subcutaneous
administration can be used, with transvaginal routes being another possibility. This
effective, safe and reversible method of blocking the reproductive axis is beneficial
in the treatment of conditions such as precocious puberty, endometriosis, uterine
fibroids, prostate cancer, premenopausal breast cancer and polycystic ovarian disease
(Barbieri, 1992; Conn and Crowley, 1994; Filicori, 1994). There are side effects to
most GnRH therapies, particularly if administration is long-term (Lemay, 1989).
These are expected and result from gonadal sex hormone deprivation. The most
serious of these is bone demineralisation. One study found a significant 3% bone
loss during the first 12 weeks of GnRH agonist treatment (Friedman et ah, 1993), and
this has been used as an index of patients likely to become osteoporotic after
menopause. Carefully controlled replacement of selected steroid hormones can be
used to alleviate most side effects, including bone demineralisation, depending on the
condition and the individual (Cedars et ah, 1990; Friedman et ah, 1993). Precocious
puberty may be an exception in that long-term GnRH therapy appears not to elicit
noticeable side effects (Conn and Crowley, 1994).
Apart from prostate cancer and premenopausal breast cancer, the use of
GnRH analogues in reproductive oncology is still at the experimental stage.
However, there does appear to be great potential for improving treatment of breast,
ovarian and endometrial cancers (Emons and Schally, 1994).
GnRH agonist and antagonist treatment is very important in assisted
fertilization where blockade of the LH surge enables control of ovulation by
exogenous gonadotropins (de Ziegler et ah, 1987). Use of GnRH analogues for
contraception has enormous potential, particularly in the male (Fraser, 1993). This
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method may have important health benefits, particularly with regard to lowering the
risk of reproductive cancers (Miller, 1991; Spicer et ah, 1991).
Theoretically, a GnRH antagonist is a better agent for inhibiting the
reproductive cascade. Competitive blockade of the GnRH receptor is more direct
and lacks the problems of initial gonadotropin stimulation prior to desensitisation
that occurs with agonists (Millar et al., 2000). Unfortunately, larger doses of
antagonists are required with the associated increase in cost, and initial antagonists
were found to have significant histamine-releasing activity (Conn and Crowley,
1994; Fraser, 1993). Clinical peptide GnRH antagonists are beginning to be used
extensively in the clinic (for example, they are used for most in vitro fertilisation
(IVF) procedures) and some are in phase III trials for prostate cancer. Recent
advances in the development of non-peptide orally active GnRH antagonists indicate
considerable therapeutic potential (Millar et al., 2000). The first orally active GnRH
antagonist that suppresses LH and testosterone levels in healthy human volunteers
(TAK-013) is currently undergoing further clinical trials (Suzuki et al., 2002).
2.1.5 Summary
Control of both male and female reproductive systems comprises a complex
interplay of hormones that regulate each other via feedback mechanisms. GnRH is
the key to this system with aberrant synthesis, storage, release or action resulting in
partial or complete loss of reproductive function (Johnson and Everitt, 1995).
The use of GnRH analogues for clinical applications is now widespread, with
sales exceeding $2 billion per annum (Millar et al., 2000). Despite this, there is room
for improvement. Minor side effects and a lack of orally active compounds continue
to present obstacles, however, there is great potential for future therapies. Improved
understanding of how GnRH analogues interact with the GnRH receptor is the key to
unlocking this potential. The binding of a ligand at its cognate receptor is dependent
upon the spatial arrangement of key molecular features that form ligand-receptor
interactions. The role of the rest of the molecule is to position these features (Millar
et al., 2000). The nature of the molecule, be it peptide or non-peptide, is unimportant
as long as the required molecular features are present and correctly positioned.
Therefore, knowledge of the spatial arrangement of molecular features involved in
GnRH ligand-receptor interactions is extremely important for the future design of
pharmaceutical compounds, including non-peptide orally active compounds, that act
at the GnRH receptor.
2.2 Ligand-Receptor Pharmacology
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The success of multicellular organisms is dependent upon accurate signalling
between their component cells. This accuracy must be spatial and temporal, i.e. a
signal from one cell must initiate the required response in the target cell at the
required time, for the required duration, and without initiating responses in non-
target cells. Multicellular organisms such as humans have evolved complex nervous
and endocrine systems so that accurate signalling can occur over short and long
distances. The key to both these systems is the highly specific interaction between
ligand and receptor.
'Ligands' are molecules that bind specifically to a 'receptor' and are
classified as full agonists, partial agonists, inverse agonists or antagonists (Gether
and Kobilka, 1998). 'Affinity' is a measure of the strength of interaction between
the ligand and the receptor (Rang et ah, 1999). All types of ligand can have high
affinity for a receptor. 'Efficacy' is a measure of the cellular response initiated
following binding of a ligand. Full agonists have high efficacy and generally require
just a fraction of the receptor population to be occupied to initiate a maximal
response. Partial agonists have intermediate efficacy, which by definition is
submaximal even when the entire receptor population is occupied. Antagonists have
zero efficacy and inverse agonists have negative efficacy, as discussed below
(Chidiacet ah, 1994).
Traditionally, agonist binding was believed to initiate a conformational
change in the receptor, resulting in a switch from the resting state to the activated
state (as suggested for enzyme-substrate interactions, such as between hexokinase
and glucose (Bennett and Steitz, 1978)). This is known as the Tigand induction'
model and is likely to be the mechanism by which a photon activates rhodopsin
(Gether and Kobilka, 1998) (See Section 2.3.3). However, for most GPCRs, the
ternary complex model is more applicable. Originally, this involved the hormone
(H), receptor (R) and G-protein (G) in the formation of two ligand-receptor
complexes: low affinity (HR) and high affinity (HRG) (De Lean et ah, 1980). More
recently, it has been extended to incorporate the concepts of constitutive activation
and inverse agonism (Chidiac et ah, 1994; Samama et ah, 1993). The extended
ternary complex model includes an R* form of the receptor and assumes that only
this form can bind the G-protein. This means that HR*G is the only possible active
ternary complex, with the equilibrium between R (inactive state) and R* (active
state) dependent upon both hormone and G-protein (Figure 2.1).
H + R + G HR+G
H + R* + G «+ HR* + G
H + R*G <- HR*G
Figure 2.1. The extended ternary complex model (Samama et al., 1993).
H, hormone; R, inactive receptor conformation; R*, active receptor conformation;
G, G-protein; HR, inactive hormone-receptor complex requiring isomerisation to
HR* before binding G-protein; R*G, hormone-independent receptor-G-protein
complex (constitutively active); HR*G, active ternary complex.
When the receptor is not bound to an agonist, the equilibrium is much closer
to R than R*. Constitutively active receptors result from mutation (Lefkowitz et al.,
1993). They are able to initiate a response without ligand binding, therefore, their
equilibrium when not bound to a ligand is closer to R* than normal receptors
(Samama et al., 1993). Agonists stabilise the R* conformation thereby shifting the
equilibrium towards the active state. Inverse agonists stabilise the R conformation,
thereby shifting the equilibrium towards the inactive state. Such ligands are able to
reduce the response produced by constitutively active receptors, hence the concept of
negative efficacy (Chidiac et al., 1994) (Figure 2.2). A true antagonist does not
affect the equilibrium, binding to R and R* with equal affinity. In reality, there is
probably no such entity; most antagonists are likely to be very weak partial agonists
or inverse agonists, the effect of which is below the threshold of detection. It is
highly unlikely that a molecule will bind to two different receptor conformations
with exactly the same affinity. In practice, unless there is detectable constitutive
activity, inverse agonists are indistinguishable from antagonists and are considered as





Basal response (without ligand










(without ligand, or with very
weak partial agonist, antagonist
or inverse agonist bound)
Figure 2.2. Theoretical dose-response curves for a constitutively active receptor
(A) and a normal receptor (B). Note that a 'true antagonist' does not increase or
decrease the basal response initiated by a constitutively active receptor. Inverse
agonists, partial inverse agonists, antagonists and very weak partial agonists cannot
be distinguished at a normal receptor.
Ligand binding models can achieve an even greater level of complexity if
intermediate transitional states between R and R* (R', R" etc.) are envisaged (Gether
and Kobilka, 1998). These occur sequentially following each ligand-receptor
interaction, several of which contribute to the binding energy required to stabilise
R*. The formation of such intermediates is supported by the surprisingly slow
kinetics of agonist-induced conformational changes observed with the |T adrenergic
receptor (Gether et ah, 1995). This model would also encompass sequential two-site
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binding phenomena, evidence for which has been provided for the GnRH receptor
(Fromme et ah, 2001), as well as the TRH receptor (Colson et ah, 1998; Perlman et
ah, 1997a) and muscarinic acetylcholine receptors (Jakubik et ah, 2000). The model
can be extended further by suggesting that the unbound receptor (R) has a different
conformation to that stabilised by inverse agonists (R°). This is to rationalise
observations that inverse agonists as well as agonists protect the P2 adrenergic
receptor from thermal denaturation and proteolysis (Gether and Kobilka, 1998).
Competitive antagonists bind to the ligand recognition site without causing
receptor activation. Therefore, they are able to interfere with the binding of agonists
as they are 'competing' for the same site. Such antagonists can bind reversibly or
irreversibly. Reversible competitive antagonism can be overcome by an excess of
agonist, whereas irreversible competitive antagonism cannot. A partial agonist can
act as an 'antagonist' if competing with a full agonist; although a submaximal
response will be initiated, this will be lower than if the full agonist was present by
itself. According to the model above, partial agonists may stabilise an intermediate
state (such as R' or R") or stabilise a different conformation with lower affinity for
the G-protein (Gether and Kobilka, 1998).
A non-competitive antagonist acts at a site other than the agonist recognition
site. It does not compete with the agonist; therefore excess agonist cannot overcome
its action. An example is when a molecule blocks the channel of a ligand-gated ion
channel. Increased agonist concentration actually leads to increased blockade as
more channels open (Rang et al., 1999). The above types of receptor antagonism
should not be confused with physiological antagonism, where the effect of one ligand
opposes that of another ligand acting on separate cells. The overall physiological
result is antagonism, however, the ligands do not interact with the same receptors.
Occasionally the term 'receptor' is used to describe any target molecule,
including enzymes and carrier molecules. In this thesis, a receptor is a specific
molecule, the sole function of which is to bind a specific agonist and initiate a
change in the target cell. Receptors can be divided into six superfamilies: G-protein
coupled receptors (GPCRs), direct ligand-gated ion channels, tyrosine kinase-linked
receptors, serine/threonine kinase-linked receptors, guanylate cyclase-linked
receptors and intracellular steroid/thyroid receptors. The subject of this thesis, the
GnRH receptor, is a member of the GPCR superfamily. The remaining superfamilies
are beyond the scope of review in this thesis (see reviews by Evans, 1988; Goy,
1991; Schlessinger and Ullrich, 1992; Karlin, 1993; Miyazono et al., 2001).
2.3 G-Protein-Coupled Receptors (GPCRs)
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A GPCR consists of a single polypeptide, which spans the plasma membrane
with seven a-helices connected by three extracellular and three intracellular loops
(Baldwin, 1994). The amino-terminus is extracellular and often contains
glycosolation sites (Ulloa-Aguirre et al., 1999). The carboxyl-terminus is
intracellular and, along with the intracellular loops, usually contains phosphorylation
sites important for intracellular signalling, uncoupling, desensitisation and
internalisation (Ulloa-Aguirre et al., 1999; Wess, 1998). Agonists stabilise the active
receptor conformation by binding between the transmembrane domains and/or to
sites in the extracellular loops/amino-terminus, depending on the particular ligand
and receptor (Gershengorn and Osman, 2001; Gether, 2000; Ji et al., 1998).
2.3.1 G-Proteins
Guanyl nucleotide binding proteins (G-proteins) relay the signal initiated by
agonist binding by associating with the intracellular C-terminal region and/or
intracellular loops of the receptor (Spiegel et al., 1992; Ulloa-Aguirre et al., 1999;
Wess, 1998). They consist of three subunits (a, (3, and y) of which there are several
subtypes (Wess, 1998). In the inactive form, the a-subunit binds guanosine
diphosphate (GDP) (Conklin and Bourne, 1993). In the active form, the GDP is
replaced by guanosine triphosphate (GTP). An activated GPCR (R*) catalyses the
exchange of GDP for GTP resulting in dissociation of the G-protein from the
receptor (Figure 2.3).
The a-subunit is released and activates particular signalling pathways
depending on its subtype (Table 2.1). The (3 and y-subunits remain bound together
and anchored to the plasma membrane. This complex is believed to have roles in
signalling although these are largely undefined. There is evidence for (3y-subunits
influencing adenylyl cyclase types I, II and IV, cardiac atrial potassium channels,
phospholipase C(3, phospholipase A2 and the yeast mating factor pathway (Spiegel et
al., 1992; Ulloa-Aguirre et al., 1999). (3y-subunits increase the affinity ofGPCRs for
a-subunits and are therefore likely to have a major role in regulating the selectivity
of receptor/G-protein interactions (Wess, 1998).
There are at least 20 different a-subunits, 6 different (3-subunits and 12
different y-subunits, enabling a large number of combinations (Wess, 1998). G-
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proteins are named after their a-subunits and can be classified into four major
families based on sequence homology: Gs, Gj/0, Gq/n and G12/13 (Ulloa-Aguirre et al.,
1999; Wess, 1998). Subtypes can also be categorised according to their sensitivity to
toxins (Table 2.1).
Figure 2.3. The G-protein cycle (Conklin and Bourne, 1993).
R*, activated receptor; aempty, a-subunit with empty guanine nucleotide-binding site;
E, effector; E*, activated effector; Pj, inorganic phosphate. ccempty, ccgdp and (Xgtp
have different conformations.
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Gs Gasi_4 T Adenylyl Cyclase, Ca2+ Channel
Ga0if T Adenylyl Cyclase
Gj/o G(Xii-3 F Adenylyl Cyclase, T K+ Channel ✓
Ga0i and 2 F Ca2+ Channel S
Ga,i and 2 T cGMP-phosphodiesterase
GCCgUst T cGMP-phosphodiesterase
Gaz F Adenylyl Cyclase, F K+ Channel
Gq/H Gaq T Phospholipase C(3
Gan T Phospholipase CP
Gai4_i6 T Phospholipase CP
G12/13 Gai2and 13 Na+, H+ antiporter?
Coupling to G-proteins has the capacity for considerable signal amplification
and enables large changes to be triggered in the target cell in response to a very small
external stimulus. Rhodopsin itself provides a good example of this sensitivity, as a
single photon is sufficient to excite a rod cell (Khorana, 1992). Such amplification
necessitates close control, which is provided by the intrinsic GTPase activity of the
a-subunit (Conklin and Bourne, 1993). GTP is rapidly hydrolysed to GDP.
Consequently, the a-subunit re-associates with the (3y complex, which in turn re-
associates with the GPCR. This limits the number of signalling molecules each a-
subunit can activate and enables the G-protein to return to its inactive state.
Therefore, G-proteins are recycled for subsequent activation by the GPCR (Figure
2.3). Cholera toxin inhibits GTPase activity, thereby causing persistent effector
activation (Spiegel et al., 1992).
More detailed consideration of G-proteins and intracellular signalling
mechanisms is beyond the scope of this thesis (see reviews by Spiegel et al., 1992;
Conklin and Bourne, 1993; Wess, 1998; Hur and Kim, 2002).
2.3.2 The Diversity of GPCRs
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It is currently estimated that about one thousand genes (approximately 1-3%
of a mammalian genome) code for GPCRs (Wess, 1998), each of which are
structurally and functionally related but nonetheless distinct. Indeed, the ligands
acting on these receptors are extremely diverse in size and structure, ranging from
single photons, calcium ions, through small catecholamines, to large polypeptide
hormones such as LH and FSH (see Section 2.1.2). With such ligand diversity, it is
understandable that the GPCR superfamily is also structurally diverse. Two
examples of classification schemes based on sequence homology, ligand structure
and G-protein coupling are shown in tables 2.2 and 2.3.
Table 2.2. The five family classification scheme (Kolakowski, 1994):
Family: Prototypical Receptor:
A P2 adrenergic receptor
B Calcitonin receptor
C Metabotropic glutamate receptors
D Fungal pheromone receptors
E D. discoideum cAMP receptors
Table 2.3. Classification scheme consisting of four major groups (Wess, 1998):
Class: Receptor Type:
I Rhodopsin-type receptor family (analogous to Family A)
II Secretin/glucagon receptor family (analogous to Family B)
III Metabotropic glutamate/calcium sensor receptor family, including basal
vomeronasal pheromone (type 2) receptors (analogous to Family C)
IV Subfamily of apical vomeronasal pheromone (type 1) receptors (not included
in the five family classification scheme)
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The major families are A, B and C (as these are analogous to Classes I, II and
III, the classification scheme proposed by Kolakowski will be used henceforth).
More than 90% of GPCRs belong to Family A, including the GnRH receptor
(Gershengorn and Osman, 2001). It can be subdivided into six major subgroups, as
shown in Table 2.4 (Gether, 2000; Kolakowski, 1994). The family can also be
divided according to type of Tigand', which include sensory stimuli, glycoprotein
hormones, peptides, and biogenic amines (Wess, 1998). Family A receptors have a
relatively short N-terminus and about 20 highly conserved residues in the
transmembrane helices. Only the arginine residue in the Asp-Arg-Tyr (DRY) motif
in helix 3 is completely conserved (Gether, 2000; Wess, 1998). Family B receptors
have a longer N-terminus containing 6 conserved cysteine residues. An example is
the VIPi receptor with an N-terminus of 144 amino acids (Laburthe et al., 1996). A
few residues in the transmembrane helices are conserved, however, these differ from
those conserved in Family A receptors. The DRY motif critical for the function of
Family A receptors is absent (Laburthe et al., 1996). Family C receptors possess a
much longer N-terminus than Family A or B receptors (500-600 amino acids
including 19 conserved cysteine residues) and this region is largely responsible for
ligand binding (Conn and Pin, 1997).
Table 2.4. Classification of Family A receptors into six subgroups (Gether, 2000;
Kolakowski, 1994)
Subgroup: Members:
1 Biogenic amine receptors (adrenergic, serotonin, dopamine, muscarinic,
histamine)
2 CCK, endothelin, tachykinin, neuropeptide Y, TRH, neurotensin,
bombesin and growth hormone secretagogues receptors, as well as
vertebrate opsins
3 Invertebrate opsins and bradykinin receptors
4 Adenosine, cannabinoid, melanocortin and olfactory receptors
5 Chemokine, fMLP, C5a, GnRH, eicosenoid, leukotriene, FSH, LH,




There are other groups of proteins believed to consist of seven
transmembrane helical domains not classified in the schemes above. These include
an Arabidopsis thaliana receptor, Bride of sevenless (BOSS) and the Frizzled family
(Josefsson, 1999). Much debate surrounds the classification of these groups,
particularly due to a lack of experimentally demonstrated receptor function or G-
protein coupling. The Frizzled family, for example, is increasingly believed to be
part of the GPCR superfamily (Barnes et al., 1998), following demonstration of rat
Frizzled-2 coupling to G-protein-linked inositol phosphate (IP) turnover (Slusarski et
al., 1997).
As the number and diversity of GPCRs increases, databases are becoming
increasingly important for integrating the huge body of data now available. A good
example is the GPCRDB at http://www.gpcr.org, which also contains links to other
GPCR databases (Florn et al., 1998).
2.3.3 The Structure of GPCRs
GPCRs exist in the hydrophobic environment of the lipid membrane and,
except for rhodopsin, have low abundance. They are hard to isolate in their native
form because of: their instability in environments lacking phospholipids; their
tendency to aggregate and precipitate; and the heterogeneity of preparations.
Therefore, crystals suitable for X-ray diffraction analysis are extremely difficult to
produce (Findlay and Eliopoulos, 1990; Teller et al., 2001). A variety of methods
have been used to gain insights into GPCR structure, largely involving rhodopsin and
bacteriorhodopsin.
Rhodopsin is a visual photoreceptor present in rod cells. It consists of a 40
kD protein, opsin, covalently bound to 11-cA-retinal. Absorption of a single photon
results in isomerisation of 11-cA-retinal to all-/ra/w-retinal. This alters the
conformation of the associated opsin causing activation of G-proteins (Khorana,
1992; Palczewski et al., 2000). Indeed, 11-czT-retinal is considered to act like an
inverse agonist as it stabilises the inactive receptor conformation (Gether and
Kobilka, 1998). Bacteriorhodopsin is a proton pump that utilises the energy of
photons to provide an electrochemical potential (Pebay-Peyroula et al., 1997). It is
an integral membrane protein found in Hcilobacterium salinarium (formerly
Halobacterium halobium), however it is not a GPCR. The relevance of
bacteriorhodopsin as a model for GPCRs is the topic of much debate, as discussed
later.
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The first map of bacteriorhodopsin was ascertained at 7 A using electron
microscopy and diffraction patterns (Henderson and Unwin, 1975). This showed the
seven closely packed transmembrane a-helices. Three years later, proteolysis of
bovine rhodopsin was found not to alter its circular dichroism spectrum, providing
evidence that retinal bound covalently in the hydrophobic core of the opsin protein
and the tertiary structure of this core was not influenced by the cleavage of
extracellular regions (Albert and Litman, 1978). Furthermore, this work predicted
that about 60% of the molecule was a-helical and that little if any of these helices
were extracellular. This led to the suggestion that rhodopsin contained either seven
or nine transmembrane a-helices and identified the possible structural similarity to
bacteriorhodopsin.
The hydropathy profile of bovine rhodopsin implicated the existence of seven
transmembrane domains (TMDs) (Nathans and Hogness, 1983). A similar
hydropathy profile was observed with the mammalian (3-adrenergic receptor (|3AR),
which also exhibited sequence and functional homology with rhodopsin (Dixon et
al., 1986). As more GPCRs were cloned impressive sequence homology was
discovered, particularly between the putative transmembrane domains. The first
GPCR model was produced using the multiple sequence alignment of 23 receptors
(Donnelly et al., 1989). The periodicity of conserved/non-conserved residues within
the putative TMDs was analysed, assuming that conserved residues tend to occur on
the internal facing side and the external side is more variable. These helices were
termed 'amphipathic'. As multiple sequence alignments became important for
identifying putative GPCRs and gaining structural insights, database pattern-
scanning methods were used in an attempt to maximise the accuracy of such
alignments (Attwood et al., 1991).
A map of bacteriorhodopsin was produced at 3.5 A resolution, using electron
cryo-microscopy (Henderson et al., 1990). This provided detailed structural
information on the heptahelical membrane protein and the potential for new insights
into GPCR structure. However, despite both having seven transmembrane helices,
rhodopsin exhibited little sequence homology with bacteriorhodopsin, calling into
question the validity of bacteriorhodopsin as a template for GPCRs (Pardo et al.,
1992). It was even suggested that exon shuffling might have resulted in a change in
helical sequential order, as greater homology was found if the order of helices was
ignored (Pardo et al., 1992).
Rhodopsin remained the GPCR for which most structural data was available
(Khorana, 1992) and the next breakthrough came when two-dimensional crystals of
bovine rhodopsin were obtained, allowing a projection density map to be produced at
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9 A resolution (Schertler et al., 1993). Density peaks representing the seven
transmembrane helices were observed, mostly oriented perpendicular to the plane of
the membrane (Figure 2.4). The probable arrangement of GPCR TMDs was
subsequently predicted based on this projection map (Baldwin, 1993). 204 GPCR
sequences of 105 different types were aligned and analysed, enabling a variety of
insights to be made. As each type of inter-helical loop was often short in length, it
was deduced that helices proximal in the one-dimensional sequence were also
proximal in the three-dimensional structure. This agreed with the model proposed by
Donnelly and co-workers. Baldwin also exploited the concept of conserved/non-
conserved residue periodicity as described previously (Donnelly et ah, 1989).
Additionally Baldwin identified positions where: variability was restricted; polar
residues could be accommodated; closely related sequences were different; and
ligands were believed to bind. The environment of the helices was found to be
different, with TMDs 1, 4 and 5 most exposed to the lipid membrane and TMD 3
least exposed. The combination of all these data enabled the orientation of the
helices to be predicted and their tentative assignment to the density peaks observed
for rhodopsin (Baldwin, 1993). TMDs 1, 2 and 3 were believed to be sloping,
thereby producing the elongated curved region observed in the projection map
(Schertler et ah, 1993). The least exposed helix, TMD 3, was assigned to the end of
this region surrounded by other helices. TMDs 4, 5, 6 and 7, believed to be nearly
perpendicular to the membrane, were assigned to the four distinct density peaks
(Figure 2.4).
The predicted arrangement of TMDs in rhodopsin differed from that observed
in bacteriorhodopsin (Baldwin, 1993). This was attributed to the helices sloping
differently relative to the plane of the membrane, a conclusion supported by the
different positions of conserved proline residues. An alternative explanation was that
differences in helical packing or in crystallisation conditions had resulted in the map
of rhodopsin (Schertler et ah, 1993) being rotated approximately 15° relative to the
map of bacteriorhodopsin (Henderson et ah, 1990), thus showing very similar
structures from a different angle (Hoflack et ah, 1994). However, the lack of
evidence for an evolutionary link between these proteins continued to undermine the
use of bacteriorhodopsin as a template for GPCRs (Soppa, 1994).
Higher resolution projection maps of frog rhodopsin in two crystal forms
were produced, at 7 and 6 A (Schertler and Hargrave, 1995). These showed virtually
identical structures to the 9 A map, although helix 5 appeared to slope more than
previously believed. TMDs 1, 2 and 3 were still not resolved, being represented by
an elongated region of electron density as before. Evidence for a similar
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arrangement of TMDs in adrenergic receptors compared with bacteriorhodopsin was
presented (Mizobe et al., 1996), however, this study did not address the increasingly
apparent differences in helical tilting and bending between bacteriorhodopsin and
GPCRs. These differences became clearer following X-ray crystallography of
bacteriorhodopsin at 2.5 A resolution (Pebay-Peyroula et ah, 1997) and electron
cryo-microscopy of frog rhodopsin (Unger et al., 1997). The latter study produced a
map with an effective resolution of 7.5 A in the plane of the membrane and 16.5 A
normal to it, resolving all seven TMDs for the first time. Tilt angles for the helices
were estimated, ignoring possible curvature or kinks (Table 2.5). TMD 4 was
believed to be the shortest helix, being almost perpendicular to the plane of the
membrane. As suggested previously, TMDs 1, 2, 3 and 5 were believed to be
sloping significantly, particularly TMD 3. The helices were shown to be closely
packed towards the intracellular side and more open towards the extracellular side,
with TMDs 3, 4, 5, 6 and 7 forming a cavity for retinal binding.
Figure 2.4. A simplified representation of the projection density map of rhodopsin
at 9 A resolution, showing the assignment of helices 1-7 to the density peaks
(Baldwin, 1993; Schertleret al., 1993).
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The major breakthrough came with the three-dimensional crystal structure of
bovine rhodopsin at 2.8 A resolution (Palczewski et ah, 2000). This modelled 97.1%
of the opsin molecule in the ground state, enabling the detailed structure of a GPCR
to be visualised for the first time. Residues 236-240 in intracellular loop 2 (ICL2)
and 331-333 in the C-terminus could not be mapped. Residues 334-338 had electron
density, but of poor quality. These regions were believed to be particularly flexible
and lack a single conformation. The remaining residues were successfully mapped,
enabling their positions and interactions to be ascertained. A summary of key
structural information is shown in Table 2.5. The structure, including overall helical
tilt angles, was consistent with the low resolution map of frog rhodopsin (Unger et
al., 1997). Following the superposition of rhodopsin on bacteriorhodopsin, TMDs 1,
2 and 3 superimposed reasonably well, however, TMDs 4 and 5 did not superimpose.
Different twists and kinks, as well as slightly longer helices in rhodopsin, added to
the disparity (Teller et al., 2001). Although studies of bacteriorhodopsin provided a
useful framework for early GPCR models, it is clear that such a role in the future is
inappropriate.
Table 2.5. Structural data for the transmembrane helices of rhodopsin.
Data produced from high resolution structure of bovine rhodopsin (Teller et al.,
2001). Overall tilt angles estimatedfrom low resolution structure offrog rhodopsin
included in brackets for comparison (Unger et al., 1997).
Length: Overall Bends within helix:
TMD: Residues: A Tilt Angle3:
Angles: Positions:
1 34-64 45 25° (28.4°) 12° Pro53
2 71-100 40 25° (27.2°) GO oo Gly89-Gly90
3 106-139 48 33° (29.6°) 12°, 11° Gly120-Gly121, Ser127
4 150-172 33 1° (3.8°) 30° Pro170-Pro171
5 200-225 36 26° (22.7°) 25°, 15° Phe203, His211
6 244-276 47 5°(7.4°) 36° Pro267
7 286-309 37 9° (13.4°) 24°, 21° Pro291, Pro303
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a, 0° defined as perpendicular to the plane of the membrane.
Rhodopsin has appreciable sequence homology with other GPCRs,
particularly in the TMDs (Josefsson, 1999; Probst et ah, 1992). Therefore, models
based on rhodopsin are likely to provide a good approximation of the membrane-
spanning region of other GPCRs, particularly those with highest homology such as
other members of Family A (Ballesteros et al., 2001). However, rhodopsin is
fundamentally different from most GPCRs. The binding of a ligand does not activate
the opsin protein as its Tigand', 11-cks-retinal, is constantly bound (Gether and
Kobilka, 1998; Palczewski et al., 2000). Most GPCRs are activated by diffusible
ligands that enter a binding pocket between the TMDs and/or interact with sites in
the extracellular domains (Baldwin, 1994; Gether, 2000; Strader et al., 1995). Little
if any information regarding the spatial arrangements of extracellular loops (ECLs)
or the N-terminus of other GPCRs can be derived from the crystal structure of
rhodopsin, particularly as residues 177-190 in ECL2 form a twisted (3-turn that
'plugs' the extracellular end of the retinal binding pocket. This structure would
prevent a diffusible ligand entering the binding pocket unless it moved considerably
in the transition from ground to high affinity state (Teller et al., 2001). The huge size
range of extracellular domains in different GPCRs demonstrates the lack of structural
as well as sequence homology in these regions (Gether, 2000).
2.3.4 Conserved Motifs
The vast majority of GPCRs appear to possess a disulphide bond connecting
highly conserved cysteine residues in ECLs 1 and 2 (Gether, 2000; Probst et al.,
1992) (Figure 2.5). This bond has been shown to be critical for stabilising correct
receptor conformation in the GnRH receptor (Davidson et al., 1997), as it has with
several other GPCRs (Table 2.6). It was predicted that all GPCRs would possess this
motif (Strader et al., 1994). However, evidence from the VIPi receptor, a member of
Family B, indicates otherwise. This receptor contains the highly conserved cysteine
residues in ECLs 1 and 2, and mutation of the ECL2 cysteine abolishes ligand
binding (Gaudin et al., 1995). However, mutation of either or both cysteines in
ECL1 does not have this effect. Instead, it is postulated that the cysteine in ECL2
interacts with one of the cysteines in the N-terminus (Laburthe et al., 1996). This
important structural difference may actually be due to a common function. In the
GnRH receptor, a number of agonist contact sites have been identified in ECL1 and
the adjoining TMDs (see Section 2.7.2). A critical residue for biogenic amine
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binding is Asp3 32 (Figure 2.5), again in one of the TMDs adjoining ECL1 (Strader et
al., 1994). As with the GnRH receptor, these receptors require the disulphide bond
linking ECLs 1 and 2 (Dohlman et ah, 1990; Savarese et ah, 1992). In contrast, the
VIP i receptor ligand binding sites are believed to be primarily located in the N-
terminus (Laburthe et ah, 1996). Therefore, the postulated disulphide bond in this
receptor would again link the key ligand binding region with ECL2.
Receptors show much greater similarity within families (see Section 2.3.2).
The GnRH receptor belongs to Family A, whose members share a number of motifs
(Figure 2.5). Most possess an intracellular C-terminal tail, usually containing at least
one palmitoylated cysteine residue (O'Dowd et ah, 1989) (Figure 2.5). Mammalian
type I GnRH receptors are exceptional in not possessing such a tail (Sealfon et ah,
1997).
Proline residues in TMDs 4, 5, 6 and 7 are highly conserved: the kinks they
introduce are likely to be important for configuring the ligand binding pocket and
structural changes involved in activation (Probst et ah, 1992). The conformations of
TMDs 4, 6 and 7 in rhodopsin resulting from proline kinks (Table 2.5) are likely to
be similar in other Family A GPCRs (Ballesteros et ah, 2001). TMD 5 in rhodopsin
appears to possess an unusual local unwinding around His211(5 46) (number in brackets
facilitates comparisons between GPCRs, as proposed by Ballesteros and Weinstein,
1995. See page xii and Section 3.1). This counteracts the kinking effect of
Pro215(5 50) and is probably due to an unconsented interaction with Glul22(3'37) in TMD
3 (Beck et al., 1998). It has been suggested that the kinking of conserved Pro3 30 in
other GPCRs, in conjunction with local distortions around certain serine residues,
results in a similar overall structure of TMD 5 to that observed in rhodopsin
(Ballesteros et al., 2001). This has been termed 'structural mimicry'.
Table 2.6. Examples of receptors in which the disulphide bond connecting ECLs
1 and 2 has been shown to be critical for receptor configuration
Receptor: Reference:
Rhodopsin (Davidson et al., 1994; Karnik and Khorana, 1990)
adrenergic (Dohlman et al., 1990)
Mi muscarinic acetylcholine (Savarese et al., 1992)
Angiotensin II (Ohyama et al., 1995; Yamano et al., 1992)
GnRH (Cook and Eidne, 1997; Davidson et al., 1997)
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Differences in the locality of the binding pocket may reflect differences in
cognate ligands. The similar overall conformation of GPCRs enables them to signal
via a common mechanism (Oliveira et al., 1994), meanwhile differences enable them
to interact with a remarkable range of structurally diverse ligands (Gether, 2000).
The concept that GPCRs are 'the same and not the same' (Sakmar, 2002) will be
continually revisited throughout this thesis.
At this stage, it is important to reiterate that the 2.8 A resolution map of
rhodopsin shows the inactive state (Palczewski et al., 2000) and that retinal has been
described as functioning as an inverse agonist (Gether and Kobilka, 1998).
Activation of rhodopsin results in significant TMD conformational changes,
particularly of TMDs 3 and 4, but also of others (Meng and Bourne, 2001).
Structural inferences from ligand binding studies of other GPCRs may imply a
different conformation to rhodopsin, however, as agonists preferentially bind to the
active receptor conformation, such discrepancies may also be due to the difference in
functional state (Ballesteros et al., 2001). Until another GPCR is crystallised, and
rhodopsin is crystallised in the active conformation, one can only speculate.
The rhodopsin crystal structure indicates that the conserved Asn33(l'30) and
Asp83(2'30> residues in TMDs 1 and 2 respectively are able to hydrogen bond with the
peptide carbonyl of Ala299(7 46) in TMD 7 (Palczewski et al., 2000). The conserved
Asn7'49 is positioned one helical turn from the residue in position 7.46 (Figure 2.5).
Evidence for the proximity of Asp2 30 and Asn7 49 had been presented for the
serotonin 5-HT2A receptor (Sealfon et al., 1995). Mutation of Asp2 30 to Asn
eliminated coupling to IP turnover, however, this mutation in combination with
Asn7 49 to Asp partially restored function. Aspartate residues in both positions were
tolerated, albeit with a lower maximal response. Interactions between Asn130,
Asp2 30 and Asn7 49 in the 5-HT2A receptor, as well as in the thyrotropin-releasing
hormone receptor, were proposed to influence receptor activation (Konvicka et al.,
1998; Perlman et al., 1997b). Mutagenesis studies ofmany GPCRs have shown the
importance of these three positions in G-protein coupling (Table 2.7). Asp2 30 has
been particularly well studied, with mutation resulting in decreased agonist affinity
in the majority of cases (van Rhee and Jacobson, 1996).
The GnRH receptor is unusual, as the Asp2 50/Asn7 49 motif is not conserved.
In mammalian type I GnRH receptors, the reciprocal arrangement is present
(Asn2 30/Asp7 49). Mutation of Asn2 50 to Asp in the mouse GnRH receptor abolished
detectable ligand binding, hence the inability to establish the role of this particular
residue in G-protein coupling (Flanagan et al., 1999; Zhou et al., 1994).
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Table 2.7. Examples of receptors in which mutations of conserved residues in
TMDs 1,2,3 and 7 have been shown to influence G-protein coupling
Residue: Receptor: Reference:











ET-A and ET-B endothelin
Thyrotropin-releasing hormone
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(Gales et ah, 2000)
(Govaerts et ah, 2001)
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Ligand binding at the Asp7 49Asn mutant mouse receptor was similar to that at
the wild type mouse receptor, as was binding at the reciprocal Asn2 5°Asp/Asp7 49Asn
mutant receptor. However, both mutant receptors exhibited poor coupling efficiency
(3-4% of wild type) (Flanagan et ah, 1999; Zhou et ah, 1994), and so Asp7 49 is
essential for receptor activation. Mammalian type II and non-mammalian GnRH
receptors have aspartate residues in both positions (see Section 2.5), a situation
tolerated in many GPCRs, but not in mammalian type I GnRH receptors (Flanagan et
2 50
al., 1999; Zhou et al., 1994). Mutation of Asp to Asn, singly or in combination
with Asp749 to Asn, abolished ligand binding at the catfish GnRH receptor
(Blomenrohr et al., 1997). A subsequent study found that the double mutation of
Asp2 50 to Asn and Met2 53 to Glu in the catfish GnRH receptor, thereby recreating the
situation in mammalian type I GnRH receptors, restored binding and coupling to IP
turnover (Blomenrohr et al., 2001). The overall structure and agonist binding mode
appears to be similar in mammalian and non-mammalian GnRH receptors. However,
localised differences in structure may contribute to differences in ligand selectivity
(Blomenrohr et al., 2001). Mutation of Asp7 49 in the mouse GnRH receptor resulted
in the abolition of initial receptor down-regulation in certain cell lines. Coupling to
IP turnover was attenuated, but not coupling to cAMP (Awara et al., 1996).
Additionally this locus excludes coupling to phospholipase D, as mutation of Asp7 49
to Asn resulted in sensitivity to inhibitors of ARF, a small G-protein that controls
phospholipase D (Awara et al., 1996; Flanagan et al., 1999). The opposite mutation
in the 5-HT2A receptor resulted in decreased sensitivity to the inhibitor (Mitchell et
al., 1998). In the P2 adrenergic receptor, mutation of Asn7 49 to Ala resulted in loss of
high affinity agonist binding and abolition of receptor sequestration, down-regulation
and phosphorylation, in addition to uncoupling (Barak et al., 1995).
The Asn/Asp7 49 residue is part of the highly conserved (N/D)PX2-3Y motif in
TMD 7 (Figure 2.5). As well as mutations of Asn/Asp749 influencing G-protein
1 CQ
coupling, studies have also shown impaired coupling following substitution of Pro '
or Tyr7'5377'54, indicating the importance of the motif and not just Asn/Asp749
(Hunyady et al., 1995; Arora et al., 1996; Barak et al., 1995). Mutation of Pro7 30 or
Tyr7 53 in the P2 adrenergic receptor had milder effects than mutation of Asn7'49, but
insertion of an alanine, thereby separating the proline and tyrosine residues by three
rather than two residues, resulted in an inactive receptor (Barak et al., 1995). The
GnRH receptor exhibited G-protein activation, IP turnover and internalisation similar
to wild type despite mutation of Tyr322<-7'53) to Phe. This was in contrast to the
Tyr322(7 53) to Ala mutation abolishing coupling to IP turnover (Arora et al., 1996).
The aromatic nature of this residue appears to be critical in the GnRH receptor.
27
Family A GPCRs characteristically contain Arg3 50 (Figure 2.5) and there are
many examples of receptors in which mutation of this residue abolishes G-protein
coupling (Table 2.7), including the GnRJf receptor (Arora et al., 1997; Ballesteros et
al., 1998). Asp3 49 and Tyr3'51 are present in most Family A GPCRs (Probst et al.,
1992). GnRH receptors are in the minority as they have Ser, Phe, Gin or His in place
of Tyr3 51 (see Section 2.5). Mutation of Serl40(3 :>1) to Tyr in the mouse GnRH
receptor did not affect IP turnover, however, both agonist binding affinity and
ligand-induced internalisation increased (Arora et al., 1995). Mutation of Serl40(3 3l)
to Ala did not affect agonist binding, expression, signalling or internalisation,
whereas mutation of Asp3 49 to Asn or Glu decreased expression, and increased
signalling and internalisation, without affecting agonist binding (Arora et al., 1997).
The position and orientation of the 'DRS' motif in the mouse GnRH receptor was
shown to be critical for G-protein coupling by inserting successive alanine residues
before or after the motif (Kitanovic et al., 2001). The 'DRY' motif is part of a larger
'(I/L)XXDRYXX(V/I)XXPL' consensus sequence (Figure 2.5), which appears to
have an important role in receptor function (Arora et al., 1995; Ballesteros et al.,
1998). In the GnRH receptor, internalisation and IP turnover were both reduced by
mutation of Leul47(3 s8) to Ala or Asp (Arora et al., 1995).
Two other highly conserved residues are Phe6 44 and Trp6 48 in TMD6 (Probst
ft 48
et al., 1992) (Figure 2.5). Trp is part of an aromatic locus believed to have a role
in agonist binding at the GnRH receptor (Chauvin et al., 2000) (see Section 2.7.2).
2.3.5 Summary
The GnRH receptor belongs to a superfamily characterised by a common
overall structure (consisting of seven TMDs) and signalling mechanism (involving
G-proteins). This GPCR superfamily is large, structurally diverse, interacts with
many types of ligand and potentially couples to multiple combinations of G-protein
subunits, as well as non-G-protein mediators of signalling. Despite this diversity,
many features are conserved and insights into the structure and function of an
individual GPCR can be gained from analysis of other GPCRs. Residues conserved
between the members of Family A are usually involved in activation or overall
receptor configuration, illustrating that structurally diverse agonists initiate signalling
through common mechanisms. Structural data derived from studies of rhodopsin are
particularly important as a framework for modelling the GnRH receptor, although it
is equally important to appreciate the limitations of such a framework.
2.4 Comparison of Different GnRHs
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14 structural forms of GnRH have been identified in chordates and a further 2
forms in a protochordate (tunicate) (Table 2.8). The peptide length of 10 amino
acids has been completely conserved for more than 500 million years of evolution
(Millar, 2002). The N (pGlu'-His2-Trp3-Ser4) and C (Pro9-Gly10-NH2) termini
(shown in red in Table 2.8) are totally conserved, except for guinea pig and lamprey I
GnRHs where a conservative substitution occurs in position 2 or 3. The N-terminus
is believed to be involved in receptor binding and activation, while the C-terminus is
believed to be involved only in receptor binding (Sealfon et ah, 1997). The residue
in position 8 is the most variable, but has an important role in the binding of
mammalian GnRH (mGnRH) to its cognate receptors (see Section 2.7.2).
The remainder of the peptide is important for configuring the N and C-
termini so that they are correctly oriented for interaction with the receptor. The
residue in position 6 is particularly important and is glycine in all GnRHs from jawed
vertebrates (shown in orange in Table 2.8) (see Sections 2.6.2 and 2.6.4).
Multiple forms ofGnRH have been demonstrated in the same organism (King
and Millar, 1992). Generally, fish have GnRH II, salmon GnRH (sGnRH) and a
third form; birds and reptiles have GnRH II and chicken GnRH I (cGnRH I); and
amphibians and mammals have GnRH II and mGnRH (King and Millar, 1992).
Amphibians may possess a third form that is yet unidentified. The gene coding for
GnRH II has been demonstrated in the human on chromosome 20, distinct from the
gene coding for mGnRH on chromosome 8 (White et ah, 1998). GnRH II has
historically been called chicken GnRH II (cGnRH II) as it was first identified in the
chicken (Miyamoto et ah, 1984). However, since it has now been identified in the
majority of vertebrates, it will be termed GnRH II in this thesis.
Algorithms have been used to produce phylogenetic trees of GnRH peptide
evolution by comparing prepro-GnRH sequences (King and Millar, 1992; Okubo et
ah, 2000a; White et ah, 1995). Jawed vertebrate GnRHs were originally grouped
into two evolutionary branches: GnRH II was separated from other GnRHs as its
primary structure has been completely conserved through 500 million years (King
and Millar, 1992). More recently, three branches have been proposed, namely GnRH
I (releasing forms), GnRH II (mesencephalic forms) and GnRH III (sGnRH)
(telencephalic forms) (Okubo et ah, 2000a; White et ah, 1995). None of these
schemes included the invertebrate tunicate GnRHs or the jawless vertebrate lamprey
GnRHs.




































































































































































































2.5 Comparison of Different GnRH Receptors
Type I GnRH receptors have now been cloned from at least 21 different
species of chordates (12 mammalian and 9 non-mammalian) (Table 2.9). At least 6
Type II (3 mammalian and 3 non-mammalian) and 3 Type III GnRH receptors have
also been cloned (Table 2.9). Additionally, GnRH receptor orthologues have
recently been identified in Drosophila melanogaster (Hauser et ah, 1998) and C.
elegans (Swanson et ah, unpublished results).
GnRH receptors have been classified as type I, II or III based on sequence
homology (Table 2.9). It should be noted that the three types of bullfrog GnRH
receptor were originally classified according to tissue distribution, and not according
to sequence homology with previously cloned GnRH receptors (Wang et ah, 2001).
Therefore, the bullfrog receptor classified as type II by Wang and co-workers is a
type I receptor according to sequence homology (Table 2.9), and the bullfrog
receptor classified as type III by Wang and co-workers is a type II receptor according
to sequence homology. This leaves the bullfrog type I receptor that should be
classified as a type III receptor according to sequence homology. This situation is
extremely confusing and so for the sake of simplicity, the bullfrog receptors will be
designated as type I, II and III according to sequence homology throughout this
thesis. Similarly, Okubo and co-workers named the two medaka GnRH receptors
that they cloned 'Medaka GnRH-Rl' and 'Medaka GnRH-R2'. However, according
to sequence homology, Medaka GnRH-Rl is a Type III GnRH receptor and Medaka
GnRH-R2 is a Type I GnRH receptor (Table 2.9). They will also be designated
according to sequence homology throughout this thesis.
Type I GnRH receptors cloned from eutherian mammals exhibit high overall
amino acid sequence homology (85% or greater) with almost identical TMD amino
acid sequences (Sealfon et ah, 1997). The lack of an intracellular C-terminal tail and
the particular Asp/Asn arrangement in TMDs 2 and 7 are exceptional for GPCRs.
Key functional motifs (see Section 2.3.4) are conserved, with the exception of the
marmoset type I receptor that has Ser3 ?l of the 'DRS' motif replaced by Phe. This
substitution may have a role in desensitisation/internalisation (Byrne et ah, 1999).
The Australian brushtail possum is a metatherian marsupial mammal, and is
therefore distinct from the eutherian mammals from which GnRH receptors have
been cloned (Table 2.9). Despite this, the possum GnRH receptor is very similar to
other mammalian type I GnRH receptors in both structure and pharmacology. It
exhibits 80% sequence homology and lacks an intracellular C-terminal tail (King et
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al., 2000). However, like the marmoset, it has Ser331 replaced by Phe (King et ah,
2000). A second marsupial GnRH receptor was recently cloned from the wallaby
(Cheung and Hearn, 2002) and is apparently very similar to the possum receptor.
Mammalian type II GnRH receptors have Gin3'51, and non-mammalian GnRH
351*351
receptors have Gin or His (see Table 2.9 for references and Figure 2.6 for
examples). The impact of these substitutions has yet to be established.
A cysteine residue in ECL2 that is highly conserved amongst Family A
GPCRs was discussed in Section 2.3.4. A second cysteine residue is conserved in
ECL2 of all mammalian type I GnRH receptors, with the apparent exception of the
pig. Furthermore, a cysteine residue is conserved in the N-terminus of all
mammalian type I GnRH receptors (at position 14, except in the dog where it is at
position 13) (Figure 2.6). Evidence has been presented for these cysteine residues
forming a disulphide bond (Davidson et al., 1997), although the disruption of this
bond appeared to have little affect on the binding of [D-Trp6,des-Gly'°]-GnRH (Cook
and Eidne, 1997). The N-terminus/ECL2 disulphide bond is not present in
mammalian type II and non-mammalian GnRH receptors as the cysteines are not
conserved. Therefore, the configuration of the extracellular domains of these
receptors is likely to differ significantly from that of the mammalian type I receptors.
An important locus for Family A GPCR configuration involves the residues
in positions 2.50 and 7.49 in TMDs 2 and 7 respectively (see Section 2.3.4).
Mammalian type I GnRH receptors have Asn2 30 and Asp7 49, whereas mammalian
type II and non-mammalian GnRH receptors have Asp2 30 and Asp7 49 (Figure 2.6).
Therefore, as discussed in Section 2.3.4, these differences between mammalian type I
receptors and other GnRH receptors at this locus suggest that interactions in this
microdomain differ, and that the TMD configuration of these receptors may also
differ (Blomenrohr et al., 1997; Sun et al., 2001).
ECL3 in mammalian type I GnRH receptors is likely to have a different
configuration to ECL3 in other GnRH receptors, due to the altered positioning of
proline residues. Mammalian type I GnRH receptors have the motif 'S(D/E)P',
whereas non-mammalian type I GnRH receptors have 'P(D/E)Y'. This may alter the
7 ^9
presentation of Asp/Glu (Flanagan et al., 1997; Petry et al., 2002), which has been
shown to interact with Arg8 in mGnRH (Blomenrohr et al., 2002; Flanagan et al.,
1994; Fromme et al., 2001) (see Section 2.7.2). Type II GnRH receptors have the
motif 'PPS'; and type III GnRH receptors have the motif 'S(H/Q)S'. The lack of an
acidic residue at position 7.32 is likely to contribute to the relatively low IP turnover
following binding ofmGnRH at such receptors (Wang et al., 2001).
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Table 2.9. Classification ofGnRH Receptor cDNA based on sequence homology
(Bullfrog and Medaka original classifications in brackets)
Species: Reference:
Type I Mouse (Reinhart et ah, 1992;
Mammalian Tsutsumi et ah, 1992)
Rat (Eidne et ah, 1992; Kaiser et ah, 1992)
Sheep (Brooks et ah, 1993; filing et al., 1993)
Cow (Kakar et al., 1993)
Human (Chi et al., 1993; Kakar et al., 1992)
Pig (Weesner and Matteri, 1994)
Marmoset I (Byrne et al., 1999)
Dog (Cui et al., 2000)
Bonnet Monkey (Santra et al., 2000)
Horse AF 018072
Possum (King et al., 2000)
Wallaby (Cheung and Hearn, 2002)
Type I Non- Catfish (Tensen et al., 1997)
Mammalian Goldfish (la and lb) (filing et al., 1999)
Xenopus laevis I (Troskie et al., 2000)
Trout (Madigou et al., 2000)
Japanese eel (Okubo et al., 2000b)
Cichlid (Robison et al., 2001)
Medaka I (Okubo: 2) (Okubo et al., 2001)
Chicken (Sun et al., 2001)
Bullfrog I (Wang: II) (Wang et al.,2001)
Type II Marmoset II (Millar et al., 2001)
Mammalian Green monkey II (Neill et al.,2001)
Rhesus monkey II (Neill et al.,2001)
Type II Non- Bullfrog II (Wang: III) (Wang et al., 2001)
Mammalian Typhlonectes natans II AF 174481
Xenopus laevis II Troskie et al. (unpublished results)
Type III Striped bass III (Alok et al., 2000)
Bullfrog III (Wang: I) (Wang et al., 2001)
Medaka III (Okubo: 1) (Okubo et al., 2001)
Amberjack III CAB 65407
33
Figure 2.6. Sequence alignment of GnRH receptors examined in this thesis (the
marmoset type II GnRH receptor is included for comparison). Note the differences
in structural motifs between mammalian type I GnRH receptors and other forms of
GnRH receptor, both mammalian and non-mammalian. In particular, note the lack of
a C-terminal domain in mammalian type I GnRH receptors.
Transmembrane domains (TMDs) indicated in red (precise TMD boundaries are unknown).
Extracellular domains (ECLs) indicated in black and intracellular domains (ICLs) indicated in green.
Residues involved in structural motifs that differ between mammalian type I GnRH receptors and
other forms ofGnRH receptors indicated in blue.
N-Terminus
Mouse MANNASLEQDPNH CSAINN 19
Rat MANNASLEQDQNH CSAINN 19
Human MANSASPEQNQNH CSAINN 19
Catfish M-SGNTTLLLSNPTN VLDNSSVL 22
Chicken M-CVPAALIEAEPPH HPTTEGDT 22
Marmoset (II) MSAVN GTPWGSSARE - - EVW 18
Xenopus (II) MDSQD LCALNR-—SCFHLKEQEKT 22






















Catfish ASNLSVLLSVTR G-RGRRLASHLRPLIASLASAD 90
Chicken CSNTAVLGSLLR- -KRRKCHVRPLILSLALAD 87
Marmoset (II) GGNLAVLWSVTR PQPSQLRPSPVRRLFAHLAAAD 86
Xenopus (II) CFNIAALWTITY- -KYK KKSHIRILIINLVAAD 90




















































































FTLT RVLHQDPHELQLNQSK-NNIPRARLKTL 2 6 6
VEIN--RQMHRSKDKAGEPCLRRSGTDMIPKARMKTL 268












































CWRNQNASAKS LPHFS GHRREVSG 3 64
-RGIEAAISQH- -VRHKPISVSEKTTKDG 355
CRRGHQELSMDSSREEGSRRMFQQDIQALRQT 358














2.6 GnRH Ligand Structure-Activity Relationships
2.6.1 The Bioactive Conformation of GPCR Ligands
Ligands such as GnRH are flexible molecules that will adopt a variety of
conformations in solution (Maliekal et al., 1997; Momany, 1976a). Each
'conformed will have a particular energy, with the most stable conformers having
the lowest energy. An equilibrium will exist between the various conformers at any
one time. The greater the percentage ofmolecules in the bioactive conformation, the
greater the binding affinity at the cognate receptor (Freidinger et al., 1980).
Intramolecular interactions can increase the stability of the bioactive conformation,
and there is evidence for this phenomenon in GnRHs (Maliekal et al., 1997; Milton
et al., 1983; Shinitzky and Fridkin, 1976; Shinitzky et al., 1976).
In addition to these intramolecular interactions, there is increasing evidence
for the environment influencing ligand conformation (Laakkonen et al., 1996). This
includes both the solvent and the receptor (Koerber et al., 2000; Mezei and
Guarnieri, 1998). Changes upon binding at the receptor may be due to desolvation or
specific interactions with receptor residues. There is evidence from the TRH and
P2Yi receptors that multiple interactions occur sequentially (Colson et al., 1998;
Moro et al., 1999; Perlman et al., 1997a). In the case of a flexible ligand, initial
contacts may stabilise the bioactive conformation, lowering the energy requirement
for subsequent interactions. Such 'induced-fit' may have evolved to increase ligand-
receptor specificity and/or reduce the need for ligand pre-configuration. An
interaction between Arg8 in mGnRH and ECL3 of the cognate receptor is proposed
to be such a ligand-conforming initial interaction (Fromme et al., 2001).
Various studies have provided insights into the bioactive conformations of
ligands acting at GPCRs, and those involving GnRH will be discussed in Section
2.6.4. Due to the structural diversity of peptide GPCR ligands, it is unlikely that
insights into the bioactive conformation of GnRH will be gained by comparison with
ligands that act at other GPCRs. Tachykinin receptors bind peptide agonists of a
similar size to GnRH, namely the undecapeptides substance P, eledoisin and
physalaemin, and the decapeptides neurokinin A (substance K) and neurokinin B
i j r
(Rang et al., 1999). However, the conformations of I-Bolton Hunter-conjugated
(125I-BH) substance P and 125I-BH eledoisin are unlikely to contain a (3-IT turn
(Cascieri et al., 1986), as predicted for mGnRH (Momany, 1976a). A study of the C-
terminal heptapeptide of neurokinin A, which is more active than the parent
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compound, implied that a turn from Ser5 to Gly8 was present in the bioactive
conformation, but was of the (3-1 type (Saviano et al., 1991).
2.6.2 Substitutions that Enhance the Activity of GnRH
A multitude of GnRH analogues have been generated to investigate the roles
of different residues in GnRH function (Sealfon et al., 1997). As early as 1973, it
was shown that replacement of Gly6 with Ala resulted in an analogue with 4% of the
activity of mGnRH both in vivo and in vitro. In contrast, replacement with D-Ala
resulted in 350-450% of the activity of mGnRH (Monahan et al., 1973). These
changes in potency have been attributed to effects on ligand conformation (see
Section 2.6.4). Bulky hydrophobic D-amino acids were found to be the most
biologically active, due to a combination of increased receptor affinity and increased
biological half-life (Coy et al., 1976; Karten and Rivier, 1986; Nestor et al., 1984;
Sealfon et al., 1997). However, the relationship between hydrophobicity and activity
is not absolute: [D-Nal(2)6]-GnRH was reportedly 200 times more potent than GnRH
in suppressing estrus in rats, but analogues with greater hydrophobicity were less
potent (Nestor et al., 1984). This was perhaps due to other factors such as steric
hindrance, insolubility or partition to the lipid environment. Aromatic side chains
appear to be favoured (Nestor et al., 1984), perhaps due to the formation of pi
electron complexes. The effects of various D-amino acid substitutions in position 6
ofmGnRH, cGnRH I, sGnRH and GnRH II are described in Chapter 4.
As well as position 6, activity-enhancing substitutions have been made at
position 10. Replacing the C-terminus with Pro9-ethylamide (Pro9-NHEt) resulted in
an analogue 5 times more potent than mGnRH at inducing ovulation (Fujino et al.,
1972). Again, combining this modification with a D-amino acid at position 6 resulted
in a cumulative increase in potency (Coy et al., 1974). In this study, [D-Ala6]-GnRH
was 8 times more potent than mGnRH, whereas [D-Ala6,Pro9-NHEt]-GnRH was 16
times more potent than mGnRH. Replacement of the C-terminus with aza-Gly10 is
even more effective, as demonstrated by [D-Ser(tBu)6,aza-Gly'°]-GnRH being at
least 5 times more potent than [D-Ser(tBu)6,Pro9-NHEt]-GnRH at inducing ovulation
(Dutta et al., 1978). Indeed, an extremely potent agonist is [D-Nal(2)6,aza-Gly10]-
GnRH, which is about 230 times more potent than native mGnRH (Ho et al., 1984).
Other substitutions, such as 3-(l-naphthyl)alanine (Nal(l)) in place of Trp3
(Yabe et al., 1976), gave small increases in potency. (A^-Me)Leu in place of Leu7
did not alter the biological activity of mGnRH on its own (Ling and Vale, 1975),
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however, it did appear to increase the potency of some analogues containing a D-
amino acid in position 6 (Karten and Rivier, 1986; Nestor et ah, 1984).
Certain substitutions did not significantly improve the affinity ofmGnRH for
its cognate receptor, but were tolerated nonetheless. Notable examples were His5
and Trp7, singly or in combination (Millar et ah, 1989). Tyr8 substitution was not
tolerated on its own, or in combination with Trp7. However, the affinity of
5 8
[His ,Tyr ]-GnRH for rat homogenised pituitary membranes was only 10-fold lower
than that of mGnRH (Millar et ah, 1989). The affinity of GnRH II ([His5,Trp7,Tyr8]-
GnRH) for a similar membrane preparation was only 6.5-fold lower than that of
mGnRH (Millar et ah, 1986; Millar et ah, 1989). It would appear that this
combination of substitutions is largely able to overcome the requirement for Arg8 in
mGnRH, perhaps by introducing additional intramolecular interactions that stabilise
the folded conformation (see Section 2.7.2). Evidence for pre-configuration of
GnRH II is presented in Chapter 4.
2.6.3 GnRH Antagonists
GnRH antagonists have great therapeutic potential, as discussed previously in
Section 2.1.4. Antagonistic properties are conferred by particular modifications to
the N-terminus. Early studies demonstrated that deletion of pGlu1 and/or His2
resulted in very little, if any, agonist potency (Vale et ah, 1972; Yanaihara et ah,
1973). A large range of natural and unnatural amino acid substitutions in positions 1
to 3 have since been evaluated in an attempt to identify analogues with a total lack of
agonist potency, but very high receptor affinity. Hydrophobic D-amino acids in all of
these positions appear to be desirable, particularly in combination with a similar
residue in position 6 (Karten and Rivier, 1986; Nestor et ah, 1984). Such
tetrasubstituted analogues can be enhanced slightly by substitutions at other
positions, such as D-Ala10 (Erchegyi et ah, 1981), and the most potent antagonists
tend to differ from mGnRH in at least half the positions (Karten and Rivier, 1986).
In order to produce antagonists with stable high affinity conformations, many
studies of mono- and dicyclic GnRH antagonists have been carried out, particularly
by Rivier and co-workers (Dutta et ah, 1978; Rivier et ah, 1988; Rivier et ah, 2000a;
Rivier et ah, 2000b; Rivier et ah, 2000c). The most potent of these analogues
involved bridges between the side chains in positions 4-10, 5-8, 4-10/5-8, 1-3, 1-3/4-
10 or 1-5/4-10. The optimal conformation of the N-terminus was assessed using a
bridge of varying lengths from position 1 to 5. Despite the apparent flexibility of the
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N-terminus in linear GnRH analogues, only a small number of conformations were
particularly potent, indicating the importance of N-terminal conformation to high
affinity antagonist binding (Rivier et al., 2000a).
In this thesis, Antagonist 135-18 ([Ac-D-Nal^)1,D-4-Cl-Phe2,D-Pal(3)3,lie3,D-
Lys(iPr)6,Lys(iPr)8,D-Ala'°-NH2]-GnRH) is of particular interest because it acts as an
antagonist at the human GnRH receptor, but as a full agonist at the chicken receptor
(Sun et ah, 2001) and a partial agonist at the Xenopus I receptor (Ott et ah, 2002).
This analogue was found to be a partial agonist at the human GnRH receptor
containing the chicken GnRH receptor ECL2, implying that ECL2 is partly
responsible for this phenomenon (Sun et ah, 2001). ECL2 was also found to be the
determining region in the Xenopus I receptor as Antagonist 135-18 was a full agonist
at the human receptor containing the Xenopus I receptor ECL2, and a partial agonist
when only portions of ECL2 were substituted (Ott et al., 2002). This study proposed
that the D-Lys(iPr)6 side chain of Antagonist 135-18 formed a charge-supported
hydrogen bond with His3 32 in the Xenopus I receptor ECL2, and that this interaction
was responsible for the agonist activity. However, the overall conformation of ECL2
was also clearly important. Chapter 5 describes the binding of Antagonist 135-18 to
human GnRH receptors containing catfish GnRH receptor ECLs in all single, double
and triple combinations.
2.6.4 Bioactive Conformations of GnRHs
Following the sequencing of mGnRH (Matsuo et al., 1971), various
techniques have been used to investigate the bioactive conformation of the peptide.
As discussed in Section 2.6.2, substitutions at position 6 have a dramatic effect on
the binding affinity of mGnRH. This was first recognised by Monahan and co¬
workers, who proposed that D-Ala6 stabilised a (3-II turn from residue 4 to 7
(Monahan et al., 1973).
Conformational energy analysis identified possible low energy conformers of
the mGnRH peptide. The molecule was analysed in two sections (1-6 and 6-10) in
order to reduce the number of variables. The resultant data was then combined to
produce putative conformers of the whole sequence (Momany, 1976a). The most
likely low energy structure deduced from this study, and therefore the likely
bioactive conformer, was the 'CC conformer' that involved a modified (3-II turn from
residue 5 to 8. A series of tetrapeptide and decapeptide analogues were analysed
using this method and the results correlated with experimental activity data. The
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findings gave further support to the proposed 'CC conformed being bioactive
(Momany, 1976b). Substitution of Gly6 with D-Ala was favoured in the proposed
structure, with the added effect of reducing the freedom of opening at this position.
The result would be an increase in the population of the bioactive conformer and
therefore an increase in activity, as observed experimentally (Monahan et al., 1973).
[(Aa-Me)Leu7]-GnRH was found to have approximately the same biological
activity as native mGnRH (Ling and Vale, 1975). This substitution would not be
allowed if the (3-II turn was from residue 4 to 7 as proposed by Monahan and co¬
workers. However, it would be permitted in the 'CC conformer', with the modified
turn from residue 5 to 8 (Momany, 1976b).
An alternative method of conformationally constraining the proposed turn
structure involved the use of a y-lactam bridge. The pro-5" hydrogen atom of Gly6
and the TV-hydrogen of Leu7 were replaced by methyl groups, which were connected
by a single bond to form a five-membered lactam ring (Freidinger et ah, 1980). This
modification gave a 9-fold increase in potency relative to mGnRH, despite retaining
an L-amino acid in position 6 and not introducing additional functional groups.
Another position of particular interest is residue 8. This is arginine in
mGnRH, glutamine in cGnRH I, and leucine in sGnRH (Table 2.8). Analogues
o o
substituted with Glu or Leu have low activity in mammals (Millar et ah, 1989),
however, they are permitted in the 'CC conformer' (Momany, 1976b). Therefore,
depending on the impact of Trp7 in sGnRH, it is likely that both cGnRH I and
sGnRH can adopt the modified (3-II turn from residue 5 to 8. The low affinity of
position 8-substituted analogues at mammalian type I receptors may be due to a low
percentage of ligand in the 'CC conformer' and/or an inability to interact with
Asp/Glu7 32 in ECL3 of the receptor (see Section 2.7.2).
The bioactive conformation proposed by Momany had closely apposed N and
C-termini (Momany, 1976a). Support for this was provided by studies using
conformation-dependent mGnRH antisera. These bound to the N and C termini and
tolerated certain amino acid substitutions in the central region of the ligand, but not
in other positions (Millar et ah, 1984).
The fluorescence intensity of Trp in mGnRH has been used to provide
insights into conformation. The resultant titration curve indicated that at
physiological pH, only Arg8 was ionised. The populations of His2 and Tyr3 were
each found to be homogeneous, suggesting a relatively homogeneous population of
conformers. Furthermore, the reduced basicity of His2 and the increased acidity of
Tyr3 indicated that their side chains were in close proximity to the side chain of Arg8
(Shinitzky and Fridkin, 1976). Indeed, the possibility of hydrogen bonds between
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these residues was suggested. Further studies by the same group used various
analogues substituted with other basic residues at position 8. These suggested a
central role of the His2-Tyr5-Arg8 structural unit (Shinitzky et ah, 1976). The
efficiency of collisional quenching was reduced by 36-39% with these analogues
compared with native mGnRH, indicating a subtle spatial distortion of the proposed
•2 5 8* 3His -Tyr -Arg unit relative to Trp . This may account for the low biological activity
o
of [Lys ]-GnRH (Chang et al., 1972). An analogue with a neutral residue at position
o
8, [oo-N02-Arg ]-GnRH, was found to have a heterogeneous population of histidine
residues and very low GnRH antibody cross-reactivity (Shinitzky et ah, 1976). This
was indicative of a heterogeneous population of ligand conformations, which was
believed to be due to disruption of the His2-Tyr5-Arg8 unit.
Subsequent fluorimetric titration ofmGnRH and [Lys ]-GnRH supported the
findings of Shinitzky and co-workers (Milton et ah, 1983). This study also showed
that cGnRH I ([Gin ]-GnRH) had a heterogeneous population of histidine residues
similar to that observed with [co-N02-Arg8]-GnRH. Therefore, cGnRH I is also
likely to exist as a series of conformers at physiological pH.
The technique of conformational memories was used to predict the relative
conformational populations ofmGnRH and [Lys8]-GnRH in solution (Guarnieri and
Weinstein, 1996). Approximately 70% of the mGnRH conformers were predicted to
possess a [3 type turn for residues 5 to 8, with about 5% expected to have an extended
backbone. These results again support the bioactive conformation proposed by
Momany. More than 70% of the [Lys8]-GnRH analogue was predicted to have an
extended backbone, with a |3 type turn for residues 5 to 8 expected to occur with a
frequency of just 3%. The low biological activity of [Lys ]-GnRH (Chang et ah,
1972; Milton et ah, 1983) may be due to the low frequency of the bioactive
conformer (Guarnieri and Weinstein, 1996), which may in turn be due to the
disruption of intramolecular interactions as discussed above.
Two-dimensional proton NMR was used to predict the conformation of a
cyclic decapeptide GnRH antagonist (Baniak et ah, 1987). The analogue was found
to exist as two conformers, both of which possessed a (3-IT turn for residues 6 to 7,
and a (3-II turn for residues 1 to 2. These were connected by extended antiparallel (3-
like strands. The backbone atoms from the Tyr5-CO to the Pro9-N of the bioactive
conformer predicted by conformational memories could be superimposed on the
structure of this high affinity analogue, with an RMS deviation in the range of just
0.6-0.8 A (Guarnieri and Weinstein, 1996). The two structures diverge between the
N-terminus and residue 4. As this analogue is an antagonist, divergence of the
region believed necessary for receptor activation is unsurprising (see Section 2.6.3).
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There are many more examples of cyclic antagonists that possess the (3-IT
turn for residues 6 to 7, as demonstrated by NMR and molecular modelling (Koerber
et ah, 2000). Indeed, Rivier and co-workers were only able to identify one
constrained high affinity GnRH antagonist that did not appear to have this structural
motif (Rivier et al., 2000c). This particular analogue possessed a (3-T turn for
residues 6 to 7. Perhaps upon binding to the receptor, this conformation changed to
form a (3-IT turn, or perhaps the unique configuration of side chains in this analogue
enabled high affinity receptor interactions to occur despite the different backbone
conformation (Koerber et al., 2000).
The study of conformational memories was extended by performing explicit
water simulations to allow for the influence of the solvent on ligand conformation
(Mezei and Guarnieri, 1998). As before, mGnRH was found to preferentially form a
P-II turn structure and [Lys8]-GnRH an extended structure. Additionally, it was
predicted that the extended form ofmGnRH is strongly solvated relative to the (3-II
turn and vice versa for [Lys8]-GnRH. Assuming that the (3-II turn structure must
desolvate to bind the receptor, mGnRH pays a small desolvation penalty upon
binding whereas [Lys ]-GnRH pays a large penalty. These differences in desolvation
penalty could contribute to the differences in binding affinity of the two ligands.
It is clear that Lys8 is detrimental to the formation of the conformer believed
to be bioactive at mammalian type I receptors (Guarnieri and Weinstein, 1996; Mezei
and Guarnieri, 1998). Indeed, Lys8 is not found in any of the naturally occurring
GnRHs identified in jawed vertebrates (Table 2.8). Lamprey and tunicate GnRHs
are likely to have different conformations compared with other GnRHs. This is
reflected in the biological activity of these ligands at jawed vertebrate receptors.
Lamprey I was shown to have a very low affinity for sheep and rat GnRH receptors,
and very low gonadotropin-releasing activity at sheep and chicken GnRH receptors
(Millar et al., 1989). Lamprey III was found to be 50-200 times weaker than
mGnRH at increasing the serum LH and FSH levels in ovarectomized rats (Kovacs et
al., 2002). Lamprey and tunicate GnRHs have an L-amino acid in position 6 that,
unlike glycine, is likely to disrupt the formation of the (3-IT turn (Momany, 1976b;
Monahan et al., 1973). It is interesting to note, however, that lamprey I, lamprey III
and tunicate I have a negatively charged Glu6, Asp6 or Asp3 along with the positively
charged Lys8 (shown in blue in Table 2.8). Perhaps a salt bridge between these
residues provides some form of turn structure, which positions the N and C termini
for cognate receptor binding (Powell et al., 1996).
Tunicate II GnRH (tGnRH-II) is especially different from other GnRHs as it
forms a dimer (Powell et al., 1996). Cys6 residues (shown in green in Table 2.8)
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were linked by a disulphide bond, which was broken under reducing conditions. It
was suggested that each of the subunits binds to a receptor molecule, thereby
enhancing receptor dimerisation (receptor dimerisation7oligomerisation is beyond the
scope of review in this thesis: see reviews by Dean et ah, 2001; Devi and Brady,
2000; Rios et al., 2001). The steric hindrance of side chains from each subunit could
conceivably result in the decapeptides assuming turn structures, thus enabling the N
and C termini to again interact with the receptor.
NMR studies have provided direct structural evidence for the conformations
of mGnRH and cGnRH I (Maliekal et al., 1997). 192 structures of mGnRH were
obtained, most of which could be grouped into three families. The backbone
conformations were very similar in all these families (Figure 2.7a). They all
exhibited a (3 type turn about Gly6 and closely apposed N and C termini, thereby
agreeing with the studies discussed above (Freidinger et al., 1980; Guarnieri and

















Figure 2.7. The mGnRH (A) and cGnRH I (B) backbones, as deduced from NMR
(Maliekal et al., 1997), showing putative interactions with GnRH receptor residues
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Several hydrogen bonds were present in all three mGnRH structures,
although only two were in all of them: one between the carbonyl oxygen of Ser4 and
8 10the side chain amino group hydrogen of Arg , and a second between the Gly NH
hydrogen and the pGlu1 carbonyl oxygen (Maliekal et ah, 1997). Additionally, the
Arg8 side chain was involved in at least one other hydrogen bond in all of the
structures: either with the side chain of His2 or the side chain of Tyr5. This supported
the suggestions of a His2-Tyr3-Arg8 structural unit based on fluorimetric titration data
(Shinitzky and Fridkin, 1976; Shinitzky et ah, 1976).
The 192 structures obtained for cGnRH I were largely grouped into four
families (Maliekal et ah, 1997). In all of these, a turn conformation was observed
around Gly6 as with mGnRH (Figure 2.7b). However, the conformations appeared to
be more variable, and the N and C termini were not closely apposed. None of the
conformers had a hydrogen bond between Ser4 and Gin8, or between Gly10 and
pGlu1. However, all conformers did possess several hydrogen bonds, with one
between Ser4 and pGlu1 in all four families.
2.6.5 Summary
An enormous number of GnRH peptide agonists and antagonists have been
characterised since mGnRH was first sequenced (Matsuo et ah, 1971). Residues
responsible for receptor binding and/or activation have been identified, along with a
number of modifications that increase potency.
Conformational energy analysis, conformational constraint, fluorimetric
titration, antibody recognition, conformational memories and NMR have all provided
evidence of the bioactive conformation ofmGnRH, in particular the presence of a (3-
IT turn from residue 5 to 8 in mGnRH acting at mammalian type I GnRH receptors.
However, the current literature is unclear as to the conformation of this
crucial central region in other forms of GnRH, or indeed the bioactive conformation
of GnRHs interacting with non-mammalian receptors (Sealfon et ah, 1997). The
relatively low sequence homology and differing structural features (see Section 2.5)
have led to suggestions that the bioactive conformational requirement of non-
mammalian receptors may differ from that of mammalian type I receptors (Sun et ah,
2001).
The study described in Chapter 4 investigates the effect of constraining the (3-
II' turn on the binding affinity of mGnRH, cGnRH I, sGnRH and GnRH II at
mammalian type I and non-mammalian GnRH receptors.
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2.7 Receptor Structure-Activity Relationships
2.7.1 The Use of Chimeric Receptors
Generally, GPCRs that are very closely related in their primary amino acid
sequence can still be distinguished pharmacologically. Such GPCRs may be
subtypes of the same receptor (Frielle et ah, 1988), or from different species
(Beinborn et ah, 1993). By using molecular techniques (see Chapter 3), regions of
one receptor can be replaced with the corresponding regions of a related receptor (see
Table 2.10 for examples and references). The resulting chimera can often be
transfected and expressed successfully in cell lines. If a series of such chimeras are
produced with different combinations of receptor regions, it is theoretically possible
to establish the domains that account for the differences in pharmacology. This
procedure can be useful for the rapid identification of functional domains, including
those involved in ligand-receptor interactions (Frielle et ah, 1988). Screening for
contact sites by mutating individual amino acid residues may be more time
consuming. Establishing the functional domain as a prelude to point mutations can
considerably reduce the effort required in identifying important amino acids. For
these reasons, chimeric receptors were utilised in this thesis to study the role of
extracellular loops in the binding of agonists and antagonists at the GnRH receptor.
The use of chimeric receptors is not without problems. Firstly, such artificial
combinations of receptor regions may not result in a functional protein correctly
folded and expressed in the plasma membrane, particularly as TMDs in close
proximity have probably evolved to maximise favourable interactions and minimise
steric hindrance and electrostatic repulsion (Frielle et ah, 1988). Secondly,
replacement of large regions may result in conformational changes that complicate
the interpretation of results (Huang et al., 1994). The use of chimeric receptors
should be followed up with point mutation studies within the region of interest. Data
derived from point-mutated receptors should also be interpreted with caution, as
differences in local receptor conformation may cause incorrect presentation of a
particular residue. Therefore, it is preferable to combine data from chimeric and
point-mutated receptors (Huang et al., 1994).
Peptide hormones of the size of GnRH and neurokinins bind to both the
TMDs and the extracellular domains of their cognate receptors (Fong et al., 1992;
Strader et al., 1995). This is in contrast to the biogenic amines, which appear to bind
entirely within the TMDs (Dixon et al., 1987; Strader et al., 1995).
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Table 2.10. Examples of chimeric receptors used to identify regions involved in
ligand-receptor interactions
Combination of Receptors: Reference:
and P2 adrenergic (Dixon et al., 1989; Frielle et al., 1988;
Marullo et al., 1990)
OC2 and P2 adrenergic (Kobilka et al., 1988; Mizobe et al., 1996)
M2 and M3 muscarinic acetylcholine (Wess et al., 1990)
Neurokinin-1 and 2 (Gether et al., 1993b)
Neurokinin-1 and 3 (Fong et al., 1992; Gether et al., 1993a;
Huang et al., 1994)
Human and canine cholecystokinin-B (Beinborn et al., 1993)
a and |3 interleukin-8 (LaRosa et al., 1992)
Thyrotropin and luteinising hormone (Nagayama et al., 1991)
C5a and formyl peptide (Perez et al., 1993)
Substance P is selective for NKi (neurokinin-1) receptors, neurokinin A for
NK2 receptors, and neurokinin B for NK3 receptors (Fong et al., 1992). Two studies
of particular relevance to this thesis involved chimeric tachykinin receptors produced
by substituting the extracellular domains of the NK3 receptor into the NKj receptor.
The second study (Huang et al., 1994) investigated point mutations in regions
identified in the first study (Fong et al., 1992). None of the substitutions reversed the
relative affinities of substance P and neurokinin B, or completely accounted for the
specificity of an NKi-selective non-peptide antagonist (L-703,606), leading the
authors to conclude that some residues within the TMDs were also responsible for
ligand selectivity. They did not consider possible interactions between extracellular
domains, a concept investigated in this thesis with respect to the GnRH receptor
(Chapters 5 and 6).
Several residues in the N-terminus, ECL1 and ECL2 of the tachykinin
receptors were found to be required for high affinity agonist binding, but not binding
of the non-peptide antagonist L-703,606 (Fong et al., 1992; Huang et al., 1994).
Different residues, in ECLs 2 and 3, appeared to influence binding of this antagonist.
A competitive antagonist interacts with a binding pocket or region that overlaps, but
is not necessarily identical to, the agonist binding pocket (Flower, 1999). Therefore,
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it is expected that some contact sites differ between agonists and antagonists. The
tachykinin receptor studies also identified residues in ECLs 2 and 3 that appeared to
affect the binding of neurokinin B, but not substance P (Fong et ah, 1992; Huang et
ah, 1994). This illustrates that agonist binding can also involve different residues,
although interactions that result in receptor activation are likely to be conserved.
Results presented in this thesis highlight differences in the binding of ligands at the
GnRH receptor, not only between agonists and antagonists, but also between
different agonists (Chapters 5 and 6).
2.7.2 Residues Involved in Ligand-Receptor Interactions
Point-mutation studies of many GPCRs have established key residues in
particular receptors that are important for ligand binding (van Rhee and Jacobson,
1996). Due to the diversity of ligands interacting with GPCRs, conservation of
contact residues is generally limited to sub-groups of receptors that interact with
similar ligands, such as the biogenic amines (Strader et ah, 1995). However, it is
now clear that certain loci are 'functionally conserved'. These positions are critical
for ligand binding in a range of receptors and they differ in nature to complement
their different cognate ligands (Ballesteros et ah, 2001). The conserved overall
structure of Family A GPCRs, particularly in the transmembrane region, indicates
that residue positions important for binding in one receptor may well be exposed to
the binding pocket/region in other receptors of the family. This provides a good
starting point for the identification of ligand interaction sites in newly modelled
receptors (Flower, 1999). Such residue positions may not interact with the
physiological cognate ligand in other receptors, however, they do have the potential
to influence the conformation of the binding pocket and may provide contact sites for
novel ligands.
The biogenic amine receptors are the most widely studied sub-group of
GPCRs (Strader et al., 1994). As mentioned in Section 2.7.1, chimeric receptor
studies indicated that the ligand binding domain was located within the TMDs
(Dixon et al., 1987). The basic nature of biogenic amines implicated the presence of
an acidic counterion in the receptor. This was identified as Asp1 13(3 32) in TMD3 of
the (^-adrenergic receptor (Strader et al., 1987; Strader et al., 1988) and the chemical
nature of the residue in this position was found to be critical (Strader et al., 1991). In
the Mi muscarinic acetylcholine (Fraser et al., 1989), Hi histamine (Ohta et al.,
1994), Ho histamine (Gantz et al., 1992), D2 dopamine (Mansour et al., 1992),
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5-HTia (Ho et al., 1992) and 5-HT2 receptors (Wang et al., 1993) the homologous
residue was also identified as a ligand contact site. Studies of the CC2 adrenergic
receptor were consistent with a similar role for the homologous residue in this
receptor, however, alteration of normal receptor processing or insertion into the
membrane were not discounted (Wang et al., 1991).
It is clear that Asp is critical for binding biogenic amines, however,
peptides such as GnRH have a very different structure (Strader et al., 1995). Despite
this, the homologous Lys3 32 in mammalian and non-mammalian GnRH receptors
(Figure 2.8) has been identified as critical for binding GnRH agonists, although not
antagonists (Blomenrohr et al., 2001; Zhou et al., 1995). Mutation of Lys121(3'32) to
Arg had little effect on agonist binding, whereas, mutation to Gin abolished agonist,
but not antagonist binding. These mutant receptors were able to stimulate IP
turnover, although the EC50 obtained with Lys121(3 32)Gln was 3 orders of magnitude
higher than wild type (Zhou et al., 1995). No IP turnover was detected with
Lys12I(3 32)Leu Qr LyS121'3 32)A.sp mutant receptors. Therefore, it would seem that the
positively charged nature of Lys'21(3 32' is important for high affinity agonist binding.
As there is not a suitable counterion for Lysl21(3 32) in mGnRH or GnRH II, the
results are consistent with a charge-strengthened hydrogen bond interaction with
these ligands. It was speculated that this involved the electron-dense aromatic rings
of His2 or Trp3, or the polar imino group of His2 (Zhou et al., 1995). Molecular
• 1 2
modelling has subsequently indicated that pGlu and/or His are likely to form these
interactions (Hoffmann et al., 2000) (Figure 2.7).
The TMD3/ICL2 boundary, (I/L)XXDR(Y/S)XX(I/V)XXPL, contains
consensus sequences believed to be critical for receptor activation (Arora et ah,
1995; Ballesteros et al., 1998). It is conceivable that agonist interaction with
Lys121(3'32) is part of the mechanism of stabilising the active receptor conformation.
As discussed in Section 2.7.1, peptide hormones of the size of GnRH bind to
both the TMDs and the extracellular domains of their cognate receptors. Asp98'2 611
at the TMD2/ECL1 boundary of the human GnRH receptor (Figure 2.8) is believed
0 'I
to interact with His ofGnRH/GnRH II, and possibly the backbone NH group ofTrp
as well (Flanagan et al., 2000) (Figure 2.7). This was proposed because position 2-
substituted analogues were found to be less sensitive to Asp98'2 61' mutations. The
putative interaction of Asp98(2 6l) with His2 in the ligand was not believed to be ionic
in nature. Nevertheless, it did appear that the charge of Asp98'2 61} had a function. It
was suggested to either interact with one or more functional groups common to all
the peptides tested and/or influence binding pocket configuration by forming
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AsnI02(2'65) in ECL1 of the human receptor (Figure 2.8) is believed to interact
with the C-terminal glycinamide of GnRH/GnRH II (Davidson et ah, 1996) (Figure
2.7). Mutation of Asn102(2 65) to Ala resulted in potency losses of between 95 and
750-fold with a range of agonists possessing a C-terminal glycinamide, but had less
of an impact on the binding of agonists and antagonists possessing a different C-
terminus, such as [Pro9-NEt]-GnRH and Cetrorelix (Davidson et al., 1996; Hoffmann
et al., 2000). Given the high affinity of these analogues, their C-termini are likely to
make alternative contacts (Millar, 2002).
In ECL3, Asp/Glu7 32 in mammalian type I receptors (Figure 2.8) is believed
to interact with Arg8 in mGnRH (Flanagan et al., 1994; Fromme et al., 2001) (Figure
2.7). G1u301(7'32) in the mouse GnRH receptor was initially identified as a ligand
binding site, following screening of conserved acidic acid residues in the
extracellular domains (Flanagan et al., 1994). The specificity of Glu301(7 32) for Arg8
was tested by comparing ligand binding and IP turnover at the wild type and
Glu301(7 32)Gln mutant mouse receptors, using a range of position 8-substituted GnRH
analogues. A subsequent study identified a similar role for Asp302(7'32) in the human
GnRH receptor, by testing position 8-substituted GnRH analogues at wild type and
Asp30l(7 32)Asn mutant human receptors (Fromme et al., 2001). Both of these studies
found that ligand conformational constraint by D-amino acid substitution for Gly6
overcame the need for Asp/Glu7 32 in the receptor and Arg8 in mGnRH. It was
proposed that the interaction of Asp/Glu7 32 with mGnRH is transient, its role being
to induce a high affinity ligand conformation in an initial binding step, which
precedes formation of the final ligand-receptor complex (Fromme et al., 2001).
It was speculated that the chicken GnRH receptor would lack an acidic
residue in position 7.32 due to its apparent inability to select between mGnRH and
[Gln8]-GnRH (Flanagan et al., 1994). However, its subsequent cloning revealed the
presence of Glu7 32 (Sun et al., 2001) and an alternative explanation regarding
differences in receptor conformation was put forward. In mammalian type I GnRH
receptors, Asp/Glu7 32 is followed by proline (S(D/E)P), whereas in non-mammalian
type I GnRH receptors it is preceded by proline (P(D/E)Y). This difference may
alter the orientation of the Asp/Glu side-chain, thereby affecting the interaction with
Arg8 in mGnRH (Millar et al., 1997; Petry et al., 2002). NMR, Raman and FT
Raman spectroscopy were used to analyse the structure of a cyclised peptide (CG
PEMLNRVSEP GC) representing ECL3 of the mouse GnRH receptor (Petry et al.,
2002). Glycine and cysteine residues were added to each end of the ECL3 peptide,
and a disulphide bond connected the cysteines to simulate the distance between the
extracellular ends of TMDs 6 and 7, as estimated from the crystal structure of
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rhodopsin (Palczewski et al., 2000). The peptide was found to have a random coil
9QA 9Q7 908
conformation, except perhaps for a p-turn around the central residues, L N R
• am
(Petry et al., 2002). This secondary structure was proposed to position the Glu
residue for interaction with Arg in mGnRH. The presence of a proline residue
between the putative P-turn and Glu301, as in non-mammalian type I receptors, may
affect this presentation. However, the implication that in non-mammalian type I
receptors the interaction does not occur is now questionable, as Arg in mGnRH
7 T9
appears to interact with Asp in the catfish receptor (Blomenrohr et al., 2002). In
this study, mutation of Asp304(7 32) to Glu, thereby conserving the negative charge,
had no affect on the binding of mGnRH, catfish GnRH (cfGnRH, [His5,Asn8]-
GnRH) or GnRH II. In contrast, mutation to Asn or Ala reduced the binding affinity
of mGnRH, but not that of cfGnRH or GnRH II. The study described in Chapter 5
investigates ligand-receptor interactions at the human and catfish GnRH receptors,
including addressing this apparent contradiction.
7 32 • •GnRH II does not appear to interact with the Asp/Glu residue, which is
• • •• • r> 8*
unsurprising considering the requirement for Arg in the ligand (Blomenrohr et al.,
2002; Flanagan et al., 1994; Fromme et al., 2001). However, GnRH II has a
relatively high affinity for mammalian type I receptors, as discussed in Section 2.6.2.
As conformationally constrained ligands also bind these receptors with high affinity
without the Asp/Glu7 32-Arg8 interaction, perhaps native GnRH II is also somewhat
constrained by intramolecular interactions. The study described in Chapter 4
provides evidence for this situation.
[Azidobenzoyl-d-Lys6]-GnRH has been shown to photoaffinity cross-link
with Cysl4(lll) in the N-terminal domain (Figure 2.8) causing irreversible activation
of the receptor. This indicates that, when GnRH is positioned in the binding pocket
in such a way that it stabilises the active receptor conformation, the residue in
position six is in the proximity of Cys14(lll) (Davidson et al., 1997). However, as an
antagonist [Ac-(4-azidobenzoyl)-d-Lys1,d-4-Cl-Phe2,d-Trp3,d-Arg6,d-Ala10]-GnRH,
in which the reactive group is in position one, also cross-linked to Cys14(1 H) (Assefa
et al., 1999), it appears that there is considerable movement of the azido-labelled d-
Lys side chain, which enables it to target the highly reactive Cys14(111) regardless of
the position in which the group is attached to GnRH. Thus, while photoaffinity
labelling gives some idea of the binding position of GnRH, the flexibility of the
labelled side chain is such that it does not give definitive information on contact
sites.
6 48
Trp in the GnRH receptor (labelled in brackets in Figure 2.8) may interact
with Trp3 in mGnRH in a model where it is part of an aromatic locus along with
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Tyr6'51, Phe738 and Phe741 (Chauvin et al., 2000). Mutation of Trp279(6 48) to Ser in
the rat GnRH receptor reduced agonist binding affinity and receptor expression, and
abolished IP turnover. Mutation to Arg abolished agonist binding and IP turnover,
but expression was demonstrated using an enhanced green fluorescent protein
(EGFP)-tagged Trp279'6 48)Arg mutant receptor.
Various other residues have been identified in the human receptor as affecting
receptor expression and/or ligand binding. The effect ofmutating Asn2'50 and Asp7 49
(indicated in red in Figure 2.8) was discussed in Section 2.3.4. Mutation of
G1u90(2'53), Arg,79(465), Trp206(5 33), Tyr211(5 38), Phe214(5 4I) or Thr2I5(5 42) (indicated in
red in Figure 2.8) to Ala abolished agonist binding, signal transduction and
antagonist binding, probably due to incorrect receptor folding (Hoffmann et ah,
2000). In the same study, Trp101(2 64) and Asn212(5'39) (labelled in brackets in Figure
2.8) were found to differentiate between agonists and antagonists, implying a role in
the configuration of the agonist binding pocket. The model of [D-Trp6]-GnRH
binding to the human GnRH receptor proposed by Hoffmann and co-workers
suggested an interaction of Trp101 with the Leu7 backbone oxygen via a hydrogen
212 2bond. It also suggested that Asn interacts with the His backbone oxygen, again
via a hydrogen bond.
Residues in TMDs 5 and 6 of various Family A GPCRs have been shown to
be important for ligand binding. Those in TMD5 include: Thr539 and Thr5 42 in Mi
and M3 muscarinic acetylcholine receptors (Allman et ah, 2000; Wess et ah, 1991);
Ser5'42, Ser543 and Ser5 46 in (32-adrenergic and Di dopamine receptors (Liapakis et ah,
2000; Pollock et ah, 1992; Strader et ah, 1989); Ser542 and Ser5 46 in the oc2A-
r tq
adrenergic receptor (Wang et ah, 1991); His in the NKi receptor (Fong et ah,
1993); Lys5'42 in the angiotensin II receptor (Yamano et ah, 1992); Asp5 42 and Thr5 46
in the H2 histamine receptor (Gantz et ah, 1992); and Asn5 46 in the Hi histamine
receptor (Ohta et ah, 1994). Those in TMD6 include: Trp6 48 and Phe6 52 in the 5-
HT2A receptor (Roth et ah, 1997); Tyr651 in Mi and M3 muscarinic acetylcholine
receptors (Ward et ah, 1999; Wess et ah, 1991); and Phe6 51 in the ocie-adrenergic
receptor (Chen et ah, 1999).
An "aromatic cluster" of residues has been shown to exist in the agonist
binding pocket of the D2 dopamine receptor by the substituted-cysteine accessibility
method (Javitch et ah, 1998). This cluster is centred around TMD6, but also extends
to TMDs 5 and 7. It is believed to play a role in agonist binding and receptor
activation in a number ofGPCRs (Javitch et ah, 1998; Roth et ah, 1997).
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The study by Hoffmann and co-workers discussed above identified the
residue Asn212(5'39) in TMD5 of the human GnRH receptor as a potential ligand
contact site, and four other residues that are likely to influence receptor folding. The
study by Chauvin and co-workers, proposed that Trp279(6 48) in the rat GnRH receptor
was also a potential ligand contact site. Combined with the body of evidence from
other Family A GPCRs implicating TMDs 5 and 6 as important constituents of the
ligand binding pocket, it is likely that the configuration of these TMDs is also
important for ligand binding at the GnRH receptor. The studies described in
Chapters 5 and 6 suggest interactions between ECLs 2 and 3 can influence the
configuration of the ligand binding pocket in the GnRH receptor, perhaps by
affecting the configuration of TMDs 5 and 6 to which they are anchored.
A non-peptide antagonist differentiated between the human and dog GnRH
receptors, despite these receptors being 92% identical (Cui et ah, 2000). The basis
for the difference in affinity was found to be a single residue in TMD7, namely
Phe3l3(7 43) in the human receptor and Leu312(743' in the dog receptor. One of the
studies described in Chapter 6 provides evidence for a single residue in ECL2
causing GnRH II to differentiate between the human and rat GnRH receptors.
2.7.3 Summary
Both chimeric and point-mutated receptors can be utilised to establish
receptor domains and/or residues involved in ligand-receptor interactions. Data from
each of these types of construct should be interpreted with caution and ideally
evaluated in combination. It is critical to consider the conformation of receptor
domains and understand that ligand contact sites must be present and orientated
correctly. A number of GnRH receptor residues have been identified as interacting
with ligands and/or contributing to the conformation of the ligand binding
pocket/domain. Recently, it has been proposed that residues from TMDs 5 and 6
have a similar role (Chauvin et al., 2000; Hoffmann et al., 2000). The studies
described in Chapters 5 and 6 of this thesis increase our understanding of how the
ECLs influence binding of mGnRH, [D-Trp6]-GnRH, GnRH II, [D-Lys6]-GnRH II
and Antagonist 135-18 at the GnRH receptor, using a combination of chimeric and
point-mutated receptors. The findings of these studies suggest that the spatial
arrangement of TMDs 5 and 6 is important for the binding of GnRH II, [D-Lys6]-
GnRH II and Antagonist 135-18.
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3 General Materials and Methods
3.1 Amino Acid Numbering Scheme
This scheme facilitates comparisons between GPCRs and has been described
previously (Ballesteros and Weinstein, 1995). The most conserved residue in each TMD
is assigned the TMD number followed by the index 50. Therefore, in the human GnRH
receptor, the conserved residues Asn53, Asn87, Arg139, Trp164, Pro223, Pro282 and Pro320
are designated Asn1'50, Asn2'50, Arg3'50, Trp4 50, Pro5 50, Pro6 50 and Pro7 50 (See page xii).
Other residues are then numbered relative to these positions, e.g. Asp2 61<98).
3.2 Molecular Cloning Techniques
The molecular cloning strategy is summarised in Figure 3.1.
3.2.1 The Polymerase Chain Reaction (PCR)
For each PCR reaction, two different oligonucleotide primers were designed.
These annealed to opposite strands of the template DNA, at either end of the region to be
amplified. The DNA was denatured by heating to 94°C and then cooled to allow the
primers to anneal. The annealing temperature depended on the sequences of the primers,
but was usually between 52 and 56°C. An approximate value was calculated as follows:
(A + T) x 2 + (G + C) x 4
where letters represent the number of bases of that type
(A=adenine, T=thymine, G=guanine, C^cytosine)
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Design and synthesize oligonucleotide primers spanning restriction sites
i
,Produce PCR fragment of receptor cDNA (Section 3.2.1)
Figure 3.1. Flow Chart summarising the molecular cloning strategy
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Increasing the annealing temperature reduced efficiency, but increased
specificity (and vice versa). At 72°C, the primer sequences were extended by the
thermostable Taq DNA polymerase, acting in the presence of excess deoxynucleoside
triphosphates (dNTPs).
For example, the PCR used for producing the catfish receptor ECL cDNA
(approximately 60 bp) consisted of an initial 5 min denaturing step at 94°C followed by
30 cycles of 1 min at 94°C, 30 s at the annealing temperature and 30 s at 72°C. There
was then a final polymerisation step of 5 min at 72°C. The products from each round
provided additional template for successive rounds. Therefore the segment of DNA
between, and including, the primers was amplified exponentially. Longer PCR products
require more time for extension at 72°C.
3.2.2 Digestion of DNA using Restriction Endonucleases
Restriction endonucleases used in molecular biology are able to cut double
stranded DNA at a particular recognition site. This site generally has a specific
sequence, but some sequences are degenerate. They are usually between four and six
nucleotides in length, often with two-fold symmetry. The enzyme may digest both
strands at the same position producing DNA fragments with blunt termini.
Alternatively, opposite strands are digested on either side of the axis of symmetry,
resulting in termini with one of the strands protruding.
Optimal conditions for digestion are specific for each endonuclease, with
different enzymes requiring different salt concentrations. Most endonucleases act
optimally at 37°C, but there are several exceptions. BSA is added to a final
concentration of 0.1 mg/ml. This has been shown to improve the activity of many
restriction endonucleases and there are no known examples of it impeding activity (see
www.promega.com/pnotes/60/6079_28/). Digestion with two endonucleases at the same
time is possible if both enzymes are able to act in similar conditions. The total
concentration of glycerol (in which the endonucleases are stored) should not exceed
10%, otherwise non-specific digestion is likely.
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3.2.3 Ligation of DNA
As described in Section 3.2.2, many endonucleases produce protruding single
strands. As the recognition site is symmetrical, a second DNA fragment digested with
the same endonuclease will have a complementary protruding strand. With the aid of
the enzyme T4 DNA ligase, these fragments can be joined together. In this thesis,
Ready-To-Go™ T4 DNA ligase was used, following the manufacturer's protocol
(Amersham Pharmacia) (see Appendix I for composition of reagents and Appendix II
for addresses of suppliers). 20 pi of DNA solution was added to the tubes, which were
then incubated at 16°C for 45 min. The ratio of DNA fragments in this solution was
calculated to account for relative concentration and size (smaller DNA fragments have
more termini per fig of DNA). When subcloning receptor DNA into vector DNA, the
ratio of receptor DNA termini to vector DNA termini was 3:1.
DNA fragments with blunt termini were also ligated with this enzyme, although
efficiency was greatly reduced. There was also a lack of specificity and this was
particularly important when both ends of a DNA fragment had blunt termini. To prevent
self-ligation, the 5' phosphates were removed using the enzyme calf intestinal alkaline
phosphatase (CIP) (New England Biolabs).
3.3 Bacterial Production of Plasmid DNA
3.3.1 Microbiological Sterile Technique
All work involving live bacteria was carried out in a microbiological laboratory
under flame. Bench surfaces were swabbed with Presept before and after work. LB
Broth, LB Agar (Anachem) and pipette tips were autoclaved and opened under flame.
Pipette tips and inoculating loops were flamed before and after use. Glass spreaders
were sterilised with burning ethanol. All plasticware used was sealed in sterile
packaging. Control cultures, not inoculated with E. coli, were grown in parallel with
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experimental cultures to check for contamination. Waste was decontaminated by
Presept or autoclaving.
3.3.2 Preparation of LB Agar Plates
LB agar was heated to 60°C and 100 pg/ml of ampicillin or 50 pg/ml of
kanamycin added (Sigma-Aldrich), depending on the antibiotic resistance gene present
in the vector. The agar was allowed to set in 100 mm2 dishes, dried in a Class I
microbiological hood and incubated at 37°C before use.
3.3.3 Transformation of E. coli
Electroporation
DNA, electrocompetent Top 10 F' cells, the electroporation cuvette and the
holder were placed on ice. 40 pi of Top 10 F' cells and 0.5 pi of DNA were pipetted
into the bottom of the cuvette. The mixture was treated with a 15 s pulse (2.5 V, 25 pF)
and added to 960 pi of SOC medium (Invitrogen) before shaking at 37°C for 1 h at 250
rpm. Using a glass spreader, 200 pi of culture was spread on an LB agar plate
containing antibiotic.
Heat-Shock
DNA and One Shot™ Top 10 cells (Invitrogen) were placed on ice. 1 pi of
DNA was added to 50 pi of cells and incubated on ice for 20 min. The cells were heat-
shocked for 45 s in a 42°C water bath and returned to ice for 2 min. 250 pi of pre-
warmed SOC medium was added before shaking at 37°C for 1 h at 250 rpm. Using a
glass spreader, 200 pi of culture was spread on an LB Agar plate containing antibiotic.
3.3.4 Amplification and Purification
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Miniprep
Small quantities of DNA were produced using the QIAprep Spin Miniprep Kit
(Qiagen). A single bacterial colony was used to inoculate 4 ml of LB Broth containing
100 pg/ml of ampicillin or 50 pg/ml of kanamycin, depending on the antibiotic
resistance gene present in the vector. This culture was shaken at 37°C for 8 h at 250 rpm
and 1.6 ml was centrifuged for 5 min at 6000 rpm. The plasmid DNA was purified
following the manufacturer's protocol, including all optional steps. DNA was eluted in
50 pi of distilled water giving a concentration of 300-400 ng/pl.
Maxiprep
Large quantities ofDNA were produced using the Wizard® Plus Maxiprep DNA
Purification System (Promega). The manufacturer's protocol was followed with some
modifications to optimise yield.
A 10 ml starter culture was inoculated as for the miniprep protocol and shaken at
37°C for 8 h at 250 rpm. This was added to 250 ml of LB Broth for a further 16 h under
the same conditions. The culture was centrifuged at 4°C for 15 min at 5000 rpm. The
supernatant was discarded and the bacterial cell pellet resuspended. The cells were
lysed for 15 min followed by neutralisation. 15 ml of the Wizard® resuspension, lysis
and neutralisation solutions were used respectively. Following centrifugation at 4°C for
20 minutes at 6000 rpm, the supernatant was filtered through Whatman GF/A filter
paper (Merck). 25 ml of isopropanol (-20°C) was added followed by incubation at 4°C
for at least 1 h. Following centrifugation at 4°C for 15 min at 6000 rpm, the supernatant
was discarded and the DNA pellet resuspended in 2 ml of TE buffer at 70°C. The
suspension was mixed with Wizard® purification resin and drawn through a Wizard®
maxiprep column using a vacuum manifold. The column was washed with 25 ml of
Wizard® column wash solution and 5 ml of 80% ethanol. Residual solution was
removed by spinning the column for 5 min at 2500 rpm using a swing-bucket rotor. The
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DNA was eluted in 1.5 ml of TE buffer or distilled water at 70°C by spinning the
column as before. The concentration was approximately 500-2000 ng/pl.
3.4 Additional DNA Purification Techniques
3.4.1 Ethanol Precipitation
0.1 volumes of sodium acetate (3 M, pH 5.2) and 2.5 volumes of ethanol were
added to the DNA solution. This was vortexed and stood at -20°C for 45 min to
precipitate the DNA, before centrifuging at 4°C for 15 min at 15000 rpm to pellet the
DNA. The ethanol was aspirated off and 1 ml of 70% ethanol added to remove residual
salt. The centrifugation was repeated, the ethanol removed, and the pellet air-dried at
37°C. The pellet was resuspended in a suitable volume of TE buffer or distilled water.
3.4.2 Extraction with Phenol/Chloroform
This procedure removes proteins from nucleic acid preparations. 1 volume of
phenol:chloroform:isoamyl alcohol (25:24:1) was added to the preparation, vortexed and
centrifuged at 15000 rpm for 1 min. The top (aqueous) layer was removed, added to 1
volume of chloroform, shaken, and centrifuged as before. The top (aqueous) layer was
again removed and an ethanol precipitation carried out as described in Section 3.4.1.
3.4.3 Purification Columns
The QIAquick Spin PCR Purification Kit (Qiagen) was used to purify DNA from
enzymatic reactions. The manufacturer's protocol was followed. DNA was adsorbed to
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a silica-gel membrane that did not bind impurities. With the aid of centrifugation, the
DNA was washed with an ethanol-based solution and eluted in distilled water.
3.4.4 Gel Purification
Agarose Gel Electrophoresis
A 1% agarose mini-gel (0.5 g of agarose and 0.5 p.1 of ethidium bromide in 50 ml
of TAE buffer) was placed in a model HE 33 mini gel tank (Amersham) and submerged
in TAE buffer. For particularly small DNA fragments a gel of up to 2% was used.
DNA was mixed with loading dye (Promega) and loaded into the wells. A suitable
DNA ladder (such as the Promega 1 kb or 100 bp ladder) was loaded in parallel and 120
V was applied to the gel for 30 min. The DNA fragments were visualised under ultra¬
violet light. Longer wavelengths were used as much as possible to minimise DNA
damage.
Extraction and Purification
The DNA fragment of interest was excised from the agarose gel using a clean
scalpel and the QIAquick Spin Gel Extraction Kit (Qiagen) used to purify it, following
the manufacturer's protocol. The gel slice was dissolved and the DNA purified using
similar columns to those described in Section 3.4.3.
3.5 Analysis of DNA
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3.5.1 Agarose Gel Electrophoresis
DNA was cut at a single site by a suitable restriction enzyme (see Section 3.2.2).
It was run on a mini-gel (see Section 3.4.4) with a marker of known concentration
loaded in parallel (for example, 5 pi of the Promega lOObp DNA ladder contains
approximately 150 ng of the 500 bp fragment and 50 ng of each of the other ten DNA
fragments). Both size and concentration were estimated by comparison with suitable
markers. Contamination with single-stranded nucleic acid could be identified as
additional bands.
3.5.2 Spectrophotometry Analysis
The DNA solution was diluted to a suitable concentration, for example a
maxiprep believed to be at a concentration of 500-2000 ng/pl was diluted 100-fold. The
optical density (OD) of 1 ml of diluted DNA was analysed in a spectrophotometer at
wavelengths of 260 nm and 280 nm. The ratio of optical density at these wavelengths
(OD260/OD280) should be 1.8. Protein or phenol contamination results in a lower ratio.
A DNA concentration of 50 ng/pl has an OD260 value of approximately 1.
3.5.3 DNA Sequencing
The Sanger Method
The Sanger method of DNA sequencing includes a low concentration of one of
the four 2',3'-dideoxynucleoside triphosphates (ddNTPs) in the polymerase reaction.
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This reaction is similar to PCR, however as one primer is used instead of two, the rate of
DNA synthesis is linear rather than exponential. Due to the lack of a hydroxy1 residue at
the 3' position of deoxyribose, the ddNTP is not able to form a phosphodiester bond
with a subsequent dNTP, therefore chain termination occurs. The concentration of
ddNTP is sufficiently low that termination occurs infrequently. Therefore
oligonucleotides of various sizes will be present and by using the four different ddNTPs
in four parallel reactions, oligonucleotides can be produced that terminate at every A, C,
G or T in the template strand. By including [32P]dNTPs or [35S]dNTPs in the reaction,
the oligonucleotides can be visualised following separation by polyacrylamide gel
electrophoresis. The order of the resultant band terminations reflects the DNA
sequence.
Automated DNA Sequencing
An automated version of the Sanger method was used to sequence DNA used in
this thesis. Fluorescent ddNTPs were used, with each type emitting light of a different
wavelength. Therefore, one reaction containing all four fluorescently labelled
termination ddNTPs was used instead of four separate reactions. The DNA was either
run on a polyacrylamide gel (for analysis with the ABI Prism™ 373 Genetic Analyser)
or through a capillary containing polymer (ABI Prism™ 310 Genetic Analyser). A laser
beam was used to excite the fluorescent dyes. The light emitted was then recorded and
analysed using ABI Prism™ base-calling software.
Polymerase Reaction Conditions
The sequencing reaction mixtures contained: 3 pi of ABI Ready Reaction Mix
(vl.O); 5 pi ofHalf Term buffer; 5 pi of primer at 5 ng/pl (see Appendix III); and 200-
1000 ng of DNA. The volume was made up to 20 pi with distilled water. The reaction
began with a hot-start at 95°C. This was followed by 25 cycles, each consisting of 95°C
for 15 s, 50°C for 25 s and 60°C for 4 min. The DNA was then ethanol precipitated (see
Section 3.4.1) and resuspended in either 4 pi of sequencing loading buffer for analysis
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on the ABI Prism™ 373 Genetic Analyser, or 8 p,l of ABI Template Suppression
Reagent for analysis on the ABI Prism™ 310 Genetic Analyser.
Analysis of Sequencing Data
Data was analysed using GeneJockey (Biosoft) sequence analysis software.
3.6 Engineered Human GnRH Receptor cDNA
The human GnRH receptor cDNA construct (Chi et al., 1993) had previously
been engineered by T. Ott to include a number of silent mutations, thereby introducing
restriction sites at the TMD/ECL boundaries (Ott et al., 2002). These sites are illustrated
in Figure 3.2 with respect to the receptor amino acid sequence.
Point mutations and substitution of receptor ECL cDNA were carried out using
this construct in one of two cloning vectors, pBluescript or pZErO-2 (Figure 3.3). These
vectors contained less restriction sites compared with vectors such as pcDNAl, thereby
avoiding the need to ligate more than two DNA fragments at any one stage. The
ampicillin resistance gene in pBluescript contained a Sea I restriction site, however, as
pZErO-2 was kanamycin-resistant instead of ampicillin-resistant, it lacked this site
(Figure 3.3). This was advantageous when cloning into the Sea I restriction site at the
ECL1/TMD3 boundary. Following engineering in the cloning vectors, the resultant
cDNA was subcloned into pcDNAl/Amp for transfection into COS-7 cells, as this
vector contains a eukaryotic promoter (Figure 3.3).
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3.7 Transient Transfection of COS-7 Cells
68
3.7.1 Origin of the COS-7 Cell Line
The COS-7 cell line was derived from monkey kidney cells transformed by the
SV40 DNA tumour virus. The cells contain viral DNA encoding several viral proteins
that stimulate proliferation of normally quiescent cells.
3.7.2 Cell Culture
COS-7 cells were cultured in the dedicated tissue culture suite using Class II
hoods. Surfaces were swabbed with 70% ethanol and Tisept. All plasticware used was
sealed in sterile packaging and only opened in the hoods. Waste was decontaminated by
Presept or autoclaving. Cells were maintained in 162 cm2 cell culture flasks at 37°C, 5%
CO2 in Complete Medium. Passaging was carried out twice per week, with cells being
split approximately 1 in 20.
3.7.3 Transfection Reagent
SuperFect (Qiagen) is an activated-dendrimer transfection reagent, which
assembles DNA into compact structures. The SuperFect-DNA complex has a net
positive charge that interacts with negatively charged receptors. After internalisation,
SuperFect buffers the lysosome once it fuses with the endosome. This causes pH
inhibition of lysosomal nucleases. The DNA can then be transported to the nucleus.
3.7.4 Transfection Protocol
COS-7 cells were seeded in 100 mm2 dishes at a density of 1.2 million cells/dish
and maintained at 37°C, 5% CO2 in 'Complete Medium'.
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After 24 h, the cells were transiently transfected with GnRH receptor cDNA.
Briefly, in 300 pi of Opti-MEM® (Life Technologies (GibcoBRL)), 30 pi of SuperFect
was incubated with 10 pg of DNA to form a complex. After 10 min, this complex was
added to each 100 mm dish of COS-7 cells for 8 h, along with 3 ml of Complete
Medium. The cells were then washed with PBS (Sigma-Aldrich) and incubated for a
further 48 h in Complete Medium. The cells were either maintained in the 100 mm2
dishes or transferred to 12 well plates, depending on the assay to be carried out.
3.7.5 Optimisation of Transfection Protocol
The protocol was optimised for quantity of SuperFect, cell density, incubation
time with SuperFect and quantity of DNA. The protocol previously established in the
laboratory was used as a starting point. The CRE-luciferase reporter gene assay was
selected as a measure of relative transfection efficiency due to its speed and sensitivity.
CRE-Luciferase Reporter Gene Assay
The CRE-luciferase plasmid DNA included the luciferase gene whose promoter
contained the cAMP response element (CRE). Luciferase is an enzyme whose activity
results in luminescence. Over the time-scale involved in this assay, the luminescence
can be considered proportional to the cAMP activity.
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COS-7 cells were seeded and maintained in 100 mm dishes. After 24 h, the
cells were transiently transfected with 5 pg of CRE-luciferase DNA and 5 pg of receptor
DNA (see Section 3.7.4). Following incubation with SuperFect, the cells were treated
with trypsin and transferred to 12-well plates (1 dish of cells/plate). After a further 48 h,
the cells were treated in triplicate with DMEM containing 0.1% BSA (Sigma-Aldrich)
and a suitable concentration ofGnRH agonist. Following incubation at 37°C for 4 h, the
cells were washed with PBS and Promega Reporter Lysis Buffer added (250 pl/well).
After shaking for 20 min, the cells were scraped and centrifuged for 1 min at 15000 rpm.
10 pi of cell extract was added to 50 pi of Promega Luciferase Assay Reagent in a




30 jliI of SuperFect was routinely added to each 100 mm dish. The effect of
increasing the quantity of SuperFect was investigated. Figure 3.4 shows the






















Quantity of SuperFect (pl/dish)
Figure 3.4. Effect of increasing quantity of SuperFect. Luminescence normalised to
that produced using 30 pl/dish. Data produced in triplicate.
Increasing the quantity of SuperFect appeared to increase transfection efficiency.
Flowever, the increase was not great enough to justify the additional expense of
• • 2





COS-7 cells were routinely seeded in 100 mm dishes at a density of 1.2 million
cells/dish. The effect of changing this density was investigated. Figure 3.5 shows the
luminescence produced using between 0.8 and 1.6 million cells/dish (relative to that
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Cell Density (millions of cells/dish)
Figure 3.5. Effect of changing cell density. Luminescence normalised to that
produced using 1.2 million cells/dish. Data produced in triplicate.
Decreasing cell density decreased transfection efficiency, however, increasing
cell density had little effect. Therefore, the practice of using 1.2 million cells/100 mm2
dish was continued.
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Incubation Time with SuperFect
COS-7 cells were routinely incubated with SuperFect for 4 h. The effect of
changing the incubation time was investigated. Figure 3.6 shows the luminescence
produced following incubation with SuperFect for between 3 and 10 h (relative to that



































Figure 3.6. Effect of changing incubation time with SuperFect. Luminescence
normalised to that produced using 8 h. Data produced in triplicate.
Increasing incubation time with SuperFect increases transfection efficiency up to
8 h, after which transfection efficiency decreases. This is probably due to cytotoxicity.
Therefore, the studies carried out in this thesis used an incubation time with SuperFect




10 pg of DNA was routinely added to each 100 mm dish. The effect of
increasing the quantity of DNA was investigated. Figure 3.7 shows the luminescence

























Quantity of DNA (pg/dish)
Figure 3.7. Effect of increasing quantity ofDNA. Luminescence normalised to that
produced using 10 pg/dish. Data produced in triplicate.
Increasing the quantity of DNA appeared to be detrimental to transfection
efficiency. Therefore, the practice of using 10 pg/100 mm2 dish was continued.
3.8 Radioligand Binding Assays
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3.8.1 lodination of [His5,D-Tyr6]-GnRH
This procedure used Iodo-Gen (Pierce), a water-insoluble oxidising agent.
Briefly, 10 pi of 125I (100 pCi/pl) was added to 20 pi of Iodo-Gen (2 pg/pl), 50 pi of
PBS and 5 pi of [His5,D-Tyr6]-GnRH (1 mM). After 90 s, 500 pi of Iodination Running
Buffer was added and the solution eluted through a column (10 mm diameter) containing
Sephadex G-25 in Iodination Running Buffer (pre-washed with 5% BSA). The eluted
radioligand was collected using a Gilson Model 201 fraction collector (Anachem). The
iodinated peptide eluted after the 123I peak due to adsorption on the gel filtration column.
3.8.2 Whole Cell Binding Assay
COS-7 cells were transiently transfected with GnRH receptor cDNA as described
in Section 3.7.4. Following the incubation with SuperFect, the cells were treated with
trypsin and transferred to 12 well plates. The cells were incubated for 48 h in Complete
Medium at 37°C, 5% C02.
Competition binding assays were carried out using radiolabelled 125I-[His5,D-
Tyr6]-GnRH (approx. 120,000 cpm/tube). The high binding affinity of this tracer
compared with conventional tracers was established previously (Flanagan et al., 1998).
The cells were incubated for 4 h at 4°C in HEPES/DMEM containing 0.1% BSA,
labelled ligand and varying concentrations of unlabelled GnRH analogues in duplicate.
The cells were washed with ice-cold PBS and solubilised by shaking for 20 min at room
temperature with 0.1 M NaOH. The solubilised radioactivity was pipetted into 12 mm
plastic tubes and counted using a multigamma counter (Perkin Elmer (Wallac)).
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3.8.3 Membrane Binding Assay
COS-7 cells were transiently transfected with GnRH receptor cDNA as described
. • • • . • 9
in Section 3.7.4. Following a 48 h incubation in the 100 mm dishes, cells were scraped
in PBS, pelleted and stored at -70°C.
The cell pellets were homogenised in ice-cold 'homogenisation buffer' using a
Dounce tissue grinder (Jencons-PLS) and centrifuged at 15000 rpm for 10 min at 4°C.
The crude membrane pellet was then resuspended in ice-cold 'assay buffer'.
Competition binding assays were carried out using radiolabeled l25I-[His5,D-Tyr6]-
GnRH (approx. 120,000 cpm/tube). The membrane suspension was incubated overnight
at 4°C with labelled ligand and varying concentrations of unlabelled GnRH analogues in
triplicate. The suspensions were filtered through a membrane harvester (Brandel) onto
Whatman GF/B filter paper (Merck) (pre-soaked in assay buffer containing 0.01% PEI)
and washed three times with ice-cold assay buffer. Bound radioactivity was counted
using a multigamma counter (Perkin Elmer (Wallac)).
3.8.4 Selection ofBinding Assay for Studies
Initial assays compared whole cell and membrane binding. Membrane binding
was selected for the studies in this thesis because receptor number could be controlled
and no change in the amount of radioligand bound was observed with cells transfected
with vector only, even at ligand concentrations of 10 nM (Figure 3.8).
3.9 Data Reduction and Statistical Analysis
Binding curves and IC50 values were generated by Prism (GraphPad) graphing
software using non-linear regression, assuming one site competition. Significant
differences in wild type to mutant IC50 values were assessed using a two-tailed, unpaired
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Figure 3.8. Antagonist 135-18 binding to whole COS-7 cells (A) and homogenised
COS-7 cell membranes (B) with and without GnRH receptor cDNA






Sixteen structural variants of GnRH have been identified (see Section 2.4).
In jawed vertebrates these cluster into three groupings: GnRH I, GnRH II and GnRH
III (Troskie et al., 1998; White et al., 1998). One of these, GnRH II, is totally
conserved in structure from bony fish to man, suggesting that each individual amino
acid is essential for biological activity (King and Millar, 1992).
The bioactive conformation of mGnRH acting on mammalian type I GnRH
receptors was originally proposed to be largely determined by a (3-II' turn involving
residues five to eight (Momany, 1976a). This conclusion was supported by a large
body of evidence derived from a variety of approaches. Conformation-dependent
mGnRH antisera that bind the N and C termini of mGnRH tolerate certain amino
acid substitutions in the central region of the ligand, but not in other positions. This
implied that mGnRH has a turn conformation resulting in closely apposed N and C
termini (Millar et al., 1984).
3 *2Fluorescence measurements of Trp at different pHs suggested that His and
Tyr5 are in close proximity to Arg8 in mGnRH (Shinitzky and Fridkin, 1976). This
correlated with the proposed (3-IT turn conformation and indicated the possibility of
intramolecular stabilising interactions between these residues. Further fluorescence
studies supported these findings by comparing mGnRH and analogues with
substitutions for Arg8 (Milton et al., 1983). Chicken GnRH I (cGnRH I, [Gln8]-
GnRH) was found to lack such stabilising interactions, implying that a less structured
conformation exists for this ligand.
The technique of conformational memories further supported the concept that
a predominant (3-11' turn conformer of mGnRH accounts for biological activity
(Guarnieri and Weinstein, 1996). Substitution of Arg8 with Lys resulted in a loss of
this structure and reduced binding affinity (Guarnieri and Weinstein, 1996; Mezei
and Guarnieri, 1998).
NMR studies have provided direct structural evidence for mGnRH in a (3 type
turn conformation consisting of three families (Maliekal et al., 1997). All possess
the (3 type turn about Gly6 and at least two hydrogen bonds: one between Ser4 and
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Arg8, and another between pGlu1 and Gly10-NH2. Hydrogen bonding of Arg8 to
either His2 or Tyr5 was also noted, supporting the conclusions from the fluorescence
studies (Shinitzky and Fridkin, 1976; Milton et ah, 1983). cGnRH I had different
conformers grouped into four families. These also possessed several hydrogen
bonds, but only that between pGlu1 and Ser4 was common to all four. This implied
much greater flexibility of this molecule compared with mGnRH.
A series of cyclic GnRH antagonists were found to have a (3-H' turn
conformation, further supporting the notion that this is the biologically relevant
structure (Rivier et ah, 2000a). However, since antagonists occupy different, but
overlapping binding sites these observations do not necessarily support the structure
of agonists. Indeed, in this study a potent cyclic antagonist was found to have a (3-T
turn at residues 6-7. This implies that, for antagonists at least, the specific turn type
may not be important as long as it results in correct presentation of the backbone and
side-chains critical for binding. Since agonists must satisfactorily bind and activate
the receptor, they are likely to have more specific structural requirements.
D-amino acid substitution for Gly6 (D-aa6 substitution) is believed to stabilise
the P-II' turn conformation, thereby increasing affinity for the receptor (Monahan et
ah, 1973). Conformational energy analysis indicates that D-aa6 substitution reduces
the freedom for opening at position six so that the population of the bioactive
conformer is increased (Momany, 1976b). A similar effect can be achieved by
utilising a lactam ring between residues 6 and 7 (6,7 y-lactam insertion) (Freidinger
et ah, 1980).
Although there is substantial evidence for the (3-IT turn conformation for
active GnRH analogues at the mammalian type I receptor, it is uncertain whether
constraint of non-mammalian GnRHs in this conformation enhances their activity at
mammalian and non-mammalian receptors.
Mammalian type I and non-mammalian GnRH receptors have low sequence
identity and structural features that suggest they may be configured differently.
These include differences in intracellular domains (absence of C-terminal tail, longer
intracellular loop 1 (ICL1) in mammalian type I receptors), extracellular disulphide
bridges, and different interactions between residues in transmembrane domains 2 and
7 (Blomenrohr et al., 1997; Flanagan et al., 1999). In view of these differences that
affect the overall three-dimensional structure of the receptor, the bioactive ligand
conformational requirement may also differ (Sun et al., 2001).
The present study provides evidence that a major determinant of bioactive
conformation at mammalian type I receptors, the (3-IT turn involving residues five to
eight, is also necessary for high affinity binding at non-mammalian receptors. The
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findings also indicate that, unlike the other GnRHs, the native GnRH II ligand is pre-
configured in a bioactive conformation, which may account for its relatively high
affinity for all GnRH receptors investigated and the conservation of its structure over
500 million years of evolution.
4.2 Materials and Methods
4.2.1 GnRH Analogues
mGnRH (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-GlyNH2), GnRH II
([His5,Trp7,Tyr8]-GnRH), cGnRH I ([Glns]-GnRH), sGnRH ([Trp7,Leu8]-GnRH), [d-
Ala6]-GnRH, [d-Lys6]-GnRH and [d-Trp6]-GnRH were supplied by Bachem. [d-
Ala6]-cGnRH I, [d-Arg6]-sGnRH, [d-Lys6]-sGnRH, [d-Trp6]-GnRH II, [d-Arg6]-
GnRH II, and [d-Lys6]-GnRH II were gifts from the University of Cape Town, South
Africa. [6,7 y-lactamj-GnRH and [6,7 y-lactam]-cGnRH I were gifts from R.
Freidinger (Merck & Co., West Point, PA, U.S.A.).
4.2.2 GnRH Receptor cDNA
The human (Chi et ah, 1993), mouse (Tsutsumi et ah, 1992), chicken (Sun et
ah, 2001) and Xenopus II (B. Troskie, N. Illing and R. Millar, unpublished results)
GnRH receptor cDNA constructs were gifts from the University of Cape Town,
South Africa. The rat GnRH receptor was cloned by this laboratory (Eidne et ah,
1992). The catfish GnRH receptor cDNA (Tensen et ah, 1997) was a gift from
Utrecht University, The Netherlands. The bullfrog II GnRH receptor cDNA was a
gift from Chonnam National University, Republic of Korea (Wang et ah, 2001). The
bullfrog II receptor was originally classified by Wang and co-workers as Type III
based on tissue distribution, however, it has greatest sequence homology for
designated Type II receptors (B. Troskie, N. Illing and R. Millar, unpublished
results) and will be considered as such in this thesis (see Section 2.5).
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The mouse GnRH receptors, each having one of the conserved extracellular
domain acidic residues mutated to its isosteric amide, were gifts from C. Flanagan
(University of Cape Town, South Africa). They were produced as described
previously (Flanagan et al., 1994).
4.2.3 Cell Culture and Transfection
COS-7 cells were cultured and transfected as described in Section 3.7.
4.2.4 Receptor Binding Assays
The procedure for receptor binding assays is described in Section 3.8.3.
Maximum specific binding ranged between approximately 5000 and 10,000
cpm/tube with non-specific binding ranging between approximately 2000 and 4000
cpm/tube. No specific binding was detected with COS-7 cells transfected with
vector only (see Section 3.8.4). Membrane concentration was adjusted to provide
• • 9 • •
similar receptor numbers, with cells from two 100 mm dishes being used for each
binding curve, with the exception of the human, chicken and catfish receptors. The
human and chicken receptors exhibited particularly low expression levels and so
cells from four 100 mm2 dishes were used for each curve. Conversely, the catfish
receptor exhibited particularly high expression levels and so cells from one 100 mm2
dish was used for each curve. Therefore, similar maximal specific radioligand
binding was observed at all receptors.
4.2.5 Data Reduction and StatisticalAnalysis
Binding curves were generated and statistical analysis carried out using Prism
graphing software (GraphPad) as described in Section 3.9.
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4.3 Results
The mouse GnRH receptor binds mGnRH and GnRH II with highest affinity
(Tables 4.1 and 4.2 and Figure 4.1). The chicken and catfish receptors bind GnRH II
with highest affinity, followed by sGnRH, mGnRH and cGnRH I (Tables 4.1 and
4.2, and Figures 4.2 and 4.3). Substitution of a D-amino acid in position six of the
ligand (D-aa6) or the insertion of a y-lactam moiety between residues six and seven
(6,7 y-lactam) significantly increases the binding affinity of mGnRH, cGnRH I and
sGnRH acting on the mouse, chicken and catfish GnRH receptors (Tables 4.1 and
4.2).
Introduction of the aromatic D-Trp6 residue into mGnRH increased the
binding affinity at the mouse, chicken and catfish GnRH receptors by a substantial
74, 8.6 and 14-fold. The affinity of [D-Trp6]-GnRH binding at the mouse receptor is
significantly higher than that of [D-Ala6]-GnRH and [6,7 y-lactam]-GnRH (p<0.05).
In contrast, substitution with the positively charged D-Lys6 residue enhanced the
binding affinity at these receptors by only 1.9, 3.6 and 2-fold.
GnRH II was unique amongst the natural GnRHs tested in binding all three
species of GnRH receptor with relatively high affinity. The affinity for the non-
mammalian receptors was particularly high. Substitution of a D-aa6 has little or no
effect on the binding affinity of the GnRH II ligand acting at the catfish and chicken
receptors. At the mouse receptor, which has a much lower affinity for GnRH II, only
D-Lys6 substitution results in a substantial (8.4-fold) increase in affinity (Table 4.2).
The latter finding suggested that the D-Lys6 in GnRH II might be interacting
with one of the seven extracellular domain acidic residues that are conserved in
mammalian type I GnRH receptors. Binding of [D-Lys6]-GnRH II to mutant mouse
GnRH receptors, in which each of these acidic residues was successively mutated to
its isosteric amide (Flanagan et al., 1994), was compared with binding at the wild
type receptor (Table 4.3 and Figure 4.4).
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Figure 4.1. Binding ofmGnRH analogues (A) and cGnRH I analogues (B) at the
mouse GnRH receptor
Binding curves representative ofbetween three and eight experiments from which the
IC50 data were generated by Prism graphing software (GraphPad) as described in
Section 3.9.
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Figure 4.1 (Continued). Binding of sGnRH analogues (C) and GnRH II
analogues (D) at the mouse GnRH receptor
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Figure 4.2. Binding of mGnRH analogues (A) and cGnRH I analogues (B) at the
chicken GnRH receptor
Binding curves representative of between three and seven experiments from which
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Figure 4.2 (Continued). Binding of sGnRH analogues (C) and GnRH II








mGnRH at Catfish Receptor
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Figure 4.3. Binding ofmGnRH analogues (A) and cGnRH I analogues (B) at the
catfish GnRH receptor
Binding curves representative ofbetween three and six experiments from which the
























































Figure 4.3 (Continued). Binding of sGnRH analogues (C) and GnRH II
analogues (D) at the catfish GnRH receptor
Table 4.3. Agonist binding at point-mutated mouse GnRH receptors
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Radioligand binding assays were performed on homogenised membranes ofCOS-7
cells transiently transfected with GnRH receptor cDNA. IC50 data (mean ± S.E.M.)
generated by Prism graphing software (GraphPad) as described in Section 3.9.
Mutation in Mouse GnRH II [D-Lys6]-GnRH II
GnRH Receptor ICj0a n ic50a n
nM nM
Wild Type 127.9 ± 19.8 6 15.3 ±2.3 4
Glu8Gln 175.9 ±37.6 ns 3 10.5 ± 3.5 ns 3
GluulGln 113.0 ± 16.1 ns 3 37.0 ± 11.4 ns 3
Aspl85Asn 175.4 ± 17.5 ns 3 20.0 ±2.1 ns 3
Asp292Asn 185.3 ±25.3 ns 3 25.7 ± 5.7 ns 3
Glu294Gln 128.7 ±32.6 ns 3 16.3 ±3.1 ns 3
Glu301Gln 130.4 ± 6.5 ns 3 9.3 ± 1.4 ns 3
a Mean ± S.E.M. of between three and six experiments carried out in triplicate
ns, Not significantly different from wild type,/?>0.05
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Figure 4.4. Binding ofGnRH II (A) and [D-Lys6]-GnRH II (B) at point-mutated
mouse GnRH receptors
Binding curves representative of between three and six experiments from which the
IC50 data were generated by Prism graphing software (GraphPad) as described in
Section 3.9.
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In initial binding assays the Glu8Gln, GluulGln, Asp185Asn, Asp292Asn,
Glu294Gln and Glu30lGln mutant receptors specifically bound radioligand, whereas
the Asp98Asn mutant receptor did not. The latter result is expected as Asp98 in the
mammalian type I receptor has been shown to interact with His2 in the GnRH ligand
and mutations of this residue severely affect ligand binding (Flanagan et al., 2000).
The mutant receptors that bound the labelled ligand were all found to have the same
binding affinity as the wild type receptor for GnRH II and [D-Lys6]-GnRH II (Table
4.3 and Figure 4.4). This indicates that an interaction of D-Lys6 with one of these
residues was not responsible for the increased affinity of [D-Lys6]-GnRH II.
D-Lys6 substitution substantially enhanced the binding affinity of GnRH II
acting at the mammalian type I receptor, but not at the non-mammalian receptors.
To examine this further, four more species of GnRH receptor were investigated: two
mammalian type I (rat and human) and two non-mammalian type II (Xenopus II and
bullfrog II). D-aa6 substitution did not significantly increase the binding affinity of
the GnRH II ligand acting at the Xenopus II or bullfrog II receptors. D-Lys6
substitution substantially increased the binding affinity of the GnRH II ligand acting
at the rat and human receptors (33.8 and 7.2-fold respectively), as noted for the
mouse receptor. Another basic amino acid (D-Arg6) substitution into GnRH II also
substantially increased binding affinity at the rat receptor (Table 4.4 and Figure 4.5).
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Figure 4.5. Binding ofGnRH II analogues at the rat (A) and human (B) GnRH
receptors
Binding curves representative ofbetween three and six experiments from which the
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Figure 4.5 (Continued). Binding ofGnRH II analogues at the Xenopus II (C) and
bullfrog II (D) GnRH receptors
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4.4 Discussion
There is now considerable accumulated evidence that mGnRH interacts with
its receptor in a (3-11' turn conformation involving residues five to eight (Momany,
1976a; Shinitzky and Fridkin, 1976; Milton et al., 1983; Millar et al., 1984; Guarnieri
and Weinstein, 1996; Maliekal et al., 1997; Mezei and Guarnieri, 1998). This
• . . 48conformation appears to be contributed by interactions between Ser and Arg , as
well as between pGlu1 and Gly10-NH2 (Maliekal et al., 1997). Others have presented
evidence for interactions of Arg8 with His2 and Tyr5 (Shinitzky and Fridkin, 1976;
Milton et al., 1983; Maliekal et al., 1997) contributing to the (3-IT turn conformation.
An interaction ofArg8 with an acidic residue in ECL3 of the receptor is also believed
to contribute to the configuration of the ligand in the folded conformation (Flanagan
et al., 1994; Fromme et al., 2001; Petry et al., 2002).
D-aa6 substitution and 6,7 y-lactam insertion further stabilises this
conformation and enhances binding affinity (Monahan et al., 1973; Momany, 1976b;
Freidinger et al., 1980; Karten and Rivier, 1986; Sealfon et al., 1997). Indeed, the D-
aa6 constraint can abrogate the need for the interaction between Arg8 ofmGnRH and
the acidic residue in ECL3 of the receptor (Fromme et al., 2001). The present studies
confirmed these concepts as D-Trp6, D-Ala6 and D-Lys6 substitution and 6,7 y-lactam
insertion all significantly increased the binding affinity of mGnRH at the mouse
GnRH receptor.
The potency ofmGnRH increases with increasing hydrophobicity of the D-aa6
(Karten and Rivier, 1986) and this is exemplified in the current study in which
binding affinity successively increased in the series D-Trp6 > D-Ala6> 6,7 y-lactam >
D-Lys6. Since [D-Trp6]-GnRH has a much higher affinity than the 6,7 y-lactam
analogue, it appears that the substitution with D-Trp6 makes additional contributions
to enhancement of affinity. Explanations for this include: possible hydrophobic
interactions with the receptor; a stabilisation of the ligand conformation by
intramolecular hydrophobic interactions or a reduction in flexibility due the size of
these side-chains; and/or a reduction in the desolvation penalty upon binding to the
receptor due to the more hydrophobic nature of the ligand (Mezei and Guarnieri,
1998). [D-Lys6]-GnRH binds to the mouse and catfish receptors with significantly
lower affinity than [6,7 y-lactam]-GnRH implying that the basic lysine side-chain is
detrimental to the binding of the GnRH ligand. The hydrophilic nature of this
residue may disrupt one or more of the effects described above. Additionally, the
positive charge of lysine may repel the positively charged Arg and so affect ligand
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conformation. D-Arg6/D-Lys6 substitution into sGnRH, which does not contain
positively charged amino acids, resulted in a much greater increase in binding
affinity in the mouse, chicken and catfish receptors. This concurs with the recorded
effects ofD-Arg6 substitution in sGnRH at the goldfish receptor (Murthy et al., 1994;
filing et al., 1999).
Previous studies have shown that some non-mammalian receptors, unlike
mammalian type I receptors, are not selective for Arg8 containing ligands (Sun et al.,
2001; Wang et al., 2001). In view of the role of Arg8 in configuring the ligand, it
was suggested that these receptors do not require GnRH to be configured in the (3-IT
turn conformation (Millar and King, 1984). This interpretation was further supported
by the observation that D-aa6 substitution did not enhance binding at the cloned
chicken receptor (Sun et al., 2001) and that NMR showed the N and C termini of
cGnRH I were not closely apposed (Maliekal et al., 1997).
However, in the present study, D-aa6 substitution clearly increased the binding
affinity ofmGnRH, cGnRH I and sGnRH at mouse, chicken and catfish receptors.
Although these observations appear to be contradictory, closer inspection
reveals that the primary data concur. The interpretation that D-aa6 substitution does
not enhance binding affinity at the cloned chicken receptor was based on [D-Arg6] -
GnRH II having the same binding affinity as GnRH II and a GnRH analogue
incorporating D-Ala6 having the same affinity as mGnRH (Sun et al., 2001). The
present study found a lack of enhancement for D-Arg6 substitution into GnRH II, and
that D-Ala6 substitution into mGnRH produced a relatively small enhancement. Our
data showing an increase in affinity resulting from D-Trp6 substitution are supported
by a study testing LH releasing activity using dispersed chicken anterior pituitary
cells, in which D-Trp6 analogues of cGnRH I and mGnRH were approximately 20-
fold more potent than cGnRH I and mGnRH respectively (Millar and King, 1983).
Furthermore, our data showing increased binding affinity of sGnRH at non-
mammalian receptors following D-aa6 substitution are supported by two studies that
showed D-Arg6 substitution in sGnRH enhanced binding affinity at the goldfish
receptor (Murthy et al., 1994; filing et al., 1999).
The NMR data show that the N and C termini of cGnRH I are not closely
apposed, however, a turn conformation around Gly6 was still identified (Maliekal et
al., 1997). Conformational energy analysis indicates that cGnRH I can adopt the (3-
II' turn conformation (Momany, 1976b). It is therefore likely that mGnRH and
cGnRH I have similar conformations around Gly6, but different conformations of the
termini. This may explain how these ligands have such different affinities for the
same receptor.
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Studies using fluorescence (Milton et al., 1983) and NMR (Maliekal et al.,
1997) have indicated a greater flexibility of the cGnRH I ligand compared with
mGnRH. This implies that the non-mammalian receptors are able to stabilise the
bioactive ligand conformation, either as a result of additional receptor contact sites,
or as a result of a different spatial arrangement of conserved receptor contact sites as
previously proposed (Sun et al., 2001). The latter concept is supported by the
observation that non-mammalian receptors have a different conformation of ECL3
due to the altered positioning of a proline residue (Millar et al., 1997). This is
examined further in Chapter 5.
Most D-aa6 substitutions had limited effect on the binding affinity of GnRH II
in contrast to that observed for mGnRH, cGnRH I and sGnRH. D-Trp6 substitution,
which gave the greatest increase in binding affinity of mGnRH (8.6 to 74-fold), did
not substantially increase the binding affinity of GnRH II to any of the receptors
(Tables 4.2 and 4.4), and none of the D-aa6 substitutions substantially increased the
binding affinity of GnRH II at the chicken, catfish, Xenopus II or bullfrog II GnRH
receptors. Since GnRH II binds with high affinity to these receptors and D-aa6
substitution does not substantially increase affinity, GnRH II would appear to be pre-
configured in a bioactive conformation suitable for binding non-mammalian
receptors.
Only D-Lys6 substantially increased the binding affinity of GnRH II at the
human and mouse GnRH receptors. In view of the failure of other D-aa6 substitutions
to increase binding affinity, it was considered that D-Lys6 might provide an additional
ligand-receptor interaction that does not occur with non-mammalian receptors. A
candidate interaction is between the basic D-Lys6 and an acidic residue. To address
this possibility, extracellular domain acidic residues conserved in mammalian type I
receptors were screened with GnRH II and [D-Lys6]-GnRH II, using point-mutated
mouse receptors. These mutations did not alter the binding affinity of either ligand
(Table 4.3). Although there are other amino acid residues that can interact with a
Lys side-chain (Ott et al., 2002), these have not been investigated. Instead, the
possibility that D-Lys6 substitution can contribute to the configuration of GnRH II
was revisited.
Despite the evidence that GnRH II is pre-configured, its lower affinity at
mammalian type I receptors (IC50 of 128 to 323 nM compared with 0.75 to 3.7 nM at
non-mammalian receptors) suggests the interaction is not optimal. Therefore, the
possibility that D-Lys6 substitution may alter the conformation of GnRH II to
improve its binding to mammalian type I receptors cannot be ruled out.
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D-Arg6 as well as D-Lys6 substantially increased the binding affinity of GnRH
II at the rat GnRH receptor. This concurs with previous findings using rat pituitary
membranes (Millar et ah, 1986). D-Lys6 increased the binding affinity ofGnRH II at
the rat receptor much more (33.8-fold) than at the human (7.2-fold) and mouse
receptors (8.4-fold). Closer inspection revealed that the binding affinity of GnRH II
at the rat receptor (IC50 of 323 nM) was significantly lower than at either the human
(IC50 of 135.6 nM) or mouse receptors (IC50 of 127.9 nM) (/?<0.05) (Tables 4.2 and
4.4), however, the binding affinity of [D-Lys6]-GnRH II was not significantly
different at the three receptors. This is remarkable considering that rat and mouse
GnRH receptors have 95% sequence homology (Eidne et al., 1992; Kaiser et al.,
1992). It appears that a property of the rat receptor results in poor binding of GnRH
II, but this is overcome by D-Lys6 substitution. This accounts for the exceptional
increase in binding affinity of GnRH II at the rat receptor following D-Lys6
substitution. Further studies described in Chapter 6 show that a single residue in
ECL2 is likely to be responsible for these different findings at the rat receptor
compared with at the human and mouse receptors.
In conclusion, data has been obtained in support of the concept that, as for the
mammalian type I receptors, the non-mammalian receptors have a preference for
GnRH in the folded conformation involving a P-IL turn for residues five to eight,
which is enhanced in mGnRH, cGnRH I and sGnRH by D-aa6 substitution. In
contrast, the evolutionarily conserved GnRH II ligand appears to have a pre-
configured P-IL turn that accounts for its relatively high affinity for all GnRH
receptors and a failure, in most instances, of any enhancement of binding affinity
with D-aa6 substitution. The surprising total conservation of GnRH II's primary
structure from bony fish to man appears to have been a product of the coordinated
evolutionary selection of amino acids contributing to binding, activation and
configuration such that its structure cannot be improved by substitution with any
natural amino acid at any position.
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5 Extracellular Loop Interactions
Differentially Affect mGnRH, GnRH II,
Superagonist and Antagonist Binding
5.1 Introduction
GnRH receptors have been cloned from a variety of species (Sealfon et al.,
1997; Millar, 2002) (see Section 2.5). Mammalian type I and non-mammalian
GnRH receptors have different affinities for different structural variants of GnRH,
such as mammalian GnRH (mGnRH) and GnRH II ([His5,Trp7,Tyr8]-GnRH) (Sun et
al., 2001) that are expressed endogenously in the human (White et al., 1998). These
differences in binding affinity are due to differences in ligand-receptor interactions or
receptor conformation. The latter can influence affinity by altering the configuration
of receptor contact sites or by affecting the ease with which a ligand can interact with
these sites. By studying chimeric receptors that combine regions of mammalian type
I and non-mammalian GnRH receptors, a greater understanding of how different
domains influence ligand binding can be achieved.
The study described in Chapter 4 identified that, at mammalian type I
receptors, [D-Trp6]-GnRH and [D-Lys6]-GnRH II are potent superagonist analogues
of mGnRH and GnRH II respectively. That study also showed that all four ligands
had significantly different binding affinities at the catfish receptor compared with
mammalian type I receptors. In the present study, catfish GnRH receptor ECLs were
substituted into the human GnRH receptor to identify structural domains
underpinning these differences in affinities.
Antagonists interact with receptors in different orientations compared with
agonists as they only need to bind the receptor and do not need to stabilise a
particular conformation (Janovick et al., 1993; Assefa et al., 1999; Cui et al., 2000).
Agonists, by definition, are required to stabilise the active conformation (see Section
2.2). If the 'antagonist' is actually an inverse agonist it will stabilise the inactive
conformation. Antagonist 135-18 is of great interest because it acts as an antagonist
at the human receptor, but as a partial agonist at the Xenopus I receptor and a full
agonist at the chicken receptor (Sun et al., 2001; Ott et al., 2002). Therefore its
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binding is able to stabilise the active conformations of the Xenopus I and chicken
receptors, but not that of the human receptor. The manner in which the interaction of
this ligand differs at mammalian type I compared with Xenopus I and chicken
receptors promises to provide insights into the differences between the active and
inactive receptor conformations. In the present study, Antagonist 135-18 was shown
to have a significantly higher binding affinity at the human compared with at the
catfish GnRH receptor. In addition to investigating the binding of the four agonists,
this study endeavoured to identify structural domains underpinning the difference in
affinity of Antagonist 135-18 at the human and catfish receptors.
A crucial locus for Family A GPCR configuration involves the residues in
positions 2.50 of TMD2 and 7.49 of TMD7 (see Section 2.3.4). Mammalian type I
GnRH receptors have Asn2'50 and Asp749. Mutation of Asn2'50 to Asp in the mouse
GnRH receptor resulted in very low receptor expression and no detectable ligand
binding (Zhou et al., 1994; Flanagan et al., 1999). However, type II and non-
mammalian GnRH receptors possess this Asp2 50 and Asp749 motif. In the catfish
receptor, mutation of Asp2 50 to Asn abolished ligand binding, probably as a result of
incorrect receptor folding (Blomenrohr et al., 1997). These differences between
mammalian type I and non-mammalian receptors at this locus suggest interactions in
this microdomain differ, and that the TMD configuration of these receptors may also
differ (Blomenrohr et al., 1997; Sun et al., 2001). If this is the case, the ECLs will
also have different configurations as they are anchored to the TMDs.
Evidence has been presented for cysteine residues forming a disulphide bond
between the N-terminus and ECL2 of mammalian type I GnRH receptors (Davidson
et al., 1997). This disulphide bond is not present in mammalian type II and non-
mammalian GnRH receptors as the cysteine residues are not conserved. Therefore,
the configuration of the extracellular domains of these receptors is likely to differ
significantly from that of the mammalian type I GnRH receptors.
Evidence has been provided for both mGnRH and GnRH II interacting with
Asp98(2 61) (Flanagan et al., 2000) and Asn102(2 65) (Davidson et al., 1996) in the human
GnRH receptor (Figure 2.8). Lys3 32(l2l) in the human receptor (Figure 2.8) is
required for the binding of mGnRH, but not for antagonists (Zhou et al., 1995). In
the catfish receptor, the homologous Lys3 32(124) is required for binding GnRH II,
implying that mGnRH and GnRH II have similar interactions with this important
locus of agonistic activity (Blomenrohr et al., 2001). As mGnRH and GnRH II
interact with these same three conserved contact sites, the differences in affinities of
these agonists at human and catfish receptors would seem to involve other, non-
conserved contact sites, or be a product of different receptor configurations.
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Asp/Glu7 32 in ECL3 (Figure 2.8) appears to interact with Arg8 in mGnRH
(Figure 2.7), but not with GnRH II (Flanagan et ah, 1994; Fromme et al., 2001;
7 "I?
Blomenrohr et al., 2002). In mammalian type I GnRH receptors, Asp/Glu is
followed by proline (S(D/E)P), whereas in non-mammalian type I GnRH receptors it
is preceded by proline (P(D/E)Y). This difference may alter the orientation of the
Asp/Glu side-chain, thereby affecting the interaction with Arg8 in mGnRH (Millar et
al., 1997; Petry et al., 2002). The implication that in non-mammalian type I
receptors this interaction does not occur (Millar et al., 1997) is now questionable, as
Arg8 in mGnRH still appears to interact with Asp732 in the catfish receptor
(Blomenrohr et al., 2002). The present study investigates ligand-receptor
interactions at the human and catfish GnRH receptors, including addressing this
apparent contradiction. The two major questions to consider are: why does mGnRH
bind at the human receptor with significantly higher affinity than at the catfish
receptor, despite apparent conservation of these four ligand-receptor interactions; and
why does GnRH II bind at the human receptor with significantly lower affinity than
2 61 2 65
at the catfish receptor, despite both ligands interacting with Asp , Asn and
Lys3'32, but not Asp7 32?
5.2 Materials and Methods
5.2.1 Amino Acid Numbering Scheme
This scheme facilitates comparisons between G-protein coupled receptors and
is described in section 3.1.
5.2.2 GnRH Analogues
mGnRH (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-GlyhftU), GnRH II
([His5,Trp7,Tyr8]-GnRH) and [D-Trp6]-GnRH were supplied by Bachem. [D-Lys6]-
GnRH II was a gift from the University of Cape Town, South Africa. Antagonist
135-18 ([Ac-D-Nal(2)1,D-4-Cl-Phe2,D-Pal(3)3,Ile5,D-Lys(iPr)6,Lys(iPr)8,D-Ala-NH210]-
GnRH) was a gift from R. Roeske (Indiana University, Indianapolis, U.S.A.).
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5.2.3 Human and Catfish GnRH Receptor cDNA
The human GnRH receptor cDNA construct (Chi et ah, 1993) was a gift from
the University of Cape Town, South Africa. The catfish GnRH receptor cDNA
(Tensen et ah, 1997) was a gift from Utrecht University, The Netherlands.
5.2.4 Production of Chimeric GnRH Receptor cDNA
Techniques utilised for molecular cloning, as well as plasmid DNA
production, purification and analysis, are described in Sections 3.2-3.5. The human
GnRH receptor cDNA construct had previously been engineered to include a number
of silent mutations, thereby introducing restriction sites at the TMD/ECL boundaries
(Ott et ah, 2002) (see Section 3.6). Oligonucleotide primers spanning these sites
were designed and synthesised (Genosys) with each coding, partly for human GnRH
receptor TMD, and partly for catfish GnRH receptor ECL (see Appendix III). DNA
coding for the catfish GnRH receptor ECLs was generated by PCR using these
primers in pairs, the proof-reading Deep Vent DNA polymerase (New England
Biolabs), and the cloned catfish GnRH receptor cDNA as template. The products
were digested with appropriate restriction endonucleases (Figure 3.2) and
successively ligated into the engineered human GnRH receptor cDNA construct in
place of the DNA coding for the analogous human ECLs. These constructs were
used to transform One Shot™ Top 10 cells (Invitrogen) by heat-shock and plasmid
DNA was extracted from the resultant colonies using the QIAprep Spin Miniprep Kit
(Qiagen). To overcome the problem of additional restriction sites in the plasmid, the
pBluescript vector (Stratagene) was used, with subcloning into the pZErO-2 vector
(Invitrogen) for substitution of ECL 1 (see Section 3.6). The DNA was initially
screened by digesting with appropriate restriction enzymes. Hsp92 I digested the
catfish receptor ECL1 cDNA, Sal I digested the catfish receptor ECL2 cDNA and
Nsp I digested the catfish receptor ECL3 cDNA. None of these enzymes digested the
engineered human receptor cDNA. The fragment sizes were confirmed by agarose
gel electrophoresis. The constructs were then subcloned into the pcDNA-l/Amp
vector (Invitrogen) for transfection into COS-7 cells. Receptor cDNA constructs
were confirmed by automated sequencing using an ABI Prism 310 Genetic Analyser.
A schematic representation of the human GnRH receptor shows the domains
substituted by catfish receptor ECLs to produce the chimeric GnRH receptors (Figure
5.1).
Figure5.1. Schematicr presentationofthhum nGnRHrec ptor,Domainsreplacedtproducech mericceptorsindicat dd showingresiduessubstitutedwi hcatfishr ceptorsid sNon-conservcarec t rECLsiindi atedbl
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5.2.5 Cell Culture and Transfection
COS-7 cells were cultured and transfected as described in Section 3.7.
5.2.6 Receptor Binding Assays
The procedure for receptor binding assays is described in Section 3.8.3. The
membrane concentration was adjusted to provide similar receptor numbers. The
cells from four 100 mm2 dishes were used for each binding curve, with the exception
of the human receptor containing catfish receptor ECLs 1 and 3, and the wild type
catfish receptor. For the human receptor containing catfish receptor ECLs 1 and 3,
cells from two 100 mm2 dishes were used for each curve. For the wild type catfish
receptor, cells from one 100 mm2 dish was used for each curve.
Maximum specific binding ranged between approximately 5000 and 10,000
cpm/tube with non-specific binding ranging between approximately 2000 and 4000
cpm/tube. No specific binding was detected with COS-7 cells transfected with
vector only.
5.2.7 Data Reduction and Statistical Analysis
Binding curves were generated and statistical analysis carried out using Prism
graphing software (GraphPad) as described in Section 3.9.
5.3 Results
The binding affinity of mGnRH and [d-Trp6]-GnRH at the wild type catfish
GnRH receptor was 6.8 and 17.3-fold lower than that at the wild type human GnRH
receptor respectively (Table 5.1). Incorporation of catfish receptor ECL3 into the
human receptor with any combination of other ECLs resulted in a significant
decrease in the binding affinity of mGnRH compared with that at the wild type
human receptor. In contrast, a significant decrease in the binding affinity of [d-
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Trp6]-GnRH compared with that at the wild type human receptor was only observed
following substitution with all three catfish ECLs. For both mGnRH and [d-Trp6]-
GnRH, triple ECL substitution reduced the binding affinity at the chimeric receptor
to a level not significantly different from that observed at the wild type catfish
receptor (Figure 5.2).
The binding affinity of GnRH II and [d-Lys6]-GnRH II at the wild type
catfish receptor was 104 and 27.1-fold higher than that at the wild type human
receptor respectively (Table 5.2). For both GnRH II and [d-Lys6]-GnRH II, in
contrast to that observed for mGnRH and [d-Trp6]-GnRH, the binding affinity at the
chimeric receptor containing all three catfish ECLs was significantly different from
that observed at the wild type catfish receptor (/?<0.05). The binding affinity of
GnRH II at the triple ECL-substituted chimeric receptor was just 3.8-fold higher than
at the wild type human receptor. The binding affinity of [d-Lys6]-GnRH II at the
triple ECL-substituted chimeric receptor was not significantly different from that at
the wild type human receptor (Figure 5.3). Thus, while introduction of the catfish
receptor ECLs into the human receptor produces a phenotype for mGnRH and [d-
Trp6]-GnRH indistinguishable from the wild type catfish receptor, these changes do
not completely convey catfish receptor binding characteristics with regard to GnRH
II and [d-Lys6]-GnRH II.
A significant increase in the binding affinity of GnRH II compared with that
at the wild type human receptor was only observed at chimeric receptors containing
both catfish ECLs 2 and 3 (Table 5.2). Surprisingly, a significant decrease in the
binding affinity of [d-Lys6]-GnRH II compared with that at the wild type human
receptor was observed at chimeric receptors containing the catfish receptor ECL3 in
combination with the human receptor ECL2. This particular combination of ECLs
appears to be detrimental for the binding of [d-Lys6]-GnRH II as its affinities at
chimeric receptors containing both catfish receptor ECLs 2 and 3 were not
significantly different from that observed at the wild type human receptor.
The binding affinity of Antagonist 135-18 at the wild type catfish GnRH
receptor was 46.7-fold lower than that at the wild type human GnRH receptor (Table
5.3). As for GnRH II and [d-Lys6]-GnRH II, and in contrast to that observed for
mGnRH and [d-Trp6]-GnRH, the binding affinity of Antagonist 135-18 at the
chimeric receptor containing all three catfish ECLs was significantly different from
that observed at the wild type catfish receptor (p<0.05). The affinity of Antagonist
135-18 for this triple ECL-substituted chimeric receptor was just 2.2-fold lower than
at the wild type human receptor (Figure 5.4).
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Table 5.1. Binding ofmGnRH and [D-Trp6]-GnRH at human-catfish chimeric
GnRH receptors
Radioligand binding assays were performed on homogenised membranes ofCOS-7
cells transiently transfected with GnRH receptor cDNA. IC50 data (mean ±S.E.M.)
generated by Prism graphing software (GraphPad) as described in Section 3.9.
mGnRH [D-Trp ]-GnRH



























110.21 10.2 0.85 ns 3 11.816.9 0.22ns 4
120.5 131.8 0.78 ns 4 1.810.2 1.44ns 4
273.1 1 14.4 0.34 ** 3 5.3 10.5 0.49ns 3
174.71 10.5 0.54 ns 3 3.610.6 0.72ns 3
342.5 1 18.7 0.27 ** 3 4.8 + 1.6 0.54ns 3
313.6150.2 0.30 * 3 14.214.8 0.11
I I I I I I I I
I I I I I I I I
395.1 161.6 0.24 * 3 35.3 + 9.3 0.07 * 3
633.8 + 90.6 0.15 ** 5 45.3 1 12.9 0.06 * 5
a Mean 1 S.E.M. of between three and six experiments carried out in triplicate
b Fold increase in binding affinity relative to that at wild type human receptor
Human and catfish receptor amino acid sequences indicated in red and blue respectively
ns Not significantly different from affinity at wild type human receptor, p>0.05
* Significantly different from affinity at wild type human receptor, p<0.05



















































Figure 5.2. Binding of mGnRH (A) and [D-Trp6]-GnRH (B) at the human and
catfish GnRH receptors, and at the triple ECL-substituted chimeric GnRH receptor
Binding curves representative ofbetween three and six experiments from which the
IC50 data were generated by Prism graphing software (GraphPad) as described in
Section 3.9.
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Table 5.2. Binding ofGnRH II and [D-Lys6]-GnRH II at human-catfish chimeric
GnRH receptors
Radioligand binding assays were performed on homogenised membranes ofCOS-7
cells transiently transfected with GnRH receptor cDNA. IC50 data (mean ±S.E.M.)
generated by Prism graphing software (GraphPad) as described in Section 3.9.
GnRH II [D-Lys ]-GnRH II








































19.0 ±4.8 1.00 5
40.0 ± 0.48ns 4
10.4
0.98ns 3 18.1 ±3.8 1.05
0.86ns 3 45.3 ± 6.6 0.42 * 4
1.02ns 3 6.8 ±1.2 2.80 ns 4
1.20ns 3 49.8 ± 5.5 0.38 * 3
54.2 ±11.1 2.50* 3 19.9 ± 1.9 0.95 ns 3
35.7 ±7.8 3.80 ** 3 10.7 ±2.2 1.78ns 3
1.3 ± 0.2 104 ** 5 0.7 ± 0.3 27.1 * 3
a Mean ± S.E.M. of between three and five experiments carried out in triplicate
b Fold increase in binding affinity relative to that at wild type human receptor
Human and catfish receptor amino acid sequences indicated in red and blue respectively
ns Not significantly different from affinity at wild type human receptor, p>0.05
* Significantly different from affinity at wild type human receptor, p<0.05
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Figure 5.3. Binding of GnRH II (A) and [D-Lys6]-GnRH II (B) at the human and
catfish GnRH receptors, and at the triple ECL-substituted chimeric GnRH receptor
Binding curves representative ofbetween three andfive experiments from which the
IC50 data were generated by Prism graphing software (GraphPad) as described in
Section 3.9.
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Table 5.3. Binding of Antagonist 135-18 at human-catfish chimeric GnRH
receptors
Radioligand binding assays were performed on homogenised membranes ofCOS-7
cells transiently transfected with GnRH receptor cDNA. IC50 data (mean ±S.E.M.)
generated by Prism graphing software (GraphPad) as described in Section 3.9.
Antagonist 135-18

































377.5 ± 65.3 0.02 * 3
a Mean ± S.E.M. of three experiments carried out in triplicate
b Fold increase in binding affinity relative to that at wild type human receptor
Human and catfish receptor amino acid sequences indicated in red and blue respectively
ns Not significantly different from affinity at wild type human receptor, p>0.05
* Significantly different from affinity at wild type human receptor, p<0.05
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Figure 5.4. Binding of Antagonist 135-18 at the human and catfish GnRH
receptors, and at the triple ECL-substituted chimeric GnRH receptor
Binding curves representative of three experiments from which the IC50 data were
generated by Prism graphing software (GraphPad) as described in Section 3.9.
A significant decrease in the binding affinity of Antagonist 135-18 compared
with that at the wild type human receptor was only observed at chimeric receptors
containing catfish receptor ECLs 1 and 2 (Table 5.3). Surprisingly, a significant
increase in the binding affinity of Antagonist 135-18 compared with that at the wild
type human receptor was observed at chimeric receptors containing the catfish
receptor ECL3 in combination with the human receptor ECL2. This particular
combination of ECLs appears to improve the binding of Antagonist 135-18 as its
affinities at chimeric receptors containing both catfish receptor ECLs 2 and 3 were
not significantly different from, or were significantly lower than, that observed at the
wild type human receptor.
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5.4 Discussion
A significant decrease in the binding affinity of mGnRH compared with that
at the wild type human receptor was observed at the chimeric receptor containing the
catfish receptor ECL3 (Table 5.1). This agrees with previous suggestions that the
conformation of ECL3 is important for high affinity binding ofmGnRH (Flanagan et
al., 1994; Fromme et al., 2001). Asp/Glu732 in mammalian type I receptors is
believed to interact with Arg8 in mGnRH (Flanagan et al., 1994; Fromme et al.,
2001). In the human receptor Asp7 32 is followed by proline (SDP), whereas in the
catfish receptor it is preceded by proline (PDY). This difference may alter the
o
orientation of the aspartate side-chain, thereby affecting the interaction with Arg in
mGnRH (Millar et al., 1997; Petry et al., 2002). A recent study suggests that Arg8 in
mGnRH interacts with Asp7 32 in the catfish receptor (Blomenrohr et al., 2002).
Therefore, if the orientation of the aspartate side-chain in the catfish receptor is
changed compared with in the human receptor, this does not appear to prevent
interaction with Arg8 in mGnRH. Instead, the interaction may position the ligand
less suitably for interaction with other contact sites compared with its positioning at
the human receptor. The ligand would still interact with these other contact sites, but
there would be an energetic penalty due to this alterative orientation. This would
explain how a change in conformation of ECL3 reduces the binding affinity of
mGnRH even though the Arg8 interaction still occurs.
mGnRH still had a significantly higher binding affinity at all single and
double ECL-substituted chimeric receptors containing the catfish receptor ECL3 than
at the wild type catfish receptor (p<0.05). However, it had an affinity at the triple
ECL-substituted chimeric receptor that was not significantly different from that at the
wild type catfish receptor (Figure 5.2). Therefore, in addition to the altered ECL3
conformation, the interaction of all three catfish ECLs appears to reduce the binding
affinity ofmGnRH.
In contrast to that observed with mGnRH, the binding affinity of [d-Trp6]-
GnRH was not changed significantly as a result of substituting ECL3. This also
agrees with previous observations that conformational constraint of mGnRH
overcomes the requirement for Arg8 to interact with Asp7 32 for high affinity binding
(Fromme et al., 2001). A significant decrease in the binding affinity of [d-Trp6]-
GnRH compared with that at the wild type human receptor was only observed
following substitution with all three catfish receptor ECLs. As with mGnRH, [d-
Trp6]-GnRH had an affinity at this triple ECL-substituted chimeric receptor that was
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not significantly different from that at the wild type catfish receptor (Figure 5.2).
The interaction of all three catfish ECLs appears to reduce the binding affinity of
mGnRH and [D-Trp6]-GnRH, by altering the spatial arrangement of ECL contact
sites, and/or by influencing the ease with which the ligand can interact with contact
sites within the TMDs.
For GnRH II, [D-Lys6]-GnRH II and Antagonist 135-18, in contrast to that
observed for mGnRH and [D-Trp6]-GnRH, triple ECL substitution had little effect on
binding affinity (Figures 5.3 and 5.4). ECL substitutions may not restore the binding
of GnRH II and [D-Lys6]-GnRH II because if contact sites are introduced, they may
be incorrectly configured. The spatial arrangement of the ECLs will, in part, be
dictated by the relative positioning of the TMDs to which they are anchored. It has
been suggested that mammalian type I and non-mammalian receptor TMDs have
different configurations (Blomenrohr et ah, 1997; Sun et ah, 2001). Therefore, the
three catfish receptor ECLs substituted into the human receptor may not be in the
same spatial arrangement as in the wild type catfish receptor. Alternatively,
additional GnRH II and [D-Lys6]-GnRH II contact sites may exist within the TMDs
or N-terminus.
It is surprising that the binding affinity of Antagonist 135-18 at the triple
ECL-substituted chimeric receptor is only 2.2-fold lower than at the wild type human
receptor, implying that this antagonist binds wholly to sites within the TMDs and N-
terminus, or that it interacts with ECL contact sites that are conserved between
human and catfish receptors, but configured differently due to the different
positioning of the ECLs by the TMDs. The latter scenario may explain how
Antagonist 135-18 acts as an antagonist at the human receptor, a partial agonist at the
Xenopus I receptor and a full agonist at the chicken receptor (Sun et ah, 2001; Ott et
al., 2002). The binding of the ligand may result in stabilisation of distinct receptor
conformations due to the different configuration of the conserved contact sites in the
different receptors. Lys3 32 is believed to be crucial for agonist binding, but not for
antagonist binding (Zhou et al., 1995). Perhaps the different configuration of the
conserved ECL contact sites alters the ability of Antagonist 135-18 to interact with
such TMD contact sites that differentiate between agonists and antagonists.
This study has highlighted differences between the binding of mGnRH,
GnRH II, superagonists and Antagonist 135-18 at GnRH receptors. The different
affinities ofmGnRH and [D-Trp6]-GnRH for the human receptor compared with the
catfish receptor can be explained by the different ECLs. This is not the case for
GnRH II, [D-Lys6]-GnRH II or Antagonist 135-18, implying that these ligands form
different interactions with GnRH receptors compared with those formed by mGnRH
115
and [D-Trp6]-GnRH. This is unsurprising for Antagonist 135-18, as antagonists have
been shown to form different receptor interactions compared with agonists (Janovick
et ah, 1993; Assefa et ah, 1999). However, Asp2 61, Asn2 65 and Lys3'32, which are all
conserved between the human and catfish receptors, are believed to interact with
both mGnRH and GnRH II (Zhou et ah, 1995; Davidson et ah, 1996; Flanagan et ah,
2000; Blomenrohr et ah, 2001). Therefore, mGnRH and GnRH II would appear to
have different ligand conformations, form different additional ligand-receptor
interactions, and/or interact with conserved contact sites that are in different spatial
arrangements in human and catfish receptors.
The study described in Chapter 4 suggested that residues five to eight of
GnRH II are pre-configured for interaction with non-mammalian receptors, but that
D-Lys6 substitution may alter this conformation to improve binding at mammalian
type I receptors. The N and C-termini may be configured differently in mGnRH
compared with GnRH II. NMR studies of mGnRH and cGnRH I ([Gln8]-GnRH)
show these two ligands having similar turn conformations around Gly6, but very
different conformations of the N and C-termini (Maliekal et ah, 1997). cGnRH I
differs from mGnRH by a single residue. Therefore, it is conceivable that GnRH II,
which has three residues different from mGnRH, also has different N and C-terminal
conformations. As discussed above, mammalian type I and non-mammalian
receptors may have different configurations. Therefore, I suggest that the
conformation ofmGnRH selects for the human receptor and that of GnRH II selects
for the differently configured catfish receptor. It has been suggested that, as Arg8 in
mGnRH interacts with Asp7 32 in the catfish receptor, the reason for mGnRH binding
to the human receptor with higher affinity is due to the side-chains of Tyr5 and Leu7
fitting better than in the catfish receptor (Blomenrohr et al., 2002). However, the
study described in Chapter 4 shows that sGnRH ([Trp7,Leu8]-GnRH) binds with low
affinity to a mammalian type I receptor (IC50 of 1134 nM at mouse receptor) and
with higher affinity to the catfish receptor (IC50 of 52 nM). Therefore, it would
5 • ... 7
appear that Tyr is tolerated by the catfish receptor (as it is present in sGnRH). Trp
seems to confer high affinity binding to ligands acting at the catfish receptor,
whereas the conformation of ECL3 appears responsible for the high binding affinity
of [Arg8]-containing ligands at the mammalian type I receptors.
Although ECL substitution did not account for the difference in binding
affinities of GnRH II, [D-Lys6]-GnRH II and Antagonist 135-18 at the human
receptor compared with the catfish receptor, there were significant changes in the
binding affinity of these ligands at chimeric receptors compared with that at the wild
type human receptor (Tables 5.2 and 5.3). A significant increase in the binding
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affinity of GnRH II compared with that at the wild type human receptor was
observed at chimeric receptors containing both catfish ECLs 2 and 3. This implies
that the interaction of these two ECLs alters the spatial arrangement of ECL contact
sites, and/or influences the ease with which the ligand can access contact sites within
the TMDs. Models of the human, rat, mouse and catfish GnRH receptors show
TMDs 5 and 6 in close proximity, implying that the C-terminus of ECL2 and the N-
terminus of ECL3 are also in close proximity (Zhou et ah, 1994; Chauvin et ah,
2000; Hoffmann et al., 2000; Blomenrohr et ah, 2001; Blomenrohr et ah, 2002).
Furthermore, a number of residues in this region affect receptor conformation and/or
ligand binding, namely Trp5 33, Tyr5 38, Asn5 39, Phe3'41, Thr5'42 and Trp6'48 (Chauvin et
al., 2000; Hoffmann et al., 2000). Therefore, the present study supports previous
suggestions that this region forms part of the ligand binding pocket (Chauvin et al.,
2000; Hoffmann et al., 2000), and implies that the interactions between ECLs 2 and 3
in the human receptor are less conducive to GnRH II binding than in the catfish
receptor.
The binding affinity of [d-Lys6]-GnRH II at the triple ECL-substituted
chimeric receptor was not significantly different from that at the wild type human
receptor. d-Lys6 appears to alter the conformation of GnRH II, or form an additional
interaction with the human receptor, so that triple catfish ECL substitution does not
significantly improve binding. If the interaction of ECLs 2 and 3 in the human
receptor is less conducive to the binding of GnRH II, d-Lys6 appears to overcome
this. It would then be a further example of conformational constraint around position
six of the ligand overcoming changes in ECL conformation, as observed with
conformationally-constrained GnRH analogues overcoming the requirement for Arg8
to interact with ECL3 (Fromme et al., 2001). Catfish ECL substitution was expected
to increase the binding affinity of [d-Lys6]-GnRH II. Therefore, a surprising
observation is that the ECL configuration resulting from the artificial interaction
between human ECL2 and catfish ECL3 appears to reduce the binding affinity of [d-
Lys6]-GnRH II at chimeric receptors compared with that at the wild type human
receptor. This also implies that [d-Lys6]-GnRH II has a different conformation to
GnRH II or that the d-Lys6 forms an additional interaction with the receptor, which is
disrupted by this particular ECL interaction.
The significant decrease in the binding affinity of Antagonist 135-18 at
chimeric receptors containing catfish ECLs 1 and 2 compared with that at the wild
type human receptor, implies that the interaction of these two ECLs alters the spatial
arrangement of ECL contact sites and/or influences the ease with which the ligand
can access contact sites within the TMDs. This interaction does not appear to affect
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agonist binding, again illustrating that Antagonist 135-18 has a different binding
mode compared to the agonists. The artificial interaction between human ECL2 and
catfish ECL3 results in a surprising observation with Antagonist 135-18. Instead of
decreasing binding affinity for Antagonist 135-18, this interaction appears to increase
binding affinity at chimeric receptors compared with that at the wild type human
receptor. It would appear that this receptor conformation is very well suited to the
binding of Antagonist 135-18, which binds at the wild type human receptor with
higher affinity than at the wild type catfish receptor (Table 5.4). On the other hand,
it is particularly unsuitable for binding [D-Lys6]-GnRH II, which binds at the wild
type catfish receptor with higher affinity than at the wild type human receptor (Table
5.4). These observations provide evidence that Antagonist 135-18 and [D-Lys6]-
GnRH II select for different receptor configurations and that, as observed for GnRH
II, the interaction of ECLs 2 and 3 influences configuration of the binding sites.
Table 5.4. Antagonist 135-18 and [D-Lys6]-GnRH II differentiate between three
apparently different configurations of GnRH receptor
Configuration A: Configuration B: Configuration C:
Wild Type Catfish Wild Type Human
GnRH Receptor GnRH Receptor
Chimeric GnRH Receptors
containing Human Receptor ECL2
and Catfish Receptor ECL3
■! 111! i imnnmmi ii 11 iiimi tin hi
Relative Affinity:
Antagonist 135-18
[D-Lys6]-GnRH II +++++ +++
Human and catfish receptor amino acid sequences indicated in red and blue respectively
Relative ligand binding affinity:
+, IC50 > 125 nM +++, IC50 of 5-25 nM +++++, ICJ0 < 1 nM
++, IC50 of 25-125 nM ++++, IC50of 1-5 nM
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In conclusion, it would appear that mGnRH, GnRH II, superagonists and
Antagonist 135-18 interact with GnRH receptors in distinct conformations that are
influenced differently by ECL interactions, particularly between ECLs 2 and 3. The
introduction of all three catfish receptor ECLs into the human receptor produces a
phenotype for mGnRH and [D-Trp6]-GnRH indistinguishable from the wild type
catfish receptor, however, these changes do not completely convey catfish receptor
binding characteristics with regard to GnRH II, [D-Lys6]-GnRH II or Antagonist 135-
18. Additional receptor contact sites for these ligands may exist within the N-
terminus/TMDs, and/or the three catfish receptor ECLs substituted into the human
receptor are not in the same spatial arrangement as in the wild type catfish receptor.
Human and catfish receptors appear to have distinct conformations that select
for different ligands. With increasing evidence of multiple GnRH ligands and
multiple GnRH receptors within each species (Powell et al., 1996; Tensen et al.,
1997; Troskie et al., 1998; White et al., 1998; filing et al., 1999; Millar et al., 2001;
Wang et al., 2001), the importance of this selectivity is beginning to be realised.
This study illustrates that point-mutation studies on G-protein coupled receptors,
while being extremely valuable, cannot in isolation explain differences between the
binding affinities of different receptors. Increased knowledge of ligand and receptor
conformations is crucial for understanding how the ligand interacts with the receptor
and, in the case of agonists, stabilises the active receptor conformation.
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6 The Effect of Extracellular Loops 2 and
3 on GnRH Analogue Binding
6.1 Introduction
As discussed in Chapter 5, models ofGnRH receptors show the outer regions
of TMDs 5 and 6 in close proximity, implying that the C-terminus of ECL2 and the
N-terminus of ECL3 are also in close proximity (Zhou et al., 1994; Chauvin et ah,
2000; Hoffmann et ah, 2000; Blomenrohr et ah, 2001; Blomenrohr et ah, 2002).
Furthermore, a number of residues in this region of TMD5/TMD6 affect receptor
conformation and/or ligand binding, namely Trp5'33, Tyr5'38, Asn5 39, Phe5 41, Thr5 42
and Trp648 (Chauvin et ah, 2000; Hoffmann et ah, 2000). Therefore, it has been
suggested that this region of TMD5/TMD6 forms part of the ligand binding pocket
(Chauvin et ah, 2000; Hoffmann et ah, 2000).
It is apparent from the study of human-catfish chimeric GnRH receptors that
the interactions of ECLs influence ligand binding, either by altering the spatial
arrangement of ECL contact sites, and/or by influencing the ease with which the
ligand can interact with contact sites within the TMDs (see Chapter 5). Interactions
between ECLs 2 and 3 were found to affect the binding affinity of GnRH II, [D-
Lys6]-GnRH II and Antagonist 135-18 at these chimeric GnRH receptors.
This chapter focuses on the putative interaction between ECLs 2 and 3 in
greater detail. The study described in Chapter 4 showed that GnRH II had a
significantly lower binding affinity at the rat receptor compared with at the human
and mouse receptors, an unexpected finding considering that rat and mouse GnRH
receptors have 95% sequence homology (Eidne et al., 1992; Kaiser et al., 1992). The
C
present study proposes that a single residue in ECL2, namely Glu , is likely to be
responsible for these different affinities. The negatively charged Glu is proposed
to repel one of the negatively charged residues (Asp6 61 or Glu6 63) in the N-terminus
ofECL3, thereby altering receptor configuration.
The human receptor has a histidine residue in the C-terminus of ECL2 and
two acidic residues in the N-terminus of ECL3, whereas the chicken receptor has the



























































































Figure 6.1. Partial amino acid sequences of different GnRH receptors: C-terminus
of ECL2/outer region of TMD5 (A); outer region of TMD6/N-terminus of ECL3 (B).
Human, rat and chicken GnRH receptor partial amino acid sequences indicated in blue
Loci investigated in the present study indicated in r ed
Loci previously found to affect GnRH receptor conformation and/or ligand binding indicated in green
Loci previously found to confer agonism to Antagonist 135-18 indicated in orange
T, Residues in the C-terminus of ECL2 that differ between Xenopus and chicken GnRH receptors
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It was hypothesised that, by studying different combinations of substitutions
at these positions in human-chicken chimeric receptors, insights would be gained as
to their role in ligand binding. Five such chimeric receptors (human receptor with
His207(5 34)Glu/Gln208(333)Glu; human receptor containing chicken receptor ECL2;
human receptor containing chicken receptor ECL3; human receptor with
His207(534)Glu/Gln208(335)Glu and containing chicken receptor ECL3; and human
receptor containing chicken receptor ECLs 2 and 3) were used to demonstrate that
ECLs 2 and 3 play an important role in ligand binding and/or receptor expression.
6.2 Materials and Methods
6.2.1 Amino Acid Numbering Scheme
This scheme facilitates comparisons between G-protein coupled receptors and
is described in section 3.1.
6.2.2 GnRH Analogues
mGnRH (pGlu-Elis-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-GlyNIHb), GnRH II
([His5,Trp7,Tyr8]-GnRH) and [D-Trp6]-GnRH were supplied by Bachem. [D-Lys6]-
GnRH II was a gift from the University of Cape Town, South Africa. Antagonist
135-18 ([Ac-D-Nal(2)1,D-4-Cl-Phe2,D-Pal(3)3,Ile5,D-Lys(iPr)6,Lys(iPr)8,D-Ala-NH210]-
GnRH) was a gift from R. Roeske (Indiana University, Indianapolis, U.S.A.).
6.2.3 GnRH Receptor cDNA Supplied to the Study
Human (Chi et al., 1993) and chicken (Sun et ah, 2001) GnRH receptor
cDNA constructs were gifts from the University of Cape Town, South Africa. The
rat GnRH receptor was cloned by this laboratory (Eidne et al., 1992). The human
receptor cDNA with Gin335 mutated to Glu (Ott et al., 2002) and the human
receptor/chicken receptor ECL2 cDNA (Sun et al., 2001) were produced previously
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by T. Ott. The human receptor/chicken receptor ECL3 cDNA was modified from a
construct produced by B. Fromme (University of Cape Town, South Africa).
6.2.4 Production of Chimeric GnRH Receptor cDNA
Techniques utilised for molecular cloning, as well as plasmid DNA
production, purification and analysis, are described in Sections 3.2-3.5. The human
GnRH receptor cDNA construct had previously been engineered to include a number
of silent mutations, thereby introducing restriction sites at the TMD/ECL boundaries
(Ott et al., 2002). All constructs were generated in the pBluescript vector
(Stratagene) and subsequently subcloned into the pcDNAl/Amp vector (Invitrogen)
for transfection into COS-7 cells (see Section 3.6).
For production of the human receptor containing the His5 34G1u and
s • .... •
Gin ' Glu mutations, an antisense oligonucleotide primer was designed and
synthesised (Genosys) that spanned the Stu I restriction site and the sequence coding
for the two mutations (see Appendix III). A PCR fragment was generated using this
primer, the T3 primer (see Appendix III), the proof-reading Deep Vent DNA
polymerase (New England Biolabs) and the engineered human GnRH receptor
cDNA as template. The PCR fragment was digested with Stu I and EcoR I, and
ligated into the engineered human GnRH receptor cDNA construct that had been
digested with the same enzymes. This was used to transform One Shot™ Top 10
cells (Invitrogen) by heat-shock and plasmid DNA was extracted from the resultant
colonies using the QIAprep Spin Miniprep Kit (Qiagen). The DNA was initially
screened by digesting with Stu I and PflM I and the fragment sizes confirmed by
agarose gel electrophoresis. Subsequently, DNA was confirmed by automated
sequencing using an ABI Prism 310 Genetic Analyser.
The human receptor/chicken receptor ECL3 cDNA construct was modified
by digesting with Hpa I and BsrG I, followed by ligation of the isolated receptor
cDNA fragment into the engineered human receptor cDNA. The cDNA encoding
the human receptor with His5 34G1u, Gin5 35Glu/chicken receptor ECL3 was generated
by digesting the human receptor/chicken receptor ECL3 cDNA with Stu I and Xho I,
followed by ligation of the isolated receptor cDNA fragment into the His5 34G1u and
Gin5 35G1u mutated human receptor cDNA. Following transformation and plasmid
DNA extraction, both of these constructs were screened by digesting with Ava I,
which cuts chicken receptor ECL3 cDNA, but not human receptor ECL3 cDNA.
Subsequently, the DNA sequence was confirmed by automated sequencing.
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The human receptor/chicken receptor ECLs 2 and 3 cDNA was generated by
digesting the human receptor/chicken receptor ECL2 cDNA with Stu I and EcoR I,
followed by ligation of the isolated receptor cDNA fragment into the human
receptor/chicken receptor ECL3 cDNA. Following transformation and plasmid DNA
extraction, this construct was screened by digesting with Dra III, which cuts chicken
receptor ECL2 cDNA, but not human receptor ECL2 cDNA. The DNA sequence
was confirmed by automated sequencing. A schematic representation of the human
GnRH receptor showing the mutated residues is shown in Figure 6.2.
6.2.5 Cell Culture and Transfection
COS-7 cells were cultured and transfected as described in Section 3.7.
6.2.6 Receptor Binding Assays
The procedure for receptor binding assays is described in Section 3.8.3. For
the human and rat receptor study, the membrane concentration was adjusted to
provide similar receptor numbers. This was achieved by using cells from four 100
mm2 dishes for each binding assay using wild type and mutated human receptors,
while cells from two 100 mm2 dishes were used for each assay using the wild type
rat receptor. Maximum specific binding was similar for all receptors, ranging
between approximately 5000 and 10,000 cpm/tube. For the human-chicken chimeric
receptor study, cells from four 100 mm2 dishes were used for each binding curve.
The human receptor containing the chicken receptor ECL2 exhibited maximal
specific binding ranging between approximately 8000 and 22,000 cpm/tube, with
wild type human and chicken receptors exhibiting between approximately 5000 and
10,000 cpm/tube. For both studies, non-specific binding ranged between
approximately 2000 and 4000 cpm/tube and no specific binding was detected with
COS-7 cells transfected with vector only (see Section 3.8.4).
6.2.7 Data Reduction and Statistical Analysis
Binding curves were generated and statistical analysis carried out using Prism
graphing software (GraphPad) as described in Section 3.9.
Figure6.2. Schematicr presentat onofthum nGnRHreceptor, showingresiduessubstit tedw hc ck nr cep oridu s
Domainsreplacedtopr ducechimericceptorsindic t dd Non-conservedhickenreceptorECLsiduesindi atedblu
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6.3 Results
Mammalian type I GnRH receptors have conserved His5 34 (H) and Gin5 35
(Q) residues in the C-terminus of ECL2, as well as conserved Asp6 61 (D) and
Asp/Glu (D/E) residues in the N-terminus of ECL3 (indicated in red in Figure
6.1). The rat GnRH receptor is an interesting exception, having the negatively
charged Glu5 35 (E) instead of the neutral Gin (Q). Substitution of d-Arg6 or d-Lys6
into GnRH II enhanced binding at the rat receptor more than at the mouse or human
receptors (see Chapter 4). Comparison of the amino acid sequences of the rat and
mouse GnRH receptors shows that there are only 17 amino acids not conserved
between these species, only 6 of which are in extracellular domains (Figure 6.3).
s• • • •
Glu ' was selected as the prime candidate for differentiating the rat receptor from
the mouse and human receptors, with respect to GnRH II binding (indicated in blue
in Figure 6.3).
The binding affinity of GnRH II at the wild type rat GnRH receptor was
significantly lower than at the wild type human GnRH receptor (p<0.05) (see
Chapter 4). When Gin5 35 was mutated to Glu, as in the rat receptor, the affinity of
GnRH II at the human receptor was indistinguishable from that at the rat receptor
(Table 6.1 and Figure 6.4). In contrast, the binding affinities of [d-Lys6]-GnRH II at
the wild type rat and mutant human receptors were not significantly different from
that at the wild type human receptor.
The lower binding affinity ofmGnRH at the wild type rat receptor compared
with that at the wild type human receptor was barely significant (p=0.0499), and the
affinity at the mutant human receptor was not significantly different from that at
either wild type receptor (Table 6.1 and Figure 6.4). The binding affinities of [d-
Trp6]-GnRH were not significantly different at the three receptors, as was the case
for Antagonist 135-18. It would appear that the residue in position 5.35 influences





















Amino acid sequence alignment of the rat (top) and mouse (bottom) GnRH receptors
•, Conserved residue Putative extracellular domains indicated in red
|, Non-conserved residue Glu/Gln5 35 indicated in blue
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Table 6.1
Ligand binding at the human, human Gln208(5,35)Glu mutant and rat GnRH receptors
Radioligand binding assays were performed on homogenised membranes ofCOS-7
cells transiently transfected with GnRH receptor cDNA. ICsodata (mean ±S.E.M.)
generated by Prism graphing software (GraphPad) as described in Section 3.9.
Wild Type Human Human Gln208(5 35)Glu Wild Type Rat
Ligand ic50a n ic50a n ic50a n
nM nM nM
GnRH II 135.6 ± 15.8 4 350.1 ± 15.5 *** 3 323.0 ±33.1 * 3
[D-Lys6]-GnRH II 19.0 ±4.8 5 20.0 ± 2.0 ns 3 9.6 ±1.1 ns 3
mGnRH 93.8 ±24.1 3 115.1 ± 12.8 ns 3 243.8 ±40.5 * 3
[D-Trp6]-GnRH 2.6 ± 1.1 6 0.53 ±0.12 ns 3 2.0 ±1.2 ns 3
Antagonist 135-18 8.1 ± 1.0 3 22.6 ±9.1 ns 3 21.9 ± 5.8 ns 3
a Mean ± S.E.M. of between three and six experiments carried out in triplicate
ns, Not significantly different from wild type human,p>0.05
*, Significantly different from wild type human, p<0.05
























































[[D-Lys6]-GnRH II] (log M)
Figure 6.4. Binding of GnRH II (A) and [D-Lys6]-GnRH II (B) at the human,
human Gin208'5 35)G1u mutant and rat GnRH receptors
Binding curves representative of between three and six experiments from which the
ICso data were generated by Prism graphing software (GraphPad) as described in
Section 3.9.
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Figure 6.4 (Continued). Binding ofmGnRH (C) and [D-Trp6]-GnRH (D) at the
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Figure 6.4 (Continued). Binding of Antagonist 135-18 (E) at the human, human
Gln208(5 35)G1u mutant and rat GnRH receptors
The chicken GnRH receptor has two acidic residues in the C-terminus of
ECL2 (Glu534 (E) and Glu535 (E)), as well as His6 61 (H) in the N-terminus of ECL3
(indicated in red in Figure 6.1). This is the opposite arrangement to most
mammalian type I GnRH receptors.
Mutation of Gin5 35 to Glu in the human receptor significantly decreases the
binding affinity of GnRH II (2.6-fold lower than at the wild type human receptor),
but not [D-Lys6]-GnRH II (Table 6.1). The double mutation of His5 34 to Glu and
Gin5 35 to Glu results in levels of specific radioligand binding too low to provide
reproducible data (n=3) (Table 6.2). Surprisingly, substitution of the entire chicken
receptor ECL2 into the human receptor resulted in apparently higher specific binding
(approximately 8000-22,000 cpm/tube) than at either the wild type human or chicken
receptors (approximately 5000-10,000 cpm/tube). The binding affinity of GnRH II
at this chimeric receptor was even lower than at the Gln5 35Glu mutant receptor (5.1-
fold lower than at the wild type human receptor), although the affinity of [D-Lys6]-
GnRH II was again not significantly different from that at the wild type human
receptor (Table 6.2 and Figure 6.5).
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The substitution of the chicken receptor ECL3 into the human receptor again
resulted in levels of specific radioligand binding too low to provide reproducible data
(n=3) (Table 6.2). Substitution of His5 34Glu/Gln5 3:>Glu or the chicken receptor
ECL2 in addition to the chicken receptor ECL3 did not restore specific radioligand
binding.
Table 6.2. Agonist binding at human-chicken chimeric GnRH receptors
Radioligand binding assays were performed on homogenised membranes ofCOS-7
cells transiently transfected with GnRH receptor cDNA. IC50 data (mean ± S.E.M.)
generated by Prism graphing software (GraphPad) as described in Section 3.9.
GnRH II [i>-Lys"|-GnRH II
Mutation in Human GnRH Receptor ICsoa n IC50a n
nM nM
Wild Type Human Receptorb 135.6 ± 15.8 4 19.0 ±4.8 5
Gln208(535)Glub 350.1 ± 15.5 *** 3 20.0 ± 2.0 ns 3
His207(5'34)Glu/Gln208(5-35)Glu N.D. 3 N.D. 3
Chicken ECL2 693.4 ±74.7 * 3 44.8 ± 10.7 ns 4
Chicken ECL3 N.D. 3 N.D. 3
His207(534)Glu/Gln208(5 35)Glu/Chicken ECL3 N.D. 3 N.D. 3
Chicken ECLs 2 and 3 N.D. 3 N.D. 3
Wild Type Chicken Receptor 0.75 ±0.21 ** 7 0.19 ±0.03 * 3
a Mean ± S.E.M. of between three and seven experiments carried out in triplicate
b Data shown in Table 6.1: included in this table for comparison
N.D., Not determined: specific binding too low to provide reproducible data (n=3)
ns, Not significantly different from wild type human, p>0.05
*, Significantly different from wild type human, p<0.05
**, Significantly different from wild type human, p<0.01











































Binding of GnRH II and [D-Lys6]-GnRH II at human-chicken chimeric GnRH
receptors compared with at the wild type human and chicken GnRH receptors
Binding curves representative ofbetween three and six experimentsfrom which the
1Cso data were generated by Prism graphing software (GraphPad) as described in
Section 3.9.
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6.4 Discussion
D-Arg6 substantially increased the binding affinity of GnRH II at the rat
receptor, but not at the mouse or human receptors. D-Lys6 increased the binding
affinity ofGnRH II at the rat receptor much more (33.8-fold) than at the human (7.2-
fold) and mouse receptors (8.4-fold) (see Chapter 4). A search for amino acids
different in the rat receptor from the mouse and human receptors revealed the
presence of a glutamate residue in ECL2 of the rat receptor in the homologous
position to a glutamine residue in the mouse and human receptors (Figures 6.1 and
C TC
#
6.2). The mutation of Gin to Glu in the human receptor reduced the binding
affinity of GnRH II to that at the rat receptor and D-Lys6 substitution increased
binding affinity by a similar amount to that found with the rat receptor. Either
C 1C
#
Gin was able to interact with GnRH II in a manner not possible by Glu in this
position, or the introduction of a negative charge was detrimental to GnRH II
binding. As GnRH II does not contain a negatively charged residue to repel Glu5 35,
an intramolecular charge repulsion that alters receptor configuration should be
considered. Models of the human, rat, mouse and catfish GnRH receptors imply that
the C-terminus of ECL2 is in close proximity to the N-terminus of ECL3 (Zhou et
al., 1994; Chauvin et al., 2000; Hoffmann et al., 2000; Blomenrohr et al., 2001;
Blomenrohr et al., 2002). In mammalian type I GnRH receptors, the N-terminus of
ECL3 contains two acidic residues: Asp6 61 and Glu/Asp663 (indicated in red in
Figure 6.1). Charge repulsion between either of these residues and Glu3 35 could
explain the low binding of GnRH II at the rat receptor, as the resultant change in
spatial arrangement of ECLs 2 and 3 could cause distortion of GnRH II binding site
configuration and/or influence the ease with which GnRH II can interact with contact
sites within the TMDs.
The concept that such a change in ECL spatial arrangement could affect
ligand binding is supported by the identification of a number of residues in this
region that affect receptor conformation and/or ligand binding (Chauvin et al., 2000;
Hoffmann et al., 2000) (indicated in green in Figure 6.1). This putative repulsion
between ECLs 2 and 3 appears to affect the binding of GnRH II, but not [D-Lys6]-
GnRH II, again implying that [D-Lys6]-GnRH II has a different conformation to
GnRH II or that the D-Lys6 forms an additional interaction with the receptor (see
Chapters 4 and 5).
The results for mGnRH were less conclusive. The binding affinity of
mGnRH at the rat receptor was significantly lower than at the human receptor, but
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only marginally (/?=0.0499). However, the affinity of mGnRH at the point-mutated
human receptor was not significantly different from that at either the human or rat
wild type receptors. [d-Trp6]-GnRH bound to both rat and human receptors with
similar affinities and so it was unsurprising that the affinity of [d-Trp6]-GnRH at the
point-mutated human receptor was similar to that at both human and rat wild type
receptors. Similarly, Antagonist 135-18 bound to all three receptors with similar
affinities, implying that the putative change in spatial arrangement of ECLs 2 and 3
did not influence binding of this ligand. This is perhaps unsurprising as, like [d-
Trp6]-GnRH and [d-Lys6]-GnRH II, it is also conformationally-constrained by a d-
amino acid in position 6 (d-Lys(iPr)).
It appears that the acidic residues in this region of both mammalian type I and
non-mammalian GnRH receptors are arranged so that they do not repel each other.
The exception appears to be the rat receptor, in which putative repulsion of acidic
residues in ECLs 2 and 3 appears detrimental to GnRH II binding (Figure 6.6).
Residues in close proximity often have reciprocal arrangements in different
receptors, an example of which is Asp2 50 and Asn7'49 in most G-protein coupled
receptors instead of Asn2 50 and Asp7 49 in mammalian type I GnRH receptors (Zhou
et al., 1994; Flanagan et al., 1999). The reciprocal arrangement of His and two
acidic residues in ECLs 2 and 3 of human and chicken GnRH receptors supports the
proposal that these regions are in close proximity.
The hypothesis that residues in ECLs 2 and 3 interact with (and
potentially repel) each other thereby affecting ligand binding was tested using
human-chicken chimeric receptors. The mutation of Gln208(5 35) to Glu in the human
receptor was detrimental to the binding of GnRH II. It was therefore envisaged that
the double mutation of His207(5 34)Glu/Gln208(5 35)G1u in the human receptor, or the
substitution of chicken receptor ECL2 in the human receptor, would be even more
detrimental. To test whether this was due to an interaction between ECLs, ECL3
was substituted for that of the chicken receptor in combination with
His207(5 34)Glu/Gln208(5 35)G1u or chicken receptor ECL2, the hypothesis being that this
would produce the reciprocal arrangement of residues and restore ligand binding.
Substitution of the chicken receptor ECL2 into the human receptor resulted in an
even greater decrease in the binding affinity of GnRH II than the Gln207(5 35>G1u
mutation, concurrent with the hypothesis. The binding affinity of GnRH II at the
wild type chicken receptor was 181 -fold higher than at the wild type human receptor.
It would appear that artificial interactions between the chicken receptor ECL2 and
the remainder of the human receptor are responsible for the lower binding affinity of
GnRH II at the human receptor containing the chicken receptor ECL2.
A. Mammalian type I GnRH Receptors,
except Rat GnRH Receptor:
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B. Rat GnRH Receptor:
ECL2 ECL3 ECL2 ECL3
C. Non-mammalian GnRH Receptors,
except Chicken GnRH Receptor:








Figure 6.6. Schematic diagrams showing possible arrangements of ECLs 2 and 3
Mammalian type I GnRH receptors except the rat GnRH receptor (A) have two
acidic residues in the N-terminus ofECL3, but none in the C-terminus ofECL2. The
rat GnRH receptor (B) has acidic residues in both the C-terminus ofECL2 and the
N-terminus of ECLS. These residues are proposed to repel each other, thereby
altering receptor configuration. Non-mammalian GnRH receptors, except the
chicken GnRH receptor (C) have acidic residues in both the C-terminus ofECL2 and
the N-terminus ofECLS. However, these residues appear to be arranged so that they
do not repel each other. The chicken GnRH receptor (D) has two acidic residues in
the C-terminus ofECL2 but none in the N-terminus ofECL3.
Acidic residues indicated in red indicates putative charge repulsion
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The human receptor with the His207(5 34)Glu/Gln208(5 35)Glu double mutation
bound radioligand too poorly to provide reproducible data. Preliminary findings by
A. Pawson indicate that this receptor produces agonist-induced inositol phosphate
(IP) turnover and therefore appears to be expressed at the cell membrane. It would
seem that the His207(5 34)Glu/Gln208(5 35)G1u mutation in the human receptor reduces
receptor expression without abolishing it, or disrupts binding of l25I-[His5,d-Tyr6]-
GnRH. This is surprising considering that substitution of the entire chicken receptor
ECL2 into the human receptor seems to result in higher specific radioligand binding
than at the wild type receptor (approximately 8000-22,000 cpm/tube compared with
5000-10,000 cpm/tube). Perhaps the conformation of the chicken receptor ECL2
presents the two acidic residues differently so that they reduce the binding of GnRH
II, but not that of conformationally-constrained GnRH analogues, as was the case
with the Gln208(;> 35)G1u mutation. Indeed, [d-Lys6]-GnRH II was found to bind at the
chicken receptor ECL2-substituted receptor with an affinity not significantly
different from that at the wild type human receptor, supporting this concept.
Previous studies have shown that substituting non-mammalian GnRH
receptor ECL2s into the human receptor influences ligand binding. Substitution of
chicken receptor ECL2 into the human receptor conferred partial agonism to
Antagonist 135-18, which was an antagonist at the wild type human receptor and a
full agonist at the wild type chicken receptor (Sun et al., 2001). Furthermore,
substitution of the Xenopus type I GnRH receptor ECL2 into the human receptor
conferred full agonism to Antagonist 135-18, with partial agonism being conferred
by substitution with portions of ECL2 (Ott et al., 2002). This study went on to
identify a double mutation required for Antagonist 135-18 to be recognised as an
agonist at the human receptor, namely Val5 24Ala and Trp5 32His (indicated in orange
in Figure 6.1), implicating an interaction between His5 32 in the receptor and d-
Lys(iPr)6 in Antagonist 135-18 through a charge-supported hydrogen bond. The
mutation of Trp5 32 to His on its own was not sufficient, suggesting that a particular
conformation of the ECL is required to present this residue for ligand interaction.
Interestingly, the wild type chicken receptor has Val5 24 and therefore would be
expected not to confer agonism to Antagonist 135-18. As this is not the case (Sun et
al., 2001), the conformation of ECL2 in the chicken receptor is likely to be different
from that in the Xenopus I receptor. The only differences between these receptors in
the C-terminus of ECL2 are indicated by arrows in Figure 6.1. It is interesting to
note that a positively-charged residue, arginine, is unique to the chicken receptor in
position 5.30, which is also unique in having two negatively-charged residues in this
region. Perhaps the interaction of these residues configures ECL2 differently in the
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chicken receptor compared with the Xenopus I receptor, and indeed the human
receptor.
Substitution of the chicken receptor ECL3 into the human receptor again
resulted in specific radioligand binding too low to provide reproducible data. It was
hoped that substitution ofHis5 34Glu/Gln5 35G1u or chicken receptor ECL2 in addition
to chicken receptor ECL3 would restore function as appears to be the case when the
chicken receptor ECL2 is substituted instead of just His5 34Glu/Gln5 35Glu.
Unfortunately this was not the case as specific radioligand binding remained low,
although preliminary data produced by A. Pawson measuring IP turnover again
indicates that these receptors are expressed at the cell membrane.
It is unclear why substitution of the chicken receptor ECL3 has this effect,
particularly as substitution of the catfish receptor ECL3 into the human receptor is
well tolerated (see Chapter 5). It would seem that the chicken receptor has a number
of differences compared with other non-mammalian type I receptors, such as
Xenopus I and catfish. It is even more surprising that the combination of chicken
receptor ECLs 2 and 3 did not restore function. The concept that mammalian type I
and non-mammalian GnRH receptors may have different configurations of the
TMDs resulting in different ECL spatial arrangements was discussed in Chapter 5.
Substitution of both chicken receptor ECLs 2 and 3 into the human receptor may not
restore function because these loops are presented differently compared with in the
wild type chicken receptor.
In conclusion, this study has shown that certain residues in the C-terminus of
ECL2 affect ligand binding and/or receptor expression, namely those in positions
5.34 and 5.35. Indeed, the presence of Glu5 35 in the rat receptor is likely to be the
reason for it binding GnRH II with low affinity, differentiating it from the mouse and
human receptors. It is suggested that residues in these positions are in sufficiently
close proximity to residues in the N-terminus of ECL3 for charge repulsion to occur,
thereby influencing receptor configuration.
7 Concluding Discussion
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This thesis has obtained data in support of the concept that, as for the
mammalian type I GnRH receptors, the non-mammalian GnRH receptors have a
preference for GnRH in the folded conformation involving a (3-IT turn for residues
five to eight, which is enhanced in mGnRH, cGnRH I and sGnRH by D-aa6
substitution. In contrast, the evolutionarily conserved GnRH II ligand appears to
have a pre-configured |3-ir turn that accounts for its relatively high affinity for all
GnRH receptors and a failure, in most instances, of any enhancement of binding
affinity with D-aa6 substitution.
Future research should include the use ofmore techniques, such as NMR and
conformational memories, to gain further insights into the bioactive conformation of
GnRH II. Three pertinent questions are: do these techniques confirm the findings of
this thesis; how do the N and C terminal configurations compare to those ofmGnRH
and cGnRH I; and if GnRH II does indeed possess a pre-configured (3-IT turn for
residues five to eight as this thesis suggests, what are the intramolecular interactions
responsible for the stabilisation of this structure?
As part of the characterisation of newly cloned mammalian type II GnRH
receptors, the effect of conformational constraint on the binding of GnRH analogues
should be assessed. In particular, does [D-Lys6]-GnRH II bind to these receptors with
higher affinity than GnRH II as at mammalian type I receptors, or is the (3-If turn
involving residues five to eight of GnRH II optimally pre-configured for interaction
with these receptors as it appears to be for non-mammalian receptors?
The study of human-catfish chimeric GnRH receptors found that mGnRH,
GnRH II, superagonists and Antagonist 135-18 interact with GnRH receptors in
distinct conformations that are influenced differently by ECL interactions,
particularly between ECLs 2 and 3. The findings confirmed the importance ofECL3
conformation in the binding ofmGnRH, despite recent indications that Asp7 32 in the
catfish receptor interacts with Arg8 in mGnRH (Blomenrohr et al., 2002).
Future studies to continue the research on human-catfish chimeric receptors
should investigate binding to the N-terminus using two further chimeric receptors: a
human receptor containing the catfish receptor N-terminus; and a human receptor
containing all of the catfish receptor extracellular domains. The results should either
implicate the N-terminus as an important determinant of ligand-receptor interactions,
or eliminate it as such. The latter finding would leave two possible reasons why
triple catfish receptor ECL substitution into the human receptor had little effect on
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the binding affinity of GnRH II, [D-Lys6]-GnRH II or Antagonist 135-18: additional
receptor contact sites exist within the TMDs and/or the three catfish receptor ECLs
substituted into the human receptor are not in the same spatial arrangement as in the
wild type catfish receptor.
In the last few years, a number of point-mutation studies have identified
various GnRH receptor residues that indirectly influence ligand binding through
effects on receptor conformation (Millar, 2002). Important microdomains have been
identified, such as the interaction between positions 2.50 and 7.49 (Flanagan et ah,
1999). This thesis identifies both ECL conformation and interactions between ECLs
as important for ligand binding. In particular, the findings indicate that a single
residue, namely Glu/Gln5 35 in ECL2, may be responsible for the lower affinity of
GnRH II for rat compared with human and mouse GnRH receptors. This residue is
proposed to influence configuration ofGnRH II binding sites due to charge repulsion
between ECLs 2 and 3. This illustrates that, while point-mutation studies on G-
protein coupled receptors are extremely valuable, they cannot in isolation explain
how ligands interact with their cognate receptors. It is critical to understand how the
ligand and receptor are configured for interaction with each other. Understanding
how contact sites are presented for interaction is as important as knowing which
residues actually interact.
The research into interactions between ECLs 2 and 3 discussed in Chapter 6
should be continued by investigating intracellular coupling to signalling pathways.
The preliminary findings by A. Pawson show that human-chicken chimeric receptors
can initiate downstream signalling events that are agonist dependent, despite
radioligand binding being too low to provide reproducible receptor binding data. If
such studies show that the interaction between these ECLs alters the EC50, this may
be due to altered ligand binding, but could also be due to changes in coupling
efficiency. A more direct approach would be to carry out binding studies using a
radiolabelled antagonist that binds to contact sites not affected by partial disruption
of the agonist binding pocket, while retaining the ability to compete with ligands still
able to occupy the agonist binding pocket. However, such an antagonist would also
need to bind the poorly expressed human GnRH receptor with high affinity. The
radiolabelled agonist used in the present study was selected due to its unusually high
affinity for the human receptor (Flanagan et ah, 1998).
A second follow-up study to investigate how interactions between ECLs 2
and 3 influence ligand binding involves the identification of residues in the
extracellular end of TMD5 that differ between the human and chicken receptors (the
extracellular end of TMD6 is completely conserved between mammalian and non-
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mammalian GnRH receptors). Point-mutated human and chicken receptors should
then be produced to examine the role of the non-conserved residues. An example is
the residue in position 5.36 at the boundary of ECL2 and TMD5 (Figure 6.1). The
residue is an alanine in all mammalian type I receptors and a threonine in all non-
mammalian receptors. A threonine residue has the capacity to form hydrogen bonds,
whereas an alanine residue does not. Additionally, the residue one helical turn below
position 5.36 in the human receptor is Asn212(5'39) (Figure 2.8), which is believed to
be involved in the ligand binding pocket (Hoffmann et ah, 2000). A second
possibility is a residue adjacent to position 5.39. Met" 40 in TMD5 is conserved in
non-mammalian receptors, but is Phe in mammalian type I receptors.
A few years ago, GnRH receptors were divided into mammalian and
non-mammalian receptors. Following the cloning of three mammalian type II GnRH
receptors (Millar et al., 2001; Neill et al., 2001), it is now clear that mammalian type
I and type II receptors have distinct structures and pharmacological profiles. Indeed,
mammalian type II receptors share many characteristics with non-mammalian
receptors, not least the presence of a C-terminal tail and the selectivity for GnRH II
over mGnRH (Millar et ah, 2001; Neill et al., 2001).
This thesis suggests that the 'non-mammalian' group will inevitably be sub¬
divided as our understanding of GnRH receptor structure and function increases.
Division into types I, II and III based on sequence homology is only the first step.
This thesis indicates that type I GnRH receptors from birds, such as the chicken, are
distinct from type I GnRH receptors from fish and amphibians, such as the catfish
and Xenopus I.
mGnRH and its cognate receptor have a critical role in the control of human
reproduction, with GnRH receptor agonists and antagonists having a wide range of
important clinical applications. The identification of new and improved agonists and
antagonists promises to have enormous health benefits, and the key to unlocking this
potential lies in a better understanding of how GnRH interacts with its cognate
receptor. This thesis has contributed to this improved understanding, by providing
novel insights into structural determinants ofGnRH ligand-receptor interactions.
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3.3.1 Presept 50% Sodium Dichloroisocyanurate
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3.3.1 LB Agar medium 1% tryptone, 0.5% yeast extract, 1% NaCl and 1.5% Agar
3.3.3 SOC medium 2% tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM




50 mM Tris-HCl, (pH 7.5), 10 mM EDTA and 100 pg/ml
RNase A.
3.3.4 Wizard® cell lysis
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80 mM potassium acetate, 8.3 mM Tris-HCl (pH 7.5),
40 pM EDTA and 55% ethanol
3.3.4 TE buffer 10 mM Tris-HCl (pH 8.0) and 1 mM EDTA
3.4.4 TAE buffer 40 mM Tris-acetate and 1 mM EDTA
3.5.3 Sequencing loading
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250 pi formamide and 50 pi 50 mM EDTA
3.5.3 ABI Ready Reaction
Mix
Dye terminators, deoxynucleoside triphosphates,
AmpliTaq DNA Polymerase, FS, xTth pyrophosphatase,
MgCE and buffer (concentrations undisclosed)
3.5.3 Half Term buffer 200 mM Tris HC1 (pH 9.0) and 5 mM MgCl2




Dulbecco's modified Eagle's medium containing: 10%
fetal calf serum, 0.3 mg/ml glutamine, 100 IU/ml
penicillin and 100 pg/ml streptomycin
3.7.4 Opti-MEM® Includes: L-glutamine, sodium bicarbonate (2.4 g/1),
HEPES, sodium pyruvate, hypoxanthine, thymidine,













0.06% glacial acetic acid and 0.1% BSA
3.8.2 HEPES/DMEM DMEM including glucose (4.5 mg/ml) E1EPES (25 mM)




20 mM Tris (pH 7.2) and 2 mM MgCl2
3.8.3 Membrane Binding
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Suppliers are listed in alphabetical order.
Supplier: Location:
ABI (PE Applied Biosystems) Warrington, UK
Amersham Pharmacia Little Chalfont, UK
Anachem Luton, UK
Bachem Saffron Walden, UK
Biosoft Cambridge, UK
Brandel St. Albans, UK
Genosys Cambridge, UK
GraphPad San Diego, USA
Invitrogen Groningen, The Netherlands
Jencons-PLS Leighton Buzzard, UK
Life Technologies (GibcoBRL) Paisley, UK
Merck Lutterworth, UK
New England Biolabs Hitchin, UK








Sequences of Oligonucleotide Primers
Primers were synthesised by Genosys and are listed in order of first reference in text.
Primers for General Subcloning and Sequencing




Internal Primers for Sequencing
Two internal sense primers annealing to the engineered human GnRH receptor cDNA
were used for sequencing, in addition to those listed above (see Section 3.5.3). These
primers were provided by T. Ott:
96-359 (Intracellular end ofTMD2): 5'-AAAGCTCTCGCGAATGAAGC-3'
96-360 (Extracellular end ofTMD3): 5' -TCTGCAAAGTACTCAGTTATC-3'
Primers for the Human-Catfish Chimeric GnRH Receptor cDNA
The human GnRH receptor cDNA construct had previously been engineered to include a
number of silent mutations, thereby introducing restriction sites at the TMD/ECL
boundaries (Ott et ah, 2002) (see Section 3.6). Each of the primers spanned one of these
178
sites and the sequence coded, partly for human GnRH receptor TMD, and partly for
catfish GnRH receptor ECL (see Section 5.2.4). The catfish receptor ECLs were
















Primer for the Human His207(5 34)Glu/Gln208(5 35)Glu mutant GnRH
Receptor cDNA
The following is the antisense primer spanning the Stu I restriction site and the sequence
coding for the His207'5 34)G1u and Gln208(5 35)G1u mutations in the engineered human
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Conformational Constraint of Mammalian, Chicken,
and Salmon GnRHs, But Not GnRH II, Enhances
Binding at Mammalian and Nonmammalian
Receptors: Evidence for Preconfiguration of GnRH II
KEVIN D. G. PFLEGER, JAN BOGERD, and ROBERT P. MILLAR
Medical Research Council Human Reproductive Sciences Unit (K.D.G.P., R.P.M.), Edinburgh, EH 16
4SB, United Kingdom; and Department of Endocrinology (J.B.), Utrecht University, 3508 TB, Utrecht,
The Netherlands
Mammalian GnRH (mGnRH) is believed to interact
with mGnRH type I receptors in a /3-II' turn confor¬
mation involving residues 5-8. This conformation can
be constrained by substitution of a d-amino acid at
position 6 or by a lactam ring involving residues 6 and
7, thereby increasing receptor binding affinity, ft has
been proposed that this is not the case for non-
mGnRH receptors. However, we show that this con¬
formational constraint increases the binding affinity
of mammalian, chicken, and salmon GnRH for the
chicken and catfish receptors, as well as for the
mouse receptor. Therefore, we conclude that the
/3-II' turn conformation enhances ligand binding for
non-mGnRH as well as mGnRH type I receptors. In
contrast, most substitutions of a d-amino acid in po¬
sition 6 have limited effect on binding affinity for
GnRH II. We suggest that this iigand is preconfigured
through intramolecular interactions, which accounts
for its high binding affinity and total conservation of
primary structure over 500 million years of evolution.
[Molecular Endocrinology 16: 2155-2162, 2002)
MAMMALIAN GnRH (mGnRH) is a decapeptidereleased from the hypothalamu to interact with
cognate receptors and regulate LH and FSH release
from pituitary gonadotroph cells (1). Fifteen structural
variants of GnRH have been identified (2, 3). In jawed
vertebrates these cluster into three groupings: GnRH I,
GnRH II, and GnRH III (4, 5). One of these, GnRH II, is
totally conserved in structure from bony fish to man,
suggesting that each individual amino acid is essential
for biological activity (6). We propose that the N and C
termini, which are conserved between all GnRHs, are
involved in receptor binding and activation as for
mGnRH, whereas the central residues are crucial for
the configuration of GnRH II and appropriate presen¬
tation of the N and C termini.
The bioactive conformation of mGnRH acting on
mGnRH type I receptors was originally proposed to be
largely determined by a j3-ll' turn involving residues
5-8 (7). This conclusion was supported by a large
body of evidence derived from a variety of ap¬
proaches. Conformation-dependent mGnRH antisera
that bind the N and C termini of mGnRH tolerate
certain amino acid substitutions in the central region of
the ligand, but not in other positions. This implied that
mGnRH has a turn conformation resulting in closely
apposed N and C termini (8).
Fluorescence measurements of Trp3 at different pH
values suggested that His2 and Tyr5 are in close prox-
Abbreviations: cGnRH, Chicken GnRH; mGnRH, mamma¬
lian GnRH; NMR, nuclear magnetic resonance; sGnRH,
salmon GnRH.
imity to Arg8 in mGnRH (9). This correlated with the
proposed /3-II' turn conformation and indicated the
possibility of intramolecular stabilizing interactions be¬
tween these residues. Further fluorescence studies
supported these findings by comparing mGnRH and
analogs with substitutions for Arg8 (10). Chicken
GnRH I (cGnRH I, [Gln8]-GnRH) was found to lack such
stabilizing interactions, implying that a less structured
conformation exists for this ligand.
The technique of conformational memories further
supported the concept that a predominant /3-II' turn
conformer of mGnRH accounts for biological activity
(11). Substitution of Arg8 with Lys resulted in a loss of
this structure and reduced binding affinity (11, 12).
Nuclear magnetic resonance (NMR) studies have
provided direct structural evidence for mGnRH in a
/3-type turn conformation consisting of three families
(13). All possess the 0-type turn about Gly6 and at
least two hydrogen bonds: one between Ser4 and Arg8
and another between pGlu1 and Gly10-NH2. Hydrogen
bonding of Arg8 to either His2 or Tyr5 was also noted,
supporting the conclusions from the fluorescence
studies (9, 10). cGnRH I had different conformers
grouped into four families. These also possessed sev¬
eral hydrogen bonds, but only that between pGlu1 and
Ser4 was common to all four. This implied much
greater flexibility of this molecule compared with
mGnRH.
A series of cyclic GnRH antagonists were found to
have a /3-II' turn conformation, further supporting the
notion that this is the biologically relevant structure
(14). However, because antagonists occupy different,
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but overlapping, binding sites, these observations do
not necessarily support the structure of agonists, in¬
deed, in this study a potent cyclic antagonist was
found to have a /3-I' turn at residues 6-7. This implies
that, for antagonists at least, the specific turn type may
not be important as long as it results in correct pre¬
sentation of the backbone and side chains critical for
binding. Because agonists must satisfactorily bind and
activate the receptor, they are likely to have more
specific structural requirements.
d-Amino acid substitution for Gly6 (d-aa6 substitu¬
tion) is believed to stabilize the /3-M' turn conformation,
thereby increasing affinity for the receptor (15). Con¬
formational energy analysis indicates that d-aa6 sub¬
stitution reduces the freedom for opening at position 6
so that the population of the bioactive conformer is
increased (16). A similar effect can be achieved by
utilizing a lactam ring between residues 6 and 7 (6,7
y-lactam insertion) (17).
Although there is substantial evidence for the /3-II'
turn conformation for active GnRH analogs at the
mGnRH type I receptor, it is uncertain whether con¬
straint of nonmammalian GnRHs in this conformation
enhances their activity at mammalian and nonmam¬
malian receptors.
mGnRH type I and non-mGnRH receptors have low
sequence identity and structural features that suggest
they may be configured differently. These include dif¬
ferences in intracellular domains (absence of C-termi-
nal tail, longer intracellular loop 1 in mGnRH type I
receptors), extracellular disulfide bridges, and different
interactions between residues in transmembrane do¬
mains 2 and 7 (18,19). In view of these differences that
affect the overall three-dimensional structure of the
receptor, the bioactive ligand conformational require¬
ment may also differ (20).
The present study provides evidence that a major
determinant of bioactive conformation at mGnRH
type I receptors, the /3-II' turn involving residues 5-8,
is also necessary for high-affinity binding at non-
mGnRH receptors. The findings also indicate that,
unlike the other GnRHs, the native GnRH II ligand is
preconfigured in a bioactive conformation, which may
account for its relatively high affinity for all GnRH
receptors investigated and the conservation of its
structure over 500 million yr of evolution.
RESULTS
The mouse GnRH receptor binds mGnRH and GnRH II
with highest affinity (Table 1). The catfish and chicken
receptors bind GnRH II with highest affinity, followed
by salmon GnRH (sGnRH), mGnRH, and cGnRH I (Ta¬
ble 1). Substitution of a d-amino acid in position 6 of
the ligand (d-aa6) or the insertion of a -y-lactam moiety
between residues 6 and 7 (6, 7 y-lactam) significantly
Table 1. Summary of Ligand Binding to Mouse, Chicken, and Catfish GnRH Receptors






































































































Radioligand binding assays were performed on homogenized membranes of COS-7 cells transiently transfected with GnRH
receptor cDNA. IC60 values were calculated as described in Materials and Methods.
" Mean ± sem of between three and eight experiments carried out in triplicate.
8 Fold increase in binding affinity relative to the wild-type ligand.
° Significantly different from wild type, P < 0.01.
d Significantly different from wild type, P < 0.05.
8 Significantly different from wild type, P < 0.001.
' Not significantly different from wild type, P > 0.05.
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increases the binding affinity of mGnRH, cGnRH I, and
sGnRH acting on the mouse, chicken, and catfish
GnRH receptors (Table 1).
Introduction of the aromatic D-Trp6 residue into
mGnRH increased the binding affinity at the mouse,
chicken, and catfish GnRH receptors by a substantial
74-, 8.6-, and 14-fold. The affinity of [D-Trp6]-GnRH
binding at the mouse receptor is significantly higher
than that of [D-Ala6]-GnRH and [6,7 -y-lactam]-GnRH
(P < 0.05). In contrast, substitution with the positively
charged D-Lys6 residue enhanced the binding affinity
at these receptors by only 1.9-, 3.6-, and 2-fold.
GnRH II was unique among the natural GnRHs
tested in binding all three species of GnRH receptor
with relatively high affinity. The affinity for the non-
mammalian receptors was particularly high. Substitu¬
tion of a D-aa6 has little or no effect on the binding
affinity of the GnRH II ligand acting at the catfish and
chicken receptors. At the mouse receptor, which has a
much lower affinity for GnRH II, only o-Lys6 substitu¬
tion results in a substantial (8.4-fold) increase in affinity
(Table 1).
The latter finding suggested that the D-Lys6 in GnRH
II may be interacting with one of the seven extracellular
domain acidic residues that are conserved in mGnRH
type I receptors. Binding of [D-Lys6]-GnRH to mutant
mouse GnRH receptors, in which each of these acidic
residues was successively mutated to its isosteric
amide (21), was compared with wild-type receptors. In
initial binding assays the Glu8Gln, Glu111Gln,
Asp185Asn, Asp292Asn, Glu294Gln, and Glu301Gln mu¬
tant receptors specifically bound radioligand, whereas
the Asp98 Asn mutant receptor did not (data not
shown). The latter result is expected as the Asp98
residue in the mGnRH type I receptor has been shown
to interact with the His2 residue in the GnRH ligand,
and mutations of this residue severely affect ligand
binding (22). The mutant receptors that bound the
labeled ligand were all found to have the same binding
affinity as the wild-type receptor for GnRH II and
[D-Lys6]-GnRH II (Table 2). This indicates that an inter¬
action of D-Lys6 with one of these residues was
not responsible for the increased affinity of [D-Lys6]-
GnRH II.
D-Lys6 substitution substantially enhanced the bind¬
ing affinity of GnRH II acting at the mGnRH type I
receptor, but not at the non-mGnRH receptors. To
examine this further, four more species of GnRH re¬
ceptor were investigated: two mGnRH type I receptors
(rat and human) and two non-mGnRH receptors
(Xenopus II and bullfrog III). D-aa6 Substitution did not
significantly increase the binding affinity of the GnRH
II ligand acting at the Xenopus II or bullfrog III recep¬
tors (Table 3). D-Lys6 substitution substantially in¬
creased the binding affinity of the GnRH II ligand act¬
ing at the rat and human receptors (33.8- and 7.2-fold,
respectively), as noted for the mouse receptor. An¬
other basic amino acid (D-Arg6) substitution into GnRH
II also increases binding affinity at the rat receptor.









Wild type 127.9 19.8 15.3 2.3
Glu8Gln 175.9 ± 37.6" 10.5 ± 3.5"
Glu111Gln 113.0 ± 16.1" 37.0 ± 11.4"
Asp165Asn 175.4 ± 17.5" 20.0 ± 2.1"
Asp292Asn 185.3 ± 25.3" 25.7 ± 5.7"
Glu294Gln 128.7 ± 32.6b 16.3 + 3.1"
Glu301Gin 130.4 -t- 6.5" 9.3 ± 1A"
Radioligand binding assays were performed on homogenized
membranes of COS-7 cells transiently transfected with GnRH
receptor cDNA. IC50 values were calculated as described in
Materials and Methods.
a Mean ± sem of between three and six experiments carried
out in triplicate.
b Not significantly different from wild type, P > 0.05.
Substitution of a basic D-aa6 into GnRH II enhances
binding at the rat receptor more than at the mouse or
human receptors. Comparison of the amino acid se¬
quences of the human, mouse, and rat GnRH receptor
extracellular loops reveals an additional acidic residue
in the rat receptor: the residues at the homologous
position to Gin208 in the human are Gin207 in the
mouse and Glu207 in the rat (Table 4). A human GnRH
receptor with the Gln208Glu point mutation was used
to investigate the effect of this residue on the binding
of GnRH II and [D-Lys6]-GnRH II. The IC50 for GnRH II
binding to the human wild-type GnRH receptor was
135.6 ± 15.8 nM, compared with 323.0 ± 33.1 nM for
binding to the rat wild-type GnRH receptor (P < 0.05).
The Gln208Glu human receptor mutant had an IC50 for
GnRH II of 350 ± 15.5 nM, which is significantly dif¬
ferent from the human wild-type receptor (P < 0.001)
but not significantly different from the rat wild-type
receptor (Fig. 1).
DISCUSSION
There is now considerable accumulated evidence that
mGnRH interacts with its receptor in a y3-ll' turn con¬
formation involving residues 5-8 (7-13). This confor¬
mation appears to be conferred by interactions be¬
tween Ser4 and Arg8, as well as between pGlu1 and
Gly10-NH2 (13). Others have presented evidence for
interactions of Arg8 with His2 and Tyr5 (9, 10, 13)
contributing to the /3-II' turn conformation. An interac¬
tion of Arg8 with an acidic residue in extracellular loop
3 of the receptor is also believed to contribute to the
configuration of the ligand in the folded conformation
(21, 23).
D-aa6 Substitution and 6,7 y-lactam insertion further
stabilize this conformation and enhance binding affin¬
ity (15-17, 24, 25). Indeed, the D-aa6 constraint can
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Table 3. Summary of Ligand Binding to Rat, Human, Xenopus II, and Bullfrog III GnRH Receptors











































Radioligand binding assays were performed on homogenized membranes of COS-7 cells transiently transfected with GnRH
receptor cDNA. IC50 values were calculated as described in Materials and Methods.
9 Mean ± sem of between three and six experiments carried out in triplicate.
8 Fold increase in binding affinity relative to the wild-type ligand.
c Significantly different from wild type, P < 0.05.
d Not significantly different from wild type, P > 0.05.
9 Significantly different from wild type, P < 0.01.
Table 4. Comparison of Human, Mouse, and Rat GnRH Receptor Extracellular Loop (ECL) Amino Acid Sequences9













9 Nonconserved residues are shown as bold letters.











Wild Type Human Wild Type
Human Gln20BGIu Rat
GnRH receptor
Fig. 1. GnRH II (open bars) and [d-Lys6]-GnRH II (filled bars)
Binding to the Human Gin208 Glu Mutant GnRH Receptor
Compared with Binding to the Wild-Type Human and Rat
GnRH Receptors
Data are presented as mean ± sem. IC60 values of between
three and five experiments carried out in triplicate. IC50 values
were calculated as described in Materials and Methods.
Significantly different from wild-type human, P < 0.05. ***,
Significantly different from wild-type human, P < 0.001.
abrogate the need for the interaction between Arg8 of
mGnRH and the acidic residue in extracellular loop 3
of the receptor (23). The present studies confirmed
these concepts as d-Trp6, d-Ala6, and d-Lys6 substi¬
tution and 6,7 -y-lactam insertion all significantly in¬
creased the binding affinity of mGnRH at the mouse
GnRH receptor.
The potency of mGnRH increases with increasing
hydrophobicity of the d-aa6 (24), and this is exempli¬
fied in the current study in which binding affinity suc¬
cessively increased in the series d-Trp6 > d-Ala6 > 6,7
y-lactam > d-Lys6. Because [d-Trp6]-GnRH has a
much higher affinity than the 6,7 y-lactam analog, it
appears that the substitution with d-Trp6 makes addi¬
tional contributions to enhancement of affinity. Expla¬
nations for this include: possible hydrophobic inter¬
actions with the receptor; a stabilization of the ligand
conformation by intramolecular hydrophobic interac¬
tions, or a reduction in flexibility due the size of these
side chains; and/or a reduction in the desolvation pen¬
alty upon binding to the receptor due to the more
hydrophobic nature of the ligand (12). [d-Lys6]-GnRH
binds to the mouse and catfish receptors with signif¬
icantly lower affinity than [6,7 y-lactam]-GnRH, imply¬
ing that the basic lysine side chain is detrimental to the
binding of the GnRH ligand. The hydrophilic nature of
this residue may disrupt one or more of the effects
described above. Additionally, the positive charge of
lysine may repel the positively charged Arg8 and so
affect ligand conformation. d-Arg6/d-Lys6 substitution
into sGnRH, which does not contain positively
charged amino acids, resulted in a much greater in¬
crease in binding affinity in the mouse, chicken, and
catfish receptors. This concurs with the recorded ef¬
fects of d-Arg6 substitution in sGnRH at the goldfish
receptor (26, 27).
Previous studies have shown that some non-
mGnRH receptors, unlike mGnRH type I receptors, are
*
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not selective for Arg8 containing ligands (20, 28). In
view of the role of Arg8 in configuring the ligand, it was
suggested that these receptors do not require GnRH
to be configured in the jS-ll' turn conformation (29).
This interpretation was further supported by the ob¬
servation that D-aa6 substitution did not enhance bind¬
ing at the cloned chicken receptor (20) and that NMR
showed the N and C termini of cGnRH I were not
closely apposed (13).
However, in the present study, D-aa6 substitution
clearly increased the binding affinity of mGnRH,
cGnRH I, and sGnRH at mouse, chicken, and catfish
receptors.
Although these observations appear to be contra¬
dictory, closer inspection reveals that the primary data
concur. The interpretation that D-aa6 substitution does
not enhance binding affinity at the cloned chicken
receptor was based on [o-Arg6]-GnRH II having the
same binding affinity as GnRH II and a GnRH analog
incorporating D-Ala6 having the same affinity as
mGnRH (20). The present study found a lack of en¬
hancement for D-Arg6 substitution into GnRH II, and
that D-Ala6 substitution into mGnRH produced a rela¬
tively small enhancement. Our data showing an in¬
crease in affinity resulting from D-Trp6 substitution are
supported by a study testing LH releasing activity
using dispersed chicken anterior pituitary cells, in
which D-Trp6 analogs of cGnRH I and mGnRH were
approximately 20-fold more potent than cGnRH I and
mGnRH, respectively (30). Furthermore, our data
showing increased binding affinity of sGnRH at non-
mGnRH receptors after D-aa6 substitution are sup¬
ported by two studies that showed D-Arg6 substitution
in sGnRH enhanced binding affinity at the goldfish
receptor (26, 27).
The NMR data show that the N and C termini of
cGnRH I are not closely apposed; however, a turn
conformation around Gly6 was still identified (13). Con¬
formational energy analysis indicates that cGnRH I can
adopt the j3-ll' turn conformation (16). It is therefore
likely that mGnRH and cGnRH I have similar confor¬
mations around Gly6, but different conformations of
the termini. This may explain how these ligands have
such different affinities for the same receptor.
Studies using fluorescence (10) and NMR (13) have
indicated a greater flexibility of the cGnRH I ligand com¬
pared with mGnRH. This implies that the nonmammalian
receptors are able to stabilize the bioactive ligand con¬
formation, either as a result of additional receptor con¬
tact sites, or as a result of a different spatial arrangement
of conserved receptor contact sites as previously pro¬
posed (20). The latter concept is supported by the ob¬
servation that non-mGnRH receptors have a different
conformation of extracellular loop 3 due to the altered
positioning of a proline residue (31).
Most D-aa6 substitutions had limited effects on the
binding affinity of GnRH II in contrast to that observed
for mGnRH, cGnRH I, and sGnRH. D-Trp6 substitution,
which gave the greatest increase in binding affinity of
mGnRH (8.6- to 74-fold), did not substantially increase
the binding affinity of GnRH II to any of the receptors
(Tables 1 and 3), and none of the D-aa6 substitutions
substantially increased the binding affinity of GnRH II
at the chicken, catfish, Xenopus II, or bullfrog III GnRH
receptors. Because GnRH II binds with high affinity to
these receptors and D-aa6 substitution does not sub¬
stantially increase affinity, GnRH II would appear to be
preconfigured in a bioactive conformation suitable for
binding non-mGnRH receptors, as proposed previ¬
ously (32). A more recent study also found that D-aa6
substitution did not improve the binding affinity of
GnRH II at the catfish receptor, again concluding that
this ligand interacts with the catfish receptor in a con¬
strained /3-II' turn conformation (33).
Only D-Lys6 substantially increased the binding af¬
finity of GnRH II at the human and mouse GnRH re¬
ceptors. In view of the failure of other D-aa6 substitu¬
tions to increase binding affinity, we considered that
D-Lys6 might provide an additional ligand-receptor in¬
teraction that does not occur with non-mGnRH recep¬
tors. A candidate interaction is between the basic
D-Lys6 and an acidic residue. To address this possi¬
bility, extracellular domain acidic residues conserved
in mGnRH type I receptors were screened with GnRH
II and [D-Lys6]-GnRH II, using point-mutated mouse
receptors. These mutations did not alter the binding
affinity of either ligand (Table 2). Although there are
other amino acid residues that can interact with a Lys
side chain, we have not investigated these. Instead,
we revisited the possibility that D-Lys6 substitution can
contribute to the configuration of GnRH II.
Although we have evidence that GnRH II is precon¬
figured, its lower affinity at mGnRH type I receptors
(IC50 of 128-323 nM compared with 0.75-3.7 nM at
non-mGnRH receptors) suggests the interaction is not
optimal. We cannot therefore rule out the possibility
that D-Lys6 substitution may alter the conformation of
GnRH II to improve its binding to mGnRH type I
receptors.
D-Arg6 as well as D-Lys6 substantially increased the
binding affinity of GnRH II at the rat GnRH receptor.
This concurs with previous findings using rat pituitary
membranes (34). D-Lys6 increased the binding affinity
of GnRH II at the rat receptor much more (33.8-fold)
than at the human (7.2-fold) and mouse receptors
(8.4-fold) (Tables 1 and 3). A search for amino acids
different in the rat from the mouse and human revealed
the presence of a glutamate residue in extracellular
loop 2 of the rat in the homologous position to a
glutamine residue in the human and mouse receptors.
The mutation of Gin208 to Glu in the human receptor
reduced the binding affinity of GnRH II to that of the rat
receptor, and D-Lys6 substitution increased binding
affinity by a similar amount to that found in the rat
receptor. The deleterious effect of Glu208 may be due
to charge repulsion between this acidic residue and
acidic residues in the N-terminal region of extracellular
loop 3, such as Asp293 and Glu295, causing distortion
of binding site configuration and/or influencing the
ease with which the ligand can interact with contact
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sites within the transmembrane domains. The binding
affinity of [D-Lys6]-GnRH II is not significantly different
between the three receptors, suggesting that D-Lys6
substitution overcomes the deleterious effect of
Glu208.
In conclusion, we have obtained data in support of
the concept that, as for the mGnRH type I receptors,
the non-mGnRH receptors have a preference for
GnRH in the folded conformation involving a /3-II' turn
for residues 5-8, which is enhanced in mGnRH,
cGnRH I, and sGnRH by D-aa6 substitution, in con¬
trast, the evolutionarily conserved GnRH II ligand ap¬
pears to have a preconfigured (3-II' turn that accounts
for its relatively high affinity for all GnRH receptors and
a failure, in most instances, of any enhancement of
binding affinity with D-aa6 substitution. The surprising
total conservation of GnRH ll's primary structure from
bony fish to man appears to have been a product of
the coordinated evolutionary selection of amino acids
contributing to binding, activation, and configuration
such that its structure cannot be improved by substi¬




[D-Trp6]-GnRH, [D-Ala6]-GnRH, [D-Lys6]-GnRH, cGnRH I
([Gln8]-GnRH), sGnRH ([Trp7,Leu6]-GnRH), and GnRH II
([His5,Trp7,Tyr8]-GnRH) were supplied by Bachem (Saffron
Walden, Essex, UK) (Table 5). [D-Ala6]-cGnRH I, [D-Arg6]-
sGnRH, [D-Lys6]-sGnRH, [D-Trp6]-GnRH II, [D-Arg6]-GnRH II,
and [D-Lys6]-GnRH II were gifts from University of Cape Town
(Cape Town, South Africa). [6,7 y-Lactam]-GnRH and [6,7
y-lactam]-cGnRH I were gifts from R. Freidinger (Merck &
Co., Inc., West Point, PA) and R. Roeske (Indiana University
School of Medicine, Indianapolis, IN).
GnRH Receptor cDNA
The human (35), mouse (36), chicken (20), and Xenopus II
(Troskie, B., N. tiling, and R. Millar, unpublished results)
GnRH receptor cDNA constructs were gifts from Cape Town
University. The rat GnRH receptor was cloned by this labo¬
ratory (37). The catfish GnRH receptor cDNA (38) was a gift
from Utrecht University (Utrecht, The Netherlands). The bull¬
frog III GnRH receptor cDNA was a gift from Chonnam Na¬
tional University (Kwangju, Republic of Korea) (28). The bull¬
frog III receptor has greatest sequence homology for
designated type II receptors (Troskie, B., N. Illing, and R.
Millar, unpublished results) and should be regarded as a type
II receptor. Its classification as type III was based on tissue
distribution.
The mouse GnRH receptors, each having one of the con¬
served extracellular domain acidic residues mutated to its
isosteric amide, were gifts from C. Flanagan (University of
Cape Town). They were produced as described previously
(21). The human receptor containing the Gin208 Glu mutation
was also produced previously (39).
Cell Culture and Transfection
COS-7 cells were seeded in 100-mm2 dishes at a density of
1.2 x 106 cells per dish. Cells were maintained at 37 C, 5%
C02 in DMEM containing 10% fetal calf serum, 0.3 mg/ml
glutamine, 100 lU/ml penicillin, and 100 jxg/ml streptomycin
(Sigma-Aldrich Corp., Poole, Dorset, UK). After 24 h, the cells
were transiently transfected with GnRH receptor cDNA from
various species (10 ^g of DNA per 100-mm2 dish) using
Superfect (QIAGEN, Crawley, West Sussex, UK) according to
manufacturer's instructions (30 /xl Superfect per 100-mm2
dish for 8 h). After a further 48-h incubation, cells were
scraped in PBS, pelleted, and stored at -70 C.
Receptor Binding Assays
The cell pellets were homogenized in ice-cold buffer (20 mrn
Tris, 2 mM MgCI2, pH 7.2) and centrifuged at 15,000 rpm for
10 min at 4 C. The crude membrane pellet was then resus-
pended in ice-cold assay buffer (40 mM Tris, 2 mM MgCI2,
0.1 % BSA, pH 7.4). Competition binding assays were carried
out using radiolabeled 125l-[His5, D-Tyr6j-GnRH (—120,000
cpm/tube). The high binding affinity of this tracer compared
with conventional tracers was established previously (40).
The membrane suspension was incubated overnight at 4 C
with labeled ligand and varying concentrations of unlabeled
GnRH analogs in triplicate. The suspensions were then fil¬
tered through a membrane harvester (Brandel, St. Albans,
Herts, UK) onto Whatman GF/B filter paper (Merck, Lutter¬
worth, Leics, UK) (presoaked in assay buffer containing
0.01 % polyethylenimine) and washed three times with ice-
cold assay buffer. Bound radioactivity was counted using a
multigamma counter [Perkin-Elmer Corp. (Wallac, Inc.), Cam¬
bridge, UK]. Maximum specific binding ranged between ap¬
proximately 5,000 and 10,000 cpm/tube with nonspecific
binding ranging between approximately 2,000 and 4,000
cpm/tube. No specific binding was detected with COS-7
cells transfected with vector only. Membrane concentration
was varied to control for expression levels, with cells from
two 100-mm2 dishes being used for each binding curve, with
the exception of the human, chicken, and catfish receptors.
The human and chicken receptors exhibited particularly low
expression levels; therefore, four 100-mm2 dishes per curve
were used. Conversely, the catfish receptor exhibited partic¬
ularly high expression levels, and so one 100-mm2 dish per
curve was used. Therefore, similar maximal specific radio¬
ligand binding was observed at all receptors.
Table 5. Sequences of GnRH Ligands
Sequence
1 2 3 4 5 6 7 8 9 10
mGnRH pGlu His Trp Ser Tyr Gly Leu Arg Pro Gly-NH2
cGnRH I a a a a a a a Gin a a
sGnRH a a a a a a Trp Leu a a
GnRH II a a a a His a Trp Tyr a a
a Residue identical to mGnRH.
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Data Reduction and Statistical Analysis
Binding curves were generated by Prism graphing software
(GraphPad Software, Inc., San Diego, CA) using nonlinear
regression, assuming one-site competition. Significant differ¬
ences in wild-type to mutant IC50 values were assessed using
a two-tailed, unpaired Student's f test with Welch's correc¬
tion (does not assume equal variances).
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